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Abstract
The term carbohydrate-active protein (CAP) encompasses the group
of proteins that either act as carbohydrate receptors (e.g. lectins) or
enzymatically catalyse reactions involving carbohydrates as at least
one of their substrates (e.g. glycosyltransferases). The fundamental
importance of CAPs has only been realised over the past few decades,
with carbohydrates playing a profound role in cellular signalling, ad-
hesion and migration. Furthermore, carbohydrates are routinely used
by pathogens in immune evasion and to modify host function, and
changes in glycosylation patterns are associated with a range of dis-
ease states, including cancer and inflammation.
However, the study of CAP-carbohydrate interactions has been
challenging, in part due to the inherently low affinity of many
CAP-carbohydrate interactions that precluded detection by many
techniques and make it difficult to obtained experimentally derived
structures of their complexes. Fortunately, STD NMR spectroscopy
is ideally suited to detecting weak interactions of this nature and
provides structural information about the interaction through ligand
epitope mapping. Furthermore, quantitative analysis of STD intensi-
ties allows three-dimensional models of the validated in the solution
state, whether these models be derived from experiment or molecular
modelling.
Within this thesis, a combination of STD NMR spectroscopy and
molecular modelling has been used to unravel structural and dynamic
detail of CAP-ligand interactions in three biologically or industrially
relevant systems - (1) CD44/LYVE-1 which may play a role in cell
trafficking across the lymphatics in cancer; (2) PsLBP which may lead
to new developments in the field of enzymatic carbohydrate synthe-
sis; (3) SseK1/2 which exhibit a novel enzymatic mechanism involving
glycosylation of arginine residues and may be involved in Salmonella
virulence.
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Chapter 1
Introduction
1.1 Carbohydrates
1.1.1 Origins of Glycobiology
In the field of molecular biology, it has long been believed that the flow
of information from DNA to RNA to protein sufficiently explains the
complex and diverse behaviour of life. In fact, this idea has become
so prolific that it is now known as the central dogma.[1] However, it
is now apparent that this is not the case and an accurate description
requires a better understanding of other key players.
Carbohydrates are another major class of biomolecule and their role
in metabolism and structural integrity has been understood for a long
time[2]. However, further progress in the study of carbohydrates has
been hampered, principally due to their inherent complexity. Unlike
proteins, which are linear chains of amino acids, each carbohydrate
monomer, known as a monosaccharide, can polymerise at multiple
positions, leading to highly branched structures. A further distinc-
tion from proteins is that carbohydrates lack any template encoding.
The sequence of a protein can be accurately predicted if the DNA se-
quence is known. Conversely, the fine balance of glycosyltransferases
and glycosidases of the endoplasmic reticulum and Golgi apparatus de-
termine the final carbohydrate structure, which is therefore dependant
on physiological conditions and on cell type.[3,4]
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Figure 1.1: The possible linkage points for DNA (a), proteins (b) and carbohy-
drates (c), shown with arrows. Both DNA and proteins are template encoded
and only possess two linkage points, leading to linear chains. Carbohydrates
have many linkage points, so can be highly branched and diverse. Taken from
[5]
It has now become evident that carbohydrates play an integral role
in biological systems and as such the field of glycobiology, a term
first coined by Raymond Dwek in 1988,[6] is now rapidly expanding.
As an example of their importance, carbohydrates are often found
covalently bound to extracellular proteins (glycoproteins), in which
they have important roles in modulating stability and activity.[6,7] In
the first case, the carbohydrate acts as a physical barrier to prevent
recognition by proteases and antibodies. In the latter, carbohydrate
residues can occupy the binding site or interact with key sidechains.
Commonly, this is achieved via terminal sialic acid residues, which
can be cleaved by sialidases to allow switching between low- and high-
activity states.[8]
Carbohydrates also play a key role in cellular signalling.[7] Specific
recognition of carbohydrates in the extracellular matrix (ECM) allows
the cell to sense its environment and facilitates adhesion and migration.
Carbohydrates are also key in inter-cell communication, by binding to
specific receptors on adjacent cells that in turn facilitate a downstream
signalling response. This also plays a key role in infection, in which
many pathogens aim to mimic the carbohydrates of their hosts to both
evade the immune response, and to facilitate host entry by binding to
host cell receptors.[9]
Clearly then the precise structure of a particular carbohydrate has
a profound impact on its function - addition or removal of single
monosaccharide unit can determine whether or not a carbohydrate
is recognised by its receptor, which may be responsible for a number
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of downstream processes. Despite the lack of templating, it is still
incredibly useful to understand the structural features of certain car-
bohydrates that give rise to their particular functionalities. These
features have been termed the sugar code and much work is currently
underway to elucidate these features.[5,10,11] Receptors that recognise
these specific carbohydrates are termed ‘readers’ of sugar-encoded in-
formation, whilst other carbohydrate-active proteins that add and re-
move sugar units are termed ‘writers’ and ‘erasers’ of sugar-encoded
information respectively. A good example of the specificity of the
glycan code is the comparison between Blood Groups A and B - the
former presenting a N-acetyl-galactosamine as the terminal residue,
whereas the terminal residue is simply a galactose residue in the lat-
ter. This seemingly small change (removing the N-acetyl group) can
be highly immunogenic where the wrong blood type is given to the
host, showing high specificity in carbohydrate recognition.
Due to their intimate roles in many biological processes, carbohydrates
are also implicated in a range of genetic and acquired diseases. The
most common carbohydrate-related genetic defect is congenital disor-
der of glycosylation (CDG) Ia, which is characterised by a deficiency
in phosphomannomutase, a key enzyme in the pathway that leads to
incorporation of mannose into carbohydrates.[12,13] CDG Ia has high
mortality rates due to susceptibility to infection and organ failure, and
leads to reduced muscle tone and mental retardation. Many acquired
diseases are characterised by a change in either glycosylation patterns
or receptor expression. For example, inflammatory diseases are caused
by changes in glycosylation in certain tissues, leading to leukocyte
homing and immune activation.[14] Furthermore, many cancers exhibit
increased levels of sialylation, which allows them to ignore extracel-
lular signals, such as apoptosis death factors, and resist anti-cancer
therapies.[14,15] Increased sialylation is also associated with increased
aggressiveness and metastatic potential.
Much of the understanding of carbohydrate function we now have has
been made possible with the advent of new technologies. For example,
recombinant DNA technology and chemical mutagenesis allow protein
glycosylation sites and carbohydrate biosynthesis to be modified,
facilitating in vivo understanding of carbohydrate function.[16,17] In
addition, isolated carbohydrates can be characterised by techniques
such as antibody-lectin arrays,[18] mass spectrometry[19] and NMR
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spectroscopy.[20] Techniques such as these allow the glycome, the
total set of expressed carbohydrates under given conditions, to be
characterised, facilitating a dynamic understanding of carbohydrate
expression.[21] In addition, X-ray diffraction, NMR spectroscopy and
molecular modelling can be used to create atomic resolution 3D
models of carbohydrates and their complexes, allowing the details
of the interaction to be understood.[22–26] In addition, the latter two
techniques also present dynamic information, which is of particular
importance in understanding the behaviour of carbohydrates.
1.1.2 Chemical Structure
In their simplest form, monosaccharides exist as polyhydroxyaldehydes
(aldoses) or polyhydroxyketones (ketoses) with an empirical formula of
Cm(H2O)n. Each hydroxymethylene unit is chiral, allowing for a huge
amount of diversity with relatively few atoms; for a given molecule
with n stereocentres, there are 2n stereoisomers. Nature tends only to
use a subset of these however, the majority of natural monosaccharides
existing in the D-configuration. In addition, only 9 monosaccharides
are commonly observed in vertebrates (Fig. 1.2).[27] Despite this, a
huge number of carbohydrate structures are possible. For example,
considering only disaccharides of glucose, 20 unique carbohydrates can
be made.
13
Figure 1.2: The nine monosaccharides commonly found in vertebrates, de-
picted here as β-anomers. All exist as pyranoses, while only Fuc is in the
L-configuration, and NeuAc, the most common form of sialic acid, is the only
ketose. Taken from [27]
In solution, monosaccharides predominantly exist in either a cyclic
furanose (5‑membered ring) or pyranose (six-membered ring) form
generated through reaction of the carbonyl with one of the hydroxyl
groups to form a hemiacetal. On cyclisation, a new stereocentre is
generated at the so-called anomeric carbon (C1 in aldoses), giving
rise to two new stereoisomers. These are known as the α- and β-
anomers and are defined by the absolute configuration of the anomeric
carbon compared to that of the highest-numbered stereocentre.[27] If
both carbons have the same configuration then it is said to be the
α‑anomer, otherwise it is the β-anomer. In solution, these anomers
can readily interconvert through a ring-opening and recyclisation pro-
cess called mutarotation. From sterics alone, it would be expected
that the α-anomer would be strongly disfavoured due to diaxial in-
teractions. However, the α-anomer is significantly populated in many
monosaccharides, and is even the major anomer in mannose.[28] This
is attributed to favourable overlap between a non-bonding orbital of
the endocyclic oxygen and the σ* orbital of the carbon to exocyclic
oxygen bond, known as the endo-anomeric effect (Fig. 1.3).[29]
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Figure 1.3: Graphical representation of the endo-anomeric (left) and exo-
anomeric (right) effects. Both the axial configuration and gauche conforma-
tion are stabilised by hyperconjugation between heteroatom non-bonding and
carbon-heteroatom anti-bonding orbitals.
As for cyclohexanes, the most favourable ring-conformation of pyra-
noses is usually the chair (C) conformation. This can further be de-
fined as 4C1 or 1C4, which refers to the carbon atoms that fall above
or below the plane of the ring when drawn as shown (Fig. 1.4). In
most cases, the 4C1 conformation is favoured as axial interactions are
minimised. Other possible conformations include half-chair (H), boat
(B), skew-boat (S) and envelope (E) (Fig. 1.4) but these are only
accessible in more exotic monosaccharides[30] or by distortion in an
enzyme active site.[31,32] Ring conformations can readily be quantified
by using the spherical coordinate system developed by Cremer and
Pople to describe ring puckering (Fig. 1.4).[33] These coordinates can
also be applied to furanoses, which are inherently more flexible than
pyranoses and can readily sample multiple ring conformations.[34,35]
Figure 1.4: Stereographic representation of the Cremer-Pople ring-puckering
coordinates proposed by Jeffery and Yates (1979). The polar (θ) and azimuthal
(ϕ) coordinates quantitatively describe each ring conformation. For example,
θ = 0◦, 180◦ (ϕ is undefined) describe the 4C1 and 1C4 conformations respec-
tively.
Polymerisation of monosaccharides occurs by condensation of the C1
hemiacetal of one monosaccharide with a hydroxyl group of another
monosaccharide, forming a glycosidic bond. The, now, acetal is no
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longer susceptible to reduction whereas the remaining hemiacetal in
the added monosaccharide is, giving the polymer a distinct polarity.
These are therefore termed the non-reducing and reducing ends re-
spectively and are equivalent to the N- and C-terminal terminology
in proteins. In addition, mutarotation is no longer possible at the
acetal, so the anomericity of each monosaccharide within the polymer
is preserved. In some carbohydrates, such as sucrose, the glycosidic
bond is formed between the anomeric positions of both monosaccha-
rides. These are termed non-reducing carbohydrates as no hemiacetal
is present at either terminus. The nomenclature of glycosidic linkages
is described in terms of the numbering of the hydroxyl atoms involved
and the anomeric form of the non-reducing residue. For example,
the disaccharide formed between β-glucose (Glc) and O4 of galactose
(Gal) would be named Glc-β-1,4-Gal. Polymers of monosaccharides
are known collectively as glycans but may be termed oligosaccharides
for short polymers (< 20 residues) or polysaccharides for longer chains.
As each monosaccharide contains multiple hydroxyl groups, condensa-
tion can occur multiple times on the same residue forming branched
structures, which confers glycans an immense capacity for bearing
structurally diverse information.
While the pyranose rings of each monosaccharide can be considered
essentially rigid, flexibility can be achieved by rotation about the gly-
cosidic bonds. The angles, ϕ and ψ, describe the conformation of
the glycosidic linkages, and are defined here as O5n‑C1n‑Oxn+1‑Cxn+1
and C1n-Oxn+1-C(x)n+1 -C(x-1)n+1 respectively (Fig. 1.5).[2] A gauche
conformation is usually favoured for ϕ due to the exo-anomeric effect
which, similar to the endo-anomeric effect, involves favourable overlap
of a non-bonding orbital of the exocyclic oxygen with the σ* orbital of
the carbon to endocyclic oxygen bond (Fig. 1.3).[29] The key relevance
of the stereoelectronic component of the exo-anomeric effect has been
experimentally demonstrated very recently by the elegant use of fluori-
nated glycomimetics.[36] Glycosidic bonds involving the oxygen of the
exocyclic hydroxymethyl group at C5 have an extra degree of freedom
by rotation around the C5-C6 bond. This allows a further torsion
angle, ω, to be defined as O6-C6-C5-O5 (Fig. 1.5). By considering ω
and the torsion angle defined by O6‑C6‑C5-C4, three rotamers can be
defined. With respect to the above torsions, these are gauche-gauche
(gg), gauche-trans (gt) and trans-gauche (tg) (Fig. 1.6). In many
cases, the gg and gt conformations are largely populated, while the
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tg conformation is virtually non‑existent.[37,38] For simple molecules,
the preference for two adjacent electronegative groups to be gauche
to one another, known as the gauche effect, is often rationalised as a
stereoelectronic effect.[29] While this may be a contributing factor in
carbohydrates, studies have shown that solvation and sterics play a
much more important role.[39]
Figure 1.5: The torsions important for carbohydrate flexibility using Glc-β-1,6-
Glc as an example. The angles ϕ and ψ are common to all glycosidic linkages,
whereas ω is unique to the 1,6 linkage.
Figure 1.6: Newman projections viewed along the C5-C6 bond showing the
gauche-gauche (gg), gauche-trans (gt) and trans-gauche (tg) rotamers. These
rotamers describe the conformation of O6 relative to C4 and O5 respectively
(highlighted in yellow).
Carbohydrate structure is further complicated by chemical modifi-
cation following synthesis, which is known as post-glycosylational
modification.[40] Common modifications include sulfation, methylation
and acetylation, all of which provide unique structural motifs that
add a further level of diversity to the carbohydrate ‘toolbox’.
1.1.3 Carbohydrates in Biology
The majority of carbohydrates are found covalently attached to other
biomolecules (glycoconjugates), either as glycolipids or glycoproteins.
Monosaccharides have also been reported bound to DNA, but this
appears only to be associated with damage and ageing.[41–43]
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Glycolipids are found both in the outer and internal (ER, Golgi etc.)
membranes of the cell, where they function as biosurfactants and
have roles in cell-cell binding and signalling (Fig. 1.7).[44] For example,
Vibrio cholera initiate host cell invasion through binding to the GM1
ganglioside.[45] In signalling, glycolipids come together, along with
cholesterol, in concentrated regions of the membrane known as lipid
rafts.[46,47] This facilitates signalling by bringing specific signalling
proteins into close association. Gram-negative bacteria produce
unique glycolipids known as lipopolysaccharides (LPS). These are
complex structures consisting of an anchoring lipid (endotoxin)
covalently bound to a core oligosaccharide.[48] This is then attached
to a repeating polysaccharide, known as the O-antigen, which extends
into the extracellular space. LPS molecules cover most of the surface
of the outer membrane and act as a physical barrier to protect the
bacterium from antibiotics, the immune system and environmental
stress. The endotoxin can be released from the membrane as a result
of cell division or death, and is highly immunogenic.[49] While such a
response helps the host fight the invading organism, Gram-negative
infections can result in septicaemia due to prolonged inflammation.[50]
Figure 1.7: Schematic representation of common classes of glycans depicted
as glycoconjugates to protein or lipid molecules. The exception is hyaluronan,
which is never conjugated to other biomolecules. Taken from [51].
Glycans are covalently attached to protein sidechains via either a ni-
trogen (N-glycan) or oxygen (O-glycan) atom. N-glycosidic bonds are
formed between the reducing terminal, almost always β-GlcNAc, of
the glycan and an asparagine sidechain (Fig. 1.7)[3,52]. Sterics per-
mitting, this occurs at a consensus sequence of N-X-S/T (where X
is any amino acid except proline), which is known as the N-glycan
sequon. While all N-glycans start out as Glc3Man9GlcNAc2Asn, var-
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ious trimming and further glycosylation steps allow N-glycans to be
separated into 3 distinct classes, all with a common biantennary core
of Man3GlcNAc2 (Fig. 1.8). These are: oligomannose, in which the
core is attached only to mannose residues, complex, in which oligosac-
charides are linked to the core via GlcNAc, and hybrid, in which one
antenna is high mannose and the other is complex. As well as being
essential for mediating glycoprotein activity and stability, N-glycans
are also crucial in the steps before the mature glycoprotein is secreted,
in roles such as quality control[53] and trafficking within the cell.[54]
Figure 1.8: Classification of N-glycans as oligomannose, complex, or hybrid
based on oligosaccharides attached to a common core glycan. Monosaccharides
are represented according to the same scheme as Fig. 1.7. Taken from [3].
O-glycosylation differs somewhat from N-glycosylation. Firstly, O-
glycosylation occurs by stepwise addition of monosaccharides to the
existing glycan chain, which is initiated via an O-glycosidic bond to a
serine or threonine residue (Fig. 1.7).[55–57] An O-glycosylation sequon
is yet to be identified. A number of different types of monosaccharide
can initiate the O‑glycan. Glycans initiated by O-GalNAc are common
and found on mucin glycoproteins, where they play mostly a protective
role in the extracellular environment.[58] Inside the cell a unique form
of O-glycosylation occurs involving GlcNAc, in which glycosylation
and deglycosylation occurs readily, providing a regulatory switching
mechanism.[59]
Proteoglycans are a specific class of glycoprotein which consist of a
protein core bound to at least one, usually many, glycosaminogly-
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cans (GAGs), linear polysaccharides consisting of repeating disaccha-
ride units (Fig. 1.7).[60,61] They are usually found in the extracellular
matrix, where they are known to contribute to tissue architecture.
More recently however, they have also been shown to play an impor-
tant role in signalling by recruiting leukocytes[62] and interacting with
cytokines.[63]
1.1.3.1 Carbohydrate Binding Proteins
Many biological roles of carbohydrates are mediated through binding
to carbohydrate‑specific proteins. Despite the immensity of the gly-
come, most carbohydrate-binding proteins (CBPs) are highly specific,
often recognising only a single glycan.[64] This interaction tends to be
very weak however, with dissociation constants typically in the mil-
limolar range. Nevertheless, these interactions usually display high
avidity through receptor clustering and multivalent ligands. Speci-
ficity is achieved by providing a contact surface complementary to
the unique geometry of the particular carbohydrate.[65] The amphi-
pathicity of carbohydrates means that both hydrogen bonding and
hydrophobic interactions are important, as well as electrostatics.[66]
Two major classes of CBP exist, lectins and GAG-binding proteins
(GBPs).
Lectins are CBPs involved in cell-cell adhesion, known as
agglutination.[67] They typically bind with only the terminal
carbohydrate residue contacting the protein. Lectins are categorised
based on highly conserved carbohydrate recognition domains (CRDs)
(Fig. 1.9). The most common of these are the Ca2+-dependant C-type
lectins, which are cell-surface receptors that have a dual role in both
activation and inhibition of the immune system.[68] The C-type lectin
fold is characterised by two antiparallel β-sheets, two α-helices and
two loops - as an example, see the structure of DC-SIGN in Fig.
1.10A. Stabilisation of these loops by Ca2+ binding facilitates glycan
binding. In addition, two disulphide bonds are highly conserved, as
well as the glycan-binding E-P-N and W-N-D motifs.
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Figure 1.9: Schematic representation of examples of common lectin classes.
Each class is characterised by conserved CRDs (GL, CL, MP, IL). Other domains
shown are EGF-like (EG), immunoglobulin C2 (IG2), transmembrane (TM),
and complement regulatory repeat (C3). Taken from [69]
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Figure 1.10: (A) Cartoon representation of DC-SIGN, a C-type lectin, bound
to GlcNAc2Man3 used to demonstrate the C-type lectin fold. Ca2+ ions are
represented as green spheres. PDB accession code: 1K9I [70] (B) The Link
domain of TSG-6, showing structural homology to the C-type fold minus the
Ca2+-binding loop. No ligand-bound structure was available at time of writing,
but NMR and modelling studies suggest binding along a shallow groove formed
between the hook-like loop and β-sheet (orange) [71]. PDB accession code
2PF5 [72].
Another interesting class of lectin are the galectins, which are
unique in that they are soluble, and are found both inside the cell
and in the extracellular matrix. They are specific for galactosides
(galactose-containing glycans) and are characterised by an essential
conserved H-N-R motif within the CRD that directly interacts
with bound galatose.[73] An important function of galectins, which
contain multiple CRDs, is intra-cell crosslinking of transmembrane
glycoproteins. Clustering of such proteins facilitates downstream
signalling, and galectins are again implicated mostly in inflammation
and the immune response.[74]
Unlike lectins, GBPs contain a binding groove that contacts several
GAG residues, allowing the repeating disaccharide pattern to be
recognised.[75] The majority of reported GBPs bind to heparan
sulphate (HS), which consists of variably sulphated disaccharides unit
of β/α‑1,4‑GlcNAc-α-1,4-GlcA/IdoA. Understanding HS specificity
is complex as different proteins have been shown to bind preferen-
tially to different HS oligosaccharides.[76] However, it is clear that
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complementarity between the sulphate and basic amino acid residues
is essential. Specificity is also achieved through IdoA, which is able to
access the 2S0 conformation.[77–79] This reorients the sulphate group,
creating a unique contact surface. This explains why dermatan
sulphate, which also contains IdoA, can bind to many HS-binding
proteins.[75] GBPs are implicated in a wide range of functions,
including cell adhesion, migration and inflammation. A particularly
well-studied system is the ternary complex formed by HS, thrombin
and anti-thrombin. Here HS acts as an anti-coagulant by increasing
anti-thrombin activity via both allostery and proximity.[80]
Specific binding of proteins to hyaluronan (HA), which is neither con-
jugated nor sulphated, has also been extensively studied. The HA-
binding Link domain is common to most of these proteins and is
structurally similar to the C-type lectin domain (Fig. 1.10 B).[81] It is
stabilised by two conserved disulphide bonds, and interacts with HA
mostly through specific recognition of the carboxylate and N-acetyl
groups. The Link module is found in many proteoglycans, which fa-
cilitates the formation of supramolecular aggregates that are essential
for tissue integrity.[82] Several cell-surface receptors containing the Link
domain have also been identified. Of these, CD44 is the primary HA
receptor in many cell types.[83] This allows HA to act as a signalling
molecule, and is implicated in cell adhesion and migration, as well as
survival and differentiation.
Figure 1.11: Examples of hyaluronan acting as a signalling molecule by interact-
ing with the cell-surface receptors CD44 (a) and RHAMM (b), both of which
induce downstream intracellular signalling. Taken from [84]
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1.1.3.2 Glycan Processing Enzymes
Glycan processing enzymes can be broadly separated into two cate-
gories: glycosyltransferases, which catalyse the formation of new gly-
cosidic bonds between a monosaccharide donor and a mono-, oligo- or
polymeric glycan chain, and glycosidases, which catalyse the removal
of monosaccharides from the glycan chain, either for trimming as part
of the glycan synthesis process, or for degradation.[85]
1.1.3.2.1 Glycosyltransferases Glycosyltransferases (GTs) are
known to be extremely specific for both their donor and acceptor
substrates, to the extent that, in most cases only the exact donor
and acceptor will be tolerated. For example, human blood group
B α-1,3 galactosyltransferase transfers a galactose residue to a
galactose-α-1,2-fucose disaccharide, but the reaction will not occur,
for example, for a galactose-α-2,6-sialic acid moiety.[85] Interestingly,
this same enzyme is capable of binding both UDP-galactose and
UDP-glucose in the donor substrate binding site, although only
UDP-galactose is active, highlighting that binding isn’t sufficient for
enzymatic activity.[86] The high specificity of GTs lead to the belief
that each GT was uniquely responsible for a single reaction in a
particular biosynthetic pathway. However, this is now known to not
be absolutely true, with a rare few GTs tolerating multiple substrates,
and in some cases there is redundancy in that multiple GTs can form
the same type of glycosidic linkage. For example, EXTL2 can use
either N-acteylglucosamine or N-acetylgalactosamine as a donor,[87]
whereas there is redundancy in fucosyltransferases (FUTs), with
α-1,3-linkages with fucose being catalysed by FUTs 3-7, 9 and 11.[88]
Regardless of these few exceptions, the rule holds true for the most
part, as exemplified by more than 500,000 known GT sequences,
spread over 106 sequence-distinct families at time of writing.[89]
Despite the large sequence variability between GT families, of all
the GTs whose 3-dimensional structures have been determined
experimentally, almost all fall into one of two structurally distinct
folds, GT-A or GT-B (Fig. 1.12).[90]
The GT-A type fold consists of two β-α-β motifs, each described as
Rossman-like, that are closely associated to form a single continuous
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β-sheet core. The GT-A fold is usually described as a single protein
domain, although some argue that this is not strictly true due to each
Rossman-like motif being separately responsible for either acceptor
or donor substrate binding. The majority of GT-A type GTs are
metal-ion dependant and coordinate a divalent metal cation through
an Asp-X-Asp (termed DXD) motif.
Figure 1.12: Cartoon representations of the the GT-A and GT-B folds. Left:
The crystal structure of Bacillus subtilis SpsA (PDB 1QGQ), a GT-A type en-
zyme. Right: The crystal structure of T4 bacteriophage β-glucosyltransferase
(PDB 1JG7). In both cases, α-helices (red), β-strands (yellow) and loops
(green) are highlighted.
The structure of GT-B type GTs also consists of two Rossman-like
folds, although here they are usually described as two separate do-
mains since they are normally separated by a longer, more flexible
linker. Each fold is again responsible for either acceptor or donor sub-
strate binding and the active site of GT-B GTs falls within the cleft
between the two Rossman-like domains.
GTs accept a nucleotide-sugar as a donor substrate and form a new gly-
cosidic bond between the donor sugar and the acceptor glycan through
cleavage of the nucleotide diphosphate, which is stabilised either by the
divalent metal cation in metal-dependant GTs or a positively charged
side chain. The mechanism is considered to be either inverting, in
which the anomeric configuration of the donor sugar is inverted as a
result of the reaction, or retaining, in which the anomeric configuration
of the donor sugar is persevered from reactant to product.[85,90]
The inverting mechanism follows an SN2 reaction in which the acceptor
initiates a backside attack of anomeric carbon of the sugar-nucleotide
donor (Fig. 1.14). A new glycosidic bond is formed between the
attacking hydroxyl of the acceptor and the donor anomeric carbon
on the pyranose face opposite the original glycosidic bond, and the
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nucleotide diphosphate is ejected, resulting in inversion of stereochem-
istry around the anomeric centre. A nearby aspartate or glutamate
residue usually acts as a base to deprotonate the attacking hydroxyl
during the reaction.
Figure 1.13: General mechanisms for inverting and retaining glycosyltrans-
ferases. Top: The inverting mechanism showing the backside attack of the
acceptor substrate leading to inversion of anomeric configuration. Bottom:
The retaining mechanism showing the formation of a donor-protein interme-
diate before attack by the acceptor substrate, leading to overall retention of
anomeric configuration. Used with permission of Dr.Brock.Schuman under the
Creative Commons license.
The retaining mechanism is not well understood, but is believed to
take place via a so-called double displacement mechanism. In such
mechanisms, the sugar of the donor substrate is first covalently linked
to the GT via nucleophilic attack by an aspartate or glutamate residue
(Fig. 1.14). This results in a protein-sugar intermediate in which the
stereochemistry is inverted. The acceptor substrate can then attack
the anomeric carbon of this intermediate, inverting the configuration
of the anomeric centre again, resulting in overall retention of anomeric
stereochemical configuration.
1.1.3.2.2 Glycosidases Glycosidases are responsible for the cleav-
age of glycosidic bonds, either by forming the free sugar product (gly-
coside hydrolases), a sugar-1-phosphate (glycoside phosphorylases) or
by β-elimination of a uronic acid residue (glycoside lyases). In nature,
glycosidases are used for a range of functions, including degradation/-
turnover of glycans and glycoconjugates, metabolism of sugars and
for processing of glycans during their biosynthesis. For example, it
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is common for the Glc3Man9GlcNAc2 glycan, which is conjugated to
an acceptor protein as a single unit, to be subsequently trimmed by
glycosidases in order to produce a wider range of complex glycans.[85]
Far more glycosidase structures have been solved compared to GTs,
due predominantly to their greater stability.[91] These structures have
revealed that there is far greater diversity in glycosidase structure
compared to GTs, with many different glycosidase folds being ob-
served. However, the majority of glycosidases follow a Koshland type
enzymatic mechanism, which is comparable to the reverse mechanism
described above for GTs. This mechanism can be either retaining or
inverting (Fig. 1.14), with the retaining mechanism forming a glycosyl-
protein intermediate, which is why GTs are expected to follow this
same double-displacement mechanism. For glycoside hydrolases the
attacking nucleophile is water, while inorganic phosphate is used in
glycoside phosphorylases.
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Figure 1.14: General mechanisms for inverting and retaining glycosidases. Top:
The inverting mechanism showing the backside attack of the nucleophile, in this
case water (glycoside hydrolase), leading to cleavage of the glycan and inversion
of anomeric configuration. Bottom: The retaining mechanism showing the
formation of a sugar-protein intermediate before attack by the nucleophile,
again water in this case, leading to cleavage of the glycan and overall retention
of anomeric configuration. Taken from [92]
Glycosidases are also of great interest for carbohydrate synthesis, both
in research and for industrial applications.[93,94] The glycosidase en-
zymatic mechanism is reversible and so can be used to form glyco-
sidic bonds, if an excess of the reaction products are present, al-
lowing for the facile synthesis of glycans in a specific and stereo-
controlled manner. Glycosidases are more attractive than GTs for
this role for a number of reasons. Firstly, glycosidases are usually
more stable and easier to isolate than GTs,[91] making production of
large quantities needed for industry more accessible. Furthermore, the
donor substrates of their reverse reaction, monosaccharides or sugar-
1-phosphates, are cheaper to produce than the donor substrates for
GTs (sugar-nucleotides).[95] Finally, glycosidases typically have a far
broader substrate specificity than GTs, allowing them to be useful
in a variety of reactions, including those involving unnatural con-
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jugates. For example, β-glycosidases have been used to synthesise
alkyl glycosides.[96] Furthermore, there are numerous accounts of di-
rected evolution and mutagenesis in order to modify the specificity of
glycosidases.[97–99]
1.2 Nuclear Magnetic Resonance
1.2.1 Spin and Energy Levels
Spin is an intrinsic angular momentum possessed by fundamental par-
ticles. This spin angular momentum is a vector (S) with magnitude:
(1) |S| = [S(S + 1)] 12ℏ
where S is the spin quantum number (which may have integer or half-
integer values) and ℏ is Planck’s constant (h) over 2pi. The direction
of S is quantised such that the z-component (Sz) value satisfies the
equation:
(2) Sz = msℏ
where ms is the spin magnetic quantum number, and may adopt 2S
+ 1 values between S and –S as shown below (Fig. 1.15):
(3) ms = S, S − 1, ...,−S + 1,−S
Figure 1.15: Quantisation of the spin angular momentum vector. As only the
z-component and the magnitude are known, the vector may lie anywhere along
the cone. If S = 12 (left) then ms = ±12 , whereas if S = 1 (right) then
ms = 1, 0,−1.
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Nucleons are spin-half particles (S = 12) and therefore their spin an-
gular momentum may have ms values of ± 12 . In a nucleus the spins of
the nucleons combine to give a total nuclear spin angular momentum
(I) described by the nuclear spin quantum number, I . Using the 2H
nucleus as an example, the two nucleons may both have the same ms
value (the spins are parallel) giving I = 1, or they may have opposite
ms values (the spins are antiparallel) giving I = 0 (Fig. 1.16). This
can be generalised with the following expression:
(4) I = |S1 − S2|, |S1 − S2|+ 1, ..., |S1 + S2|
Figure 1.16: Possible nuclear spin states of the 2H nucleus. A parallel ar-
rangement of spins (mS1 = mS2 = 12) gives I = 1, while an anti-parallel
arrangement (mS1 = 12 ,mS2 = 12) gives I = 0.
A similar approach may be taken for larger nuclei. In the case of 2H,
the I = 1 state is the ground state and the I = 0 is the excited state.
The energy difference between nuclear spin states is so large that,
ignoring exceptional circumstances, for any nucleus it may always be
assumed that it is in the ground nuclear spin state.[100] There is no
way to predict exactly what the ground nuclear spin state will be; this
must simply be determined experimentally. However the following
may be said: nuclei with an odd number of nucleons have a ground
state with half-integer spin (I = 12 , 32 , ...), while nuclei with an even
number of nucleons have a ground state with zero- or integer-spin
(I = 0, 1, ...).[101] The following discussion will concern only spin-half
nuclei (I = 12) as the techniques employed in this thesis employ only
such nuclei and quadrupolar nuclei (I > 12) suffer from additional
complexities such as quadrupolar coupling and relaxation.
The direction of the nuclear spin angular momentum is quantised as
for fundamental particles, giving a nuclear magnetic quantum number
(mI) with 2I + 1 possible values. As nuclei possess both charge and
an angular momentum they generate a magnetic moment (µ) defined
as:
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(5) µ = γI
where γ is the gyromagnetic ratio, an intrinsic property of a particular
nucleus type defined as the ratio of the nucleus’ magnetic moment to
its angular momentum. Most nuclei, such as 1H and 13C, possess a
positive gyromagnetic ratio. In such cases the nuclear spin and the
magnetic moment are parallel (Fig 1.17).[100] However a minority of
nuclei, including 15N, have a negative gyromagnetic ratio resulting in
antiparallel alignment of nuclear spin and magnetic moment.
Figure 1.17: Alignment of the nuclear magnetic moment and the nuclear spin
angular momentum in a magnetic field. The magnetic moment aligns with
an external magnetic field such that the α-state is the ground state for nuclei
with positive gyromagnetic ratios (left) and the β-state is the ground state for
nuclei with negative gyromagnetic ratios (right).
In the absence of an external magnetic field, where the z-axis is ar-
bitrary, there is no energetic preference for the nuclear spin angular
momentum to be orientated in a particular direction. Therefore the
mI = 12 and mI = −12 states are equally populated. However when
an external magnetic field is applied, now defined as the z-axis, the
degeneracy is lifted because the nuclear magnetic moment interacts
differently with the external magnetic field depending on its orienta-
tion. For nuclei, this phenomenon is known as the as the Nuclear
Zeeman Effect (Fig. 1.18).
31
Figure 1.18: The Nuclear Zeeman Effect. The energy of α and β states as a
function of external magnetic field strength. These states are split to a greater
extent in nuclei with large gyromagnetic ratios such as 1H (left) compared to
nuclei with small gyromagnetic ratios such as 15N (right).
A population difference is therefore generated with mI = 12 (or α-
state) as the ground state and mI = −12 (or β-state) as the excited
state, for nuclei with positive gyromagnetic ratios. It is important
here to emphasise the difference between nuclear spin states, which
involve a change in the value of mI , and nuclear magnetic states which
involve a change in the value of mI .[100] Nuclear magnetic resonance
spectroscopy concerns transitions between mI states, not changes in I .
The difference in energy between mI states is such that there is only
a very slight preference for the α-state. For example, for 1H nuclei in
a 500 MHz field (298 K) the population difference is only 1 in every
10,000, giving an inherently weak NMR signal. This is made worse by
nuclei with small gyromagnetic ratios, the states of which are split to
a lesser extent by the external magnetic field than nuclei with larger
gyromagnetic ratios.[102]
The energy of a particular nuclear magnetic state may be defined as:
(6) EmI = −mIℏγB0
where B0 is the magnitude of the external magnetic field in Tesla (T).
Therefore the difference in energy (when I = 12) between mI states
may be defined as:
(7) ∆E = γℏB0
If energy matching this difference is supplied to the system, a transi-
tion between the mI states may be induced. As practically this energy
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is delivered using a linearly oscillating magnetic field, it is often more
convenient to describe the difference in energy in terms of a frequency,
redefining the above equation as:
(8) ν0 = −γB02pi (in Hz) or ω0 = −γB0 (in rad s
-1)
where ν0 or ω0 are known as the Larmor frequency. The negative sign
is a consequence of Larmor precession, which is discussed later.
1.2.2 Chemical Shift
The above description predicts that every nucleus of the same type
would have the same Larmor frequency, whereas real NMR spectra
contain a multitude of peaks across a range of frequencies. For ex-
ample, a typical 1H spectrum is expected to contain a peak for each
1H nucleus in the molecule (ignoring chemical equivalence). To ex-
plain this, it is said that each nucleus has a chemical shift (δ in ppm),
which modifies the Larmor frequency of each individual nucleus with
the expression:[103]
(9) ν0 = −−γB0[1 + (δ × 10
−6)]
2pi or −γ[1 + (δ × 10
−6)]B0
The chemical shift arises because each individual nucleus within a
molecule actually experiences a slightly different magnetic field.[102] In
a molecule the nucleus is surrounded by electrons in molecular orbitals.
These electrons which also possess an angular momentum and charge
(but of opposite sign to the nucleus) generate a local magnetic field
opposed to the external field. The nucleus therefore experiences a
field weaker than the actual external field and is said to be shielded.
This effective field will be different for each nucleus depending on the
exact electronic structure surrounding it. The current generated from
electrons within orbitals, which in turn generates the opposing local
magnetic field described above, is known as a diamagnetic current. It
is also possible for electrons to generate a paramagnetic current, which
generates a magnetic field aligned with the external magnetic field. In
this case the nucleus experiences a magnetic field greater than the
external magnetic field and is deshielded. This paramagnetic current
is generated by movement of electrons between orbitals aligned in the
xy-plane, for example between px and py orbitals. This can occur when
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distortion causes orbital mixing; in the above example the px orbital
will have some py character and vice versa. The net chemical shift
of an individual nucleus is therefore the sum of local diamagnetic and
paramagnetic currents, magnetic fields generated around neighbouring
atoms and other sources that cause perturbation of the local electronic
environment, such as hydrogen bonding and charged moieties
1.2.3 The Vector Model
In the absence of an external magnetic field, the magnetic moments
of individual nuclei are oriented randomly such that the sample as a
whole has no net magnetic moment. When the sample is subjected to
an external magnetic field there is a slight preference for the magnetic
moments of the nuclei to align parallel to the magnetic field. Therefore
the vector sum of the magnetic moments of the whole sample gives a
bulk magnetisation parallel to the external magnetic field (convention-
ally the z-axis) known as the equilibrium magnetisation.[103] It should
be noted that formation of the equilibrium magnetisation is not in-
stantaneous; it develops over a finite period of time (Fig. 1.19). The
bulk magnetisation can be manipulated using weak, linearly oscillat-
ing magnetic fields. The interaction between this magnetic field and
the nuclei in the sample is greatest at the Larmor frequency. For the
1H nucleus within the magnetic field of a typical spectrometer, the Lar-
mor frequency is of the order of hundreds of MHz, which corresponds
to the radiofrequency (RF) region of the electromagnetic spectrum.
For this reason, these weak magnetic fields are commonly termed RF
fields. The most common manipulation of the bulk magnetisation is
the 90x° pulse, which applies a RF field along the x-axis for a given
amount of time such that the bulk magnetisation is rotated 90° from
the z-axis. Due to chemical shift, the RF field cannot be precisely on
resonance with every nucleus in the sample. Therefore in a 90° pulse
the magnetisation of nuclei slightly off-resonance with the pulse will
not be fully on the xy-plane (transverse), but the effect of this is usu-
ally negligible. In some cases this effect may be utilised to selectively
excite certain regions of the spectrum by intentionally choosing the
strength and frequency of the RF field such that only specific reso-
nances are effectively manipulated by the field.[103]
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Figure 1.19: The bulk magnetisation. In a sample each nuclear magnetic
moment is aligned randomly such that the bulk magnetisation is zero. Applying
an external magnetic field gives a preference for the magnetic moments to be
aligned with the magnetic field such that, after a period of time, an equilibrium
magnetisation develops aligned parallel to the external magnetic field.
Immediately following the 90x° pulse the bulk magnetisation is aligned
along the y-axis but then begins to precess at the Larmor frequency as
a consequence of a torque generated as a product of the nuclear mag-
netic moments and the external magnetic field. As mentioned earlier,
the Larmor frequency is defined as being negative with respect to the
gyromagnetic ratio. This is because nuclei with a positive gyromag-
netic ratio precess in a clockwise direction about the z-axis, which in
the axis system used corresponds to a negative rotation.[103] The pre-
cession of the bulk magnetisation about the z-axis is able to induce a
current in a coil aligned along the xy-plane. The signal generated in
this manner is known as the free induction decay (FID), due to the
decay back to equilibrium magnetisation caused by relaxation. This
is the essence of the most basic of NMR experiments, known as pulse
acquire. A sample is subjected to an external magnetic field and af-
ter a finite period of time reaches an equilibrium magnetisation. The
FID resulting from a 90° pulse is then recorded, generating a spectrum
with peaks at the Larmor frequency of each nucleus in the sample (Fig.
1.20).
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Figure 1.20: Diagram showing the origin of the NMR spectrum. Precession of
the bulk magnetisation in the transverse plane induces a signal that is recorded
by the spectrometer in the time domain (FID). The Fourier transform (FT) of
the FID leads to the spectrum in the frequency domain, in which each peak
corresponds to a frequency deconvoluted from the FID. Taken from [104]
Another common pulse is the 180° pulse which is named as such be-
cause it will flip the equilibrium magnetisation through an angle of
180° to be aligned along the -z-axis. However, when the bulk magneti-
sation is aligned in the xy-plane, the 180°x pulse has the effect of a
reflection in the xz-plane. The 180° pulse operates in the same manner
as the 90° pulse except that the RF field is left on for twice as long. In
fact, the 90° pulse is calibrated by finding the pulse length that gives
no FID. This corresponds to a 180° pulse, as complete inversion gives
no transverse magnetisation, so the 90° pulse must be half this time.
1.2.4 The Rotating Frame
The above description uses a frame of reference known as the labora-
tory frame; the external observer ‘sees’ the spins precessing as they
do in reality. However it simplifies the mathematics of more complex
experiments if a rotating frame is considered, as the time dependence
of the RF fields is removed.[102] Here the frame of reference rotates
about the z-axis at the frequency of the RF field (ωrf). The offset (Ω)
is defined as:
(10) Ω = ω0 − ωrf
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and gives the apparent frequency of precession for a given nucleus. Nu-
clei that are completely on resonance with the RF field will therefore
appear static. When the gyromagnetic ratio is positive, nuclei that
precess faster than ωrf appear to rotate clockwise, while nuclei that
precess slower appear to rotate anticlockwise.
1.2.5 Relaxation
Relaxation is the process in which the bulk magnetisation returns to
its equilibrium position, either following manipulation or on first in-
troduction of the sample into the external magnetic field. This can be
separated into two separate processes: longitudinal relaxation, which
describes the return of the z-component of the bulk magnetisation
to its equilibrium position, and transverse relaxation, which describes
the loss of coherence in the xy-plane such that, at equilibrium, it sums
to zero. Both of these processes are dependent on fluctuations in the
local magnetic field. For spin-half nuclei, the changes in the local mag-
netic field are dominated by dipolar interactions and chemical shift
anisotropy.[101]
The dipole-dipole mechanism is the interaction of the magnetic field of
one nucleus with the magnetic field of another. The interaction has an
inverse-cube distance dependence and is dependent on the gyromag-
netic ratios of the interacting nuclei. As a result, dipolar interactions
rarely take place over more than a few Ångstroms. The strength of
the interaction is also dependent on the angle between the two field
vectors, meaning that this dipolar coupling changes as the molecule
tumbles in solution. The chemical shift was previously described as
the nucleus experiencing a field different from the external magnetic
field due to shielding from the surrounding electrons. However, as
alluded to above, the magnitude of this shielding is dependent on
the relative orientations of the nucleus and the surrounding electrons.
Therefore, the chemical shift of a nucleus changes as the orientation
of the molecule within the sample changes. This is known as chemical
shift anisotropy. The effect of this is not observed in solution-state
spectra due to averaging by fast molecular tumbling. However, it still
provides a mechanism for relaxation. From the above description, it
is clear that the molecular motions present in a sample have a direct
impact on relaxation. This motion is typically described by the cor-
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relation time (τc), which is defined as the average amount of time
taken for a molecule in a sample to rotate through an angle of one ra-
dian. The correlation time is affected by factors such as temperature
and viscosity, but is principally dependent on molecular weight; the
larger the molecule, the longer the correlation time. The issue with
describing motion using the correlation time is that it only describes
the average amount of motion present. It would be much more useful
to be able to describe how this motion is distributed across different
timescales.[103] This can be achieved using the spectral density function
(J(ω)), which describes the relative intensity of motion as a function
of frequency:
(11) J(ω) = B¯2loc
2τc
1 + ω2τ 2c
A plot of J(ω) against ω takes the form of a Lorentzian curve with a
maximum at J(0) (Fig. 1.21). An important feature of J(ω) is that
its integral is independent of the correlation time. In other words, the
area under the plot remains constant for all values of τc. Therefore,
long correlation times correspond to a spectral density function with
a large value of J(0) that quickly decays with increasing frequency.
However, short correlation times will give a plot with a smaller value
of J(0) but that extends into higher frequencies.
Figure 1.21: The spectral density function plotted for long (red) and short
(blue) values of τc. Frequencies analysed by reduced spectral density analysis
are marked.
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1.2.5.1 Longitudinal Relaxation
Longitudinal relaxation is the process that returns the z-component
of the bulk magnetisation to its equilibrium position, which requires
nuclei to lose energy to their surroundings. For longitudinal relaxation
to occur, the spectral density function must therefore have a compo-
nent of motion at the Larmor frequency, in order to induce transitions
between the two nuclear magnetic states. The longitudinal relaxation
time constant (T1) is therefore related to the spectral density function
as follows:[102]
(12) 1
T1
= γ2⟨B2⟩J(ω0)
Analysis of the spectral density equation shows that J(ω0) is max-
imised, making T1 relaxation most rapid, when τc =
1
ω0
(Fig. 1.22).
Rearranging this to ω0τc = 1 allows two motional regimes to be de-
fined. Fast motion (or the extreme narrowing limit) is defined as
ω0τc << 1. In this regime analysis of the spectral density function
equation shows that J(ω0) = 2τc, and therefore J(ω0) increases with
longer correlation times up to a maximum at τc =
1
ω0
. The slow
motion regime (or spin diffusion limit) is defined as ω0τc >> 1 and
analysis of the spectral density function equation gives J(ω0) =
J(0)
ω20τ
2
c
,
meaning at the spin diffusion limit J(ω0) increases with shorter values
of τc.
Figure 1.22: A plot of J(ω0) as a function of correlation time (left) shows a
maximum at τc =
1
ω0
. As T1 relaxation is dependent on the amount of motion
at the Larmor frequency, it is also shortest at τc =
1
ω0
(right, taken from [105]).
The plot also shows how T2 becomes more rapid with longer correlation times.
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A common method for measuring the longitudinal relaxation time is
inversion recovery (Fig. 1.23). First the equilibrium magnetisation
is inverted using a 180° pulse such that it points along the –z-axis.
During the following delay period (τ ) the magnetisation begins to relax
back to equilibrium. A 90° pulse is then applied and the resulting FID
is recorded. The experiment is performed multiple times with varying
values of τ .
Figure 1.23: The inversion recovery pulse sequence. The magnetisation is first
inverted by a 180° pulse (blank). After a delay (τ), a 90° pulse is applied
(filled) and the resulting FID is recorded.
If τ is short then the bulk magnetisation will still point along the –z-
axis immediately before the 90° pulse. In this case, the magnetisation
is rotated towards the -y-axis, and the peaks in the resulting spec-
trum will be negative (Fig. 1.24). As τ increases, the magnitude of
the bulk-magnetisation decreases to zero, giving negative spectra with
decreasing intensities. If τ is extended further, the bulk magnetisation
will begin to increase along the +z-axis up to the equilibrium magneti-
sation. In these cases the 90° pulse rotates the magnetisation along
the y-axis, giving positive spectra with increasing peak intensities.
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Figure 1.24: Relaxation recovery at increasing delay times (t). As t increases,
the negative peak intensities decrease to zero before becoming positive.
Assuming that relaxation is exponential, the magnetisation at a given
time (Mz(τ)) can be expressed as:
(13) Mz(τ) = M0(1− 2e
−τ
T1 )
where M0 is the equilibrium magnetisation, τ is the time between the
180° and 90° pulses, and T1 is the longitudinal relaxation constant.
1.2.5.2 Transverse Relaxation
Transverse (T2) relaxation is caused by loss of coherence in the trans-
verse plane, meaning the individual spins precess at slightly different
rates such that eventually the magnetisation in the xy-plane sums to
zero. T2 relaxation is responsible for line broadening in NMR spectra
and is related to spectral linewidth as shown:
(14) ∆ν 1
2
= 1
piT2
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where ∆ν 1
2
is linewidth at half height.
The above description for longitudinal relaxation also contributes to
the transverse relaxation, as fields oscillating at the Larmor frequency
can manipulate the orientation of the magnetisation.[103] The second
contribution comes from the fact that each nucleus will precess at
a slightly different rate due to experiencing different local magnetic
fields. This contribution is maximised with slower molecular motion as
each spin will experience a different magnetic field for longer, causing
a rapid loss of coherence.[101] When a molecule tumbles quickly, the
local magnetic field changes more rapidly and its effect is averaged
out, reducing the effectiveness of this contribution (Fig. 1.22). The
transverse relaxation time constant can therefore be described as:
(15) 1
T2
= 12γ
2⟨B2⟩J(ω0) + 12γ
2⟨B2⟩J(0)
As J(0) is much greater than J(ω0) (Fig. 1.21), the contribution from
slow motion dominates T2. Therefore it is expected that T2 will always
become shorter with longer correlation times (Fig. 1.22).
The observed transverse relaxation (T ∗2 ) is due to both external field
inhomogeneities and molecular motion. However, the true transverse
relaxation is only due to molecular motion. The two processes can be
separated using a spin echo pulse sequence (Fig. 1.25). This pulse
sequence begins with a 90°x pulse followed by a delay of time, τ . Dur-
ing the delay some coherence will be lost due to spins precessing at
slightly different rates (Fig. 1.26). The use of a 180°x pulse causes the
magnetisation to be reflected in the xz-plane. After a second delay,
any coherence lost due to constant inhomogeneities (external magnetic
field) will be refocused. However, random loss of coherence (molecular
motion) will not be, so the observed loss in intensity of the FID must
be from T2.
Figure 1.25: The spin-echo pulse sequence. After the 90° pulse (filled), the
FID decays with a time constant, T ∗2 (red, solid). After a delay (τ), a 180°
pulse is applied. After a total time of 2τ , some coherence is refocused. The
lost intensity is from T2 (red, dashed).
42
Figure 1.26: Refocusing of magnetisation in the xy-plane using a spin-echo
pulse. Over a period of time (2τ) the magnetisation fans out due to loss of
coherence. The 180° pulse flips the magnetisation in the xz-plane, and after
2τ the magnetisation is refocused.
The intensity of a peak in the spectrum following the spin echo (I(2τ))
may be expressed as:
(16) I(2τ) = I(0)exp−2τ
T2
where I(0) is the intensity when τ = 0.[102]
1.2.5.3 The Nuclear Overhauser Effect (NOE)
In a homonuclear system containing two spins (I and S), there are
four energy levels with a total of six possible relaxation pathways (Fig.
1.27). Four of these pathways are single quantum transitions (W1)
that correspond to self relaxation as described above for longitudinal
relaxation. These transitions are therefore dependent on the spectral
density at the Larmor frequency of that spin:
(17) W S1 =
3
40b
2J(ω0,I)
(18) W I1 =
3
40b
2J(ω0,S)
where b = µ0γIγSℏ4pir3
In addition to these self-relaxation mechanisms, it is also possible for
cross relaxation to occur, in which the relaxation of one spin perturbs
the energy state of the spin it is coupled to. The double quantum
transition (W I,S2 ) between αIαS and βIβS corresponds to an energy
difference of ω0,I + ω0,S. Therefore, according to the spectral density
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this rate of this transition is dependent on the spectral density at
ω0,I + ω0,S (Eqn. 19). The zero quantum transition (W I,S0 ) between
αIβS and βIαS corresponds to an energy difference of ω0,I − ω0,S.
Therefore, according to the spectral density this rate of this transition
is dependent on the spectral density at ω0,I − ω0,S (Eqn. 20).
(19) W2 =
3
10b
2J(ω0,I + ω0,S)
(20) W0 =
1
20b
2J(ω0,I − ω0,S)
Figure 1.27: The energy level diagram for two dipole-dipole coupled spins,
I and S, showing allowed transitions (top). Zero-quantum transitions (W0)
result in a reduction in the population difference of I (middle), leading to a
negative enhancement. Double quantum transitions (W2) result in an increase
in the population difference of I (bottom), leading to a positive enhancement.
In the W2 transition, relaxation of the S-spin also causes relaxation
of the I-spin whereas in the W0 transition, relaxation of the S-spin
(β→α) causes excitation of the I-spin (α→β). To understand which
transition will dominate in a given system, it is necessary to define the
rate constants for self relaxation(RIz and RSz ) and for cross relaxation
(σI,S):
(21) RIz = 2W I1 +W2 +W0
(22) RSz = 2W S1 +W2 +W0
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(23) σI,S = W2 −W0
Substituting in the definitions of the single- (Eqns. 17 - 18), double-
(Eqn. 19) and zero-quantum (Eqn. 20) rates constants gives:
(24) RIz = b2[
3
20J(ω0,I) +
3
10J(ω0,I + ω0,S) +
1
20J(ω0,I − ω0,S)]
(25) RSz = b2[
3
20J(ω0,S) +
3
10J(ω0,I + ω0,S) +
1
20J(ω0,I − ω0,S)]
(26) σI,S = b2[
3
10J(ω0,I + ω0,S)−
1
20J(ω0,I − ω0,S)]
From here, it is clear that self-relaxation will always dominate since
all the single, double and zero-quantum pathways contribute in an
additive manner to the rate constant. Therefore the effect of cross
relaxation is not usually directly observable unless conditions are set
up to do so. Such experiments will be discussed later.
The cross relaxation rate is dependent on the difference between the
double- and zero-quantum transition rates, such that the cross relax-
ation rate is positive where W2 dominates and negative where W0
dominates (Eqns. 23 and 26). From their definitions, clearly W2 will
dominate when a significant fraction of the spectral density can be
found at ω0,I + ω0,S - in other words fast motion or a short value of
τc, whereas W0 will dominate when a more significant fraction of the
spectral density is at ω0,I−ω0,S - in other words slow motion or a large
value of τc. Clearly the cross-over point will occur when W2 = W0.
Although the exact rate of cross relaxation is dependent on a number
of factors, including field strength, it is typically expected that small
organic molecules will exhibit a positive cross-relaxation rate, whereas
macromolecules such as proteins will have a negative cross-relaxation
rate (Fig. 1.28).
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Figure 1.28: The dependency on the NOE enhancement on correlation time
(dashed). The enhancement is positive for short correlation times and becomes
negative with longer correlation times. Transient rotating frame NOE (blue)
and rotating frame NOE (red) are also shown
Although the above equations describe the rate constants for self-
relaxation and cross-relaxation, how these rate constants affect the
actual longitudinal magnetisation of each spin has not yet been dis-
cussed. For this, the Solomon equations are described below:[106]
(27) dIIz
dt
= −RIz(IIz − I0Iz)− σIS(ISz − I0Sz)
(28) dISz
dt
= −RSz (ISz − I0Sz)− σIS(IIz − I0Iz)
As one might expect, the rate of change in the longitudinal magneti-
sation of each spin is proportional to its own self-relaxation rate con-
stant, given that the spin itself has been perturbed from equilibrium
(Iz ̸= I0z ). In addition to this, the second term states that the rate of
change in the longitudinal magnetisation in the first spin (I) is depen-
dent on the cross-relaxation rate constant between the two spins (σI,S)
given that the second spin (S) has been perturbed from equilibrium.
The fact that cross-relaxation has an effect on the longitudinal mag-
netisation as described above is known as the Nuclear Overhauser
Effect (NOE), and experiments can be designed such that such an
effect can be detected.
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1.2.5.3.1 Transient NOE The transient NOE experiment
requires two separate pulse sequences. The first starts by selectively
inverting just one resonance with a selective 180° pulse, followed by a
delay(τ ) (Fig. 1.29). During this time, the single resonance relaxes by
both self- and cross-relaxation processes - the latter of which perturbs
other spins close in space from their equilibrium magnetisations. A
non-selective 90° pulse then prepares all spins for detection. The
second pulse sequence is simply a reference spectrum generated from
a single 90° pulse. Subtracting the reference spectrum from the first
experiment produces a difference spectrum in which any observed
intensity must be from cross-relaxation. Signals in the difference
spectrum may be positive or negative depending on the sign of the
cross-relaxation.
Figure 1.29: The pulse sequence for the transient NOE experiment. A single
resonance is inverted with a selective 180° pulse. After a delay period (τm)
non-selective 90° pulse is applied prior to detection.
If I is the spin that is inverted and S is spin coupled through dipo-
lar interaction, the experiment can be described using an initial rate
approximation:
(29) dISz
dt
(init) = −RSz (I0Sz − ISz)− σIS(−I0Iz − IIz)
(30) dISz
dt
(init) = 2σISI0Iz
This can be integrated to give:
(31) ISz(t) = 2σISI0Izt+ c
(32) ISz(t) = 2σISI0Izt+ I0Sz
The constant of integration is known here since at t = 0 the z-
magnetisation of spin-S (ISz(0)) will be its equilibrium value (I0Sz).
Since the 90° pulse will convert all the z-magnetisation after the delay
(τ ) into observable signal, the observed signal is therefore proportional
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to:
(33) ISz(τ) = 2σISI0Izτ + I0Sz
whereas in the reference spectrum the observed signal will simply be
proportional to I0Sz. Therefore, overall the so called NOE enhancement
(η) can be described as:
(34) η = (2δISI0Izτ + I0Sz)− I0Sz = 2σISI0Izτ
Therefore, the cross-relaxation rate constant can be calculated by mea-
suring the the NOE enhancement directly. Since the cross-relaxation
is dependent on the distance between the two spins, such measure-
ments are useful in structural calculations in order to produce distance
restraints.
1.2.5.3.2 Steady State NOE The scheme for the steady state
NOE experiment is similar to that of the transient NOE, except that
the inverting 180° pulse is replaced with a continuous low power satu-
rating pulse. This pulse is still selective for a single resonance (I), but
instead of inverting the z-magnetisation, the population is equalised
such that there is no net magnetisation. Since the self-relaxation
pathway is inaccessible due to the constant saturating pulse keeping
equalised populations, the only available relaxation pathway is via
cross relaxation to a nearby spin (S). The z-magnetisation of the S-
spin will continue to change until eventually it reaches a steady state
in which the cross-relaxation rate from the I-spin equals that of its
self-relaxation. In this case, the Solomon equation for spin S is:
(35) 0 = −RSz (ISz,SS − I0Sz)− σIS(−I0Iz)
(36) ISz,SS =
σIS
RSz
I0Iz + I0Sz
Subtracting the reference spectrum from the saturated spectrum gives
an NOE enhancement described as:
(37) ηSS =
σIS
RSz
One disadvantage of using the steady state NOE is that the observed
enhancement isn’t due only to the cross-relaxation but also due to the
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self-relaxation. Therefore this approach can only be treated qualita-
tively, but it does have the advantage that theoretically the maximum
enhancement should be larger than that of the transient NOE, since
the irradiated spin can only relax via cross-relaxation.
1.2.5.3.3 Truncated Driven NOE The steady state NOE de-
scribed above depends heavily on the self relaxation rate (Rz) of each
proton and so cannot be used to directly measure distances. Con-
versely, the transient NOE is typically too weak to accurately measure
distances with practical acquisition times.
A solution to this is to apply the saturating pulse utilised in the steady
state experiment for a shorter period of time (typically 100s of ms),
such that the initial rate of NOE build up is measured instead if the
equilibrium value. This approach is known as the truncated driven
NOE (TOE),[107] and is useful since, during the initial build up of NOE,
the cross-relaxation rate (σIS) dominates over the self relaxation rate
(Rz).
Since the self relaxation rate is not significant during the initial build
up of the NOE, internuclear distances can be extracted with reason-
able accuracy by calibrating using a TOE value between two nuclei
of known distance (covalently bound). The TOE is advantageous
over the transient NOE in that experimental times are significantly
lowered.[107] The TOE is also the basis of the STD NMR technique
described below.
1.2.6 Saturation Transfer Difference NMR
spectroscopy
Saturation Transfer Difference (STD) NMR spectroscopy is mostly
employed as a ligand-based NMR experiment for detecting the in-
teraction between a small molecule ligand (e.g. carbohydrate) and a
macromolecular receptor (e.g. protein), although it also has other ap-
plications, such as detecting the kinetics of internal rotations in small
molecules.[108] It is a NOE-based technique that relies on the detection
of an intermolecular transfer of magnetisation from a saturated recep-
tor molecule onto a small molecule ligand. To understand this, the
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thermodynamics and kinetics of binding must first be described.
1.2.6.1 Thermodynamics and Kinetics of Binding
The simplest description of a bimolecular association process is the
one-site model, in which there is a reversible exchange between the
free macromolecule (M) and ligand (L) and the complex of the two
(ML). The model assumes no other intermediate species, such as re-
arrangement of either molecule upon binding. The rate of association
and dissociation can be described by the kinetic rate constants kon
and koff respectively.
(38) M + L kon−−⇀↽−
koff
ML
Equilibrium is achieved when rate of association of the two individual
species is equal to the rate of dissociation of the complex. The rela-
tive proportions of free and bound species present at equilibrium are
dependent on the affinity of the two species for forming the complex -
that is, for species with high affinity for one another, the complex will
be present in greater proportion at equilibrium compared to species
with lower affinity for one another. This can be described by the molar
dissociation constant:
(39) kon[M ][L] = koff [ML]
(40) Kd =
[M ][L]
[ML] =
koff
kon
A smaller value for Kd indicates a higher affinity complex. Therefore
it is clear to see that smaller values of koff and larger values of kon con-
tribute to a higher affinity complex. This is because koff is inversely
proportional to the residence time of the ligand - that is how long the
ligand remains bound to the macromolecule - and kon is proportional
to the probability of forming the complex. Usually kon is assumed to
be limited by diffusion, in which case it can be assumed to be of the
order of 108 M-1 s-1.
Alternatively the interaction can be described by the fraction of bound
macromolecule present at equilibrium:
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(41) fMB =
[ML]
[M ] + [ML] =
[L]
[L] +Kd
where the final term in the expression is derived from Eqns. 39 and
40, and corresponds to the Langmuir binding isotherm (Fig. 1.30).
Here it is clear that the fractional occupancy of the macromolecule
can be increased with increasing ligand concentration. The equation
follows a hyperbolic function in which the fraction of bound macro-
molecule initially increases linearly with ligand concentration in the
limit of [L] << Kd and then asymptotically approaches fully satu-
rated macromolecule as [L] >> Kd.
Figure 1.30: Representative Langmuir binding isotherms for two ligands, one
with lower affinity (blue, Kd,1) amd one with higher affinity (red, Kd,2). The
dissociation constant (Kd) values correspond to ligand concentrations at which
the macromolecule is 50% saturated with bound ligand at equilibrium.
1.2.6.2 The STD NMR experiment
The STD NMR experiment is essentially equivalent to the truncated
driven NOE (TOE) experiment but here the saturating pulse is applied
selectively to the macromolecule. Since this selective pulse can only
‘hit’ a narrow range of resonances, only small subset of macromolecule
spins are directly irradiated. However, for large molecules that tumble
slowly in solution, cross-relaxation is very efficient and spins that are
nearby to those that are directly irradiated are also rapidly saturated.
Importantly, it is possible for the indirectly saturated spins - those
that become saturated by cross-relaxation of the directly irradiated
spins - to produce a so-called relayed NOE, in which they too can
relax by cross-relaxation with there neighbours. By this relay of cross-
relaxation, all of the spins of the macromolecule are rapidly saturated.
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This process is know as spin diffusion.
Figure 1.31: Cartoon showing the process of spin diffusion in STD NMR. Cer-
tain macromolecule protons are directly saturated by the saturating pulse (dark
blue). This saturation is transferred (red arrows) to other protons that are
close in space (light blue) and eventually to the bound ligand (orange). Ligand
protons in closer proximity to the surface of the macromolecule receive more
saturation (darker).
The macromolecule-ligand complex is formed spontaneously between
the saturated macromolecule and the unperturbed ligand, allowing
for saturation to be transferred intermolecularly to the ligand by in-
termolecular spin diffusion (Fig. 1.32). This is made possible since,
in the bound state, the NMR parameters of the ligand (such as cor-
relation time) become those of a macromolecule. Therefore, cross-
relaxation of ligand spins with macromolecule spins within the bound
state is very effective. However, it is necessary for the ligand to then
dissociate into the free state in order to be detectable as the efficient
transverse relaxation (and the low concentration of the complex) pre-
cludes the observation of the ligand signals in the bound state. Cross-
relaxation in rapidly tumbling small-molecules is relatively ineffective
and so the saturated spins can remain saturated for the duration of
the experiment. The constant exchange of ligand between the free
and the bound state allows for bulk saturation of the ligand, which re-
sults in an observable reduction in ligand peak intensity. As with the
steady state NOE experiment, subtraction of the saturated spectrum
(Isat) from a reference spectrum (I0) results in a difference spectrum
(Idiff) in which the intensity of the ligand peaks are proportional to
the amount of saturation transferred from the macromolecule to that
ligand resonance.
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Figure 1.32: Diagram showing the principle of STD NMR spectroscopy. The
receptor is selectively saturated, which can transfer magnetisation to any bound
ligand through an intermolecular NOE. Ligand protons in closest proximity to
the receptor surface receive the most saturation. This saturation accumulates
in the bulk free ligand which is detected in the STD NMR difference spectrum.
Taken from [109]
(42) Idiff = I0 − Isat
(43) STD(%) = Idiff
I0
× 100
One important consideration for STD NMR spectroscopy is that the
exchange between the free and the bound states must be fast - that
is the residence time of the ligand within the bound state must be
much shorter than the relaxation time of that ligand proton within the
bound state. Otherwise the magnetisation transferred to the ligand
from the macromolecule would relax before it is able to accumulate
in solution. For macromolecules, T1 is typically relatively long (~1
s) but T2 may be expected to be as short as 1-10 ms (Fig. 1.22).
Typically then one might expect that the high affinity limit would
be for complexes with dissociation constants in the micromolar range,
giving a residence time of approximately 0.1-10 ms, assuming diffusion
controlled association.
Furthermore, the ligand should be in a large excess over the macro-
molecule. Firstly, in the fast exchange limit, the average NMR prop-
erties of the bulk ligand (⟨QL⟩) can be assumed to be the weighted
sum of its properties in the free (QLf ) and the bound state QLb :
(44) ⟨Q⟩ = fLf QLf + fLb QLb
Therefore, by maintaining a large ligand excess, the bulk ligand be-
haves as a small molecule and so benefits from sharp peaks and limited
spin diffusion. In addition, the large excess ensures that the macro-
molecule binding sites are fully saturated with ligand, ensuring the
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maximum amount of signal can be gained from the experiment. Fi-
nally, the large excess minimises the chance of ligand rebinding mean-
ing that most likely only unperturbed ligand will bind to the macro-
molecule, allowing for more accumulation of saturation on the bulk
ligand.[110]
1.2.6.3 Binding epitope mapping by STD NMR
The presence of peaks in the STD NMR difference spectrum is in-
dicative of binding of the small molecule ligand to the macromolecule,
assuming that the small ligand is not directly irradiated by the sat-
urating pulse. This is commonly utilised in fragment screening as it
provides a relatively facile method for detecting the binding of low
affinity fragments to their targets, which may not be accessible to
other commonly used techniques[111] (Fig. 1.33).
Figure 1.33: Reference (top) and STD NMR difference spectra of glucose
(red) and tryptophan (blue) in the presence of bovine serum albumin (BSA).
The difference spectrum contains only tryptophan resonances showing that
tryptophan binds to BSA, whereas glucose does not.
However, an important advantage of STD NMR spectroscopy is that
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since the strength of the dipolar interaction is dependent on the dis-
tance between the two spins, those ligand protons that are in closest
proximity to the macromolecule surface receive the most saturation
and so would be expected to have the strongest peaks in the STD
NMR difference spectrum. Unfortunately, the magnitude of the STD
intensity cannot be directly correlated with distances because, as with
the steady state NOE, the observed cross-relaxation rate is also depen-
dent on the self-relaxation term, as well as the exchange between the
free and the bound states. Nevertheless, mapping of the relative STD
intensities onto a structure of the small-molecule can give important
information about the orientation of the small molecule within the
binding site, since the most intense STD values should be in close
proximity to the macromolecule surface - as an example see Fig. 1.34.
Figure 1.34: Example of binding epitope mapping using Man-α(1,2)-Man-α-
O(CH2)NH~ in the presence of anti-HIV-1 human antibody 2G12. (Left) STD
build up curves are constructed by measuring the STD intensity for each proton
over a number of saturation times. Fitting to this data gives the initial growth
rate, which is normalised and mapped onto a structure of the ligand (Right).
Taken from the Doctoral Thesis of Pedro M. Enríquez-Navas (University of
Seville, 2011).
In practice, the ‘initial growth rates’ method is usually used.[112] Using
this method the STD intensity of each ligand proton is measured for
a range of saturation times (tsat). The resulting ‘build-up curve’ takes
the form of a monoexponential curve that plateaus at a maximum
STD value (STDmax). This is because at longer saturation times the
self-relaxation will be such that no more saturation can accumulate
by cross-relaxation. The build-up curve can be modelled using the
equation:
(45) STD(tsat) = STDmax(1− exp(−ksattsat))
where ksat is the rate constant for saturation transfer. The curve can
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be fitted to the experimental data by using STDmax and ksat as fitting
parameters. Initially the STD intensity increases linearly according
to the rate of saturation transfer. Therefore the initial growth rate
(STD0) can be defined as:
(46) STD0 = limtsat→0
δSTD(tsat)
δtsat
= STDmaxksat
The initial growth rate is then determined for each ligand proton.
These rates are then normalised against the largest growth rate be-
fore mapping onto a structure of the ligand (Fig. 1.34).
The main advantage of the initial growth rates method is that it ef-
fectively eliminates the effect of self-relaxation on the observed value.
This is important because protons with slower longitudinal relaxation
times (e.g. typically aromatic protons) accumulate magnetisation more
effectively than those with faster relaxation times. Therefore, the ob-
served STD intensity at longer saturation times is significantly skewed
by self-relaxation and may lead to misinterpretation of the binding epi-
tope map.
1.3 Molecular Modelling
NMR spectroscopy experiments do not directly produce a set of co-
ordinates that generate a 3D molecular model of the protein-ligand
complex. In NMR spectroscopy intensities are measured, and those
intensities must be interpreted in the context of a 3D model of the
macromolecule and the ligand that matches the experimental obser-
vations. In this case we resort to molecular modelling, where we can
generate different models of the molecules based on energetic grounds,
and combine them with the experimental NMR observations to gener-
ate NMR-derived structures. Even if a crystal structure is available for
the complex, molecular modelling is typically needed (in the form of
molecular dynamics) to give flexibility to the structure to better match
the experimental NMR observables. In the last section of this intro-
duction the most commonly used methods for modelling biomolecular
structures will be discussed.
56
1.3.1 Molecular Mechanics
Molecular mechanics (MM) is the application of classical mechanics
to describing and predicting the chemical and physical properties of
molecular systems, usually utilising the power of modern computa-
tional systems to perform the calculations. Often these are atomistic
models of the system in question in which each atom is modelled by
virtual ‘particle’ and the relationship between each particle and an-
other is described by a set of terms that model properties such as
atomic radii, bonds and charges (which will be discussed in depth
later). The number of particles in a system can vary considerably de-
pending on the nature of that system and the particular MM method
being utilised, but, for example, an atomistic MM model of a protein
can easily exceed 10,000’s particles. This can make modelling very
computationally demanding and limits the size of system that can
reasonably be studied, as well as the timescale (e.g. molecular dynam-
ics). In response to this, further simplified models (atomistic classical
mechanics in itself is already a simplified approximation of the true
system) have been developed that hope to extend both the size and
time dimensions of molecular mechanics models. These include course
graining,[113] in which the virtual particles instead represent multiple
atoms, or indeed entire molecules or groups of molecules, or simplified
descriptions of the particle interactions, such as only considering the
Lennard-Jones or torsional interactions.[114] Of course, these also have
their limitations, since it becomes increasingly difficult to accurately
represent a complicated system with fewer parameters.
1.3.1.1 Molecular Mechanics Forcefields
The total energy of a molecular mechanics (MM) model system can
be described as the sum of all the terms that describe the interaction
of a particle with the other particles in the system, for all particles of
the system. Over time many different MM forcefields have been devel-
oped, but they can typically be termed generic or specific forcefields,
meaning that they are designed to either work for as broad a range of
molecules as possible or a particular class of molecule respectively. Of
course, with the generalisation of a forcefield comes a penalty in accu-
racy since the classical nature of MM cannot inherently describe effects
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of a quantum nature. However, specific forcefields can be optimised
to reproduce such quantum behaviours. A good example would be
GLYCAM[115] a carbohydrate specific parameter set based on the AM-
BER forcefield[116] The conformation of a carbohydrate ring is heavily
influenced by the anomeric effect, which of course can be explained by
quantum mechanics. Therefore, generic forcefields cannot accurately
reproduce the known ring conformation of many carbohydrates, but
GLYCAM is optimised to do so. The drawback to this is that the spe-
cific GLYCAM parameters cannot be extended to non-carbohydrates
as they do not make physical sense outside of their intended use case.
The exact functional forms of different forcefields varies but typically
they can be generalised to the sum of covalent and non-covalent terms:
(47) Epot = Ecovalent + Enon−covalent
where the covalent potential typically contains terms that describe
the bond-length, bond-angle and torsion-angle, whereas non-covalent
interactions such as van der Waals and electrostatic forces are de-
scribed by the Lennard-Jones (LJ) and Coulombic potentials respec-
tively. Some forcefields include additional terms that account for more
nuanced or specific effects, such as coordination to metal ions.[117]
1.3.1.1.1 The AMBER Forcefield The AMBER (Assisted
Model Building with Energy Refinement) forcefield is a biomolec-
ular forcefield developed primarily for modelling protein systems,
although it has since been extended to nucleic acids,[118] lipids[119] and
carbohydrates.[115] It has been parametrised primarily from protein
X-ray structures and to reproduce backbone dihedral angles of small
peptides. It is perhaps one of the most popular forcefields for protein
simulations due to its performance at accurately reproducing protein
structure, especially at longer timescales (see molecular dynamics)
compared to other forcefields. The group responsible for the AMBER
forcefield have also produced an excellent suite of software (Am-
berTools) that makes building, simulating and analysing far more
accessible compared to many other modelling programs. It has been
commented that the AMBER forcefield does have a bias towards
helical secondary structure, although this has been improved in more
recent versions based on parametrisation including experimental
NMR data.[116]
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The covalent potential for the AMBER forcefield is defined as:
(48) Ecovalent =
∑
bondsKr(r − r0)2 + ∑anglesKθ(θ − θ0)2 +∑
dihedrals
Vn
2 [1 + cos(nϕ− γ)]
where the first term is in the form of a harmonic potential dependent
on the length of each chemical bond (r) compared to an equilibrium
length (r0) and the magnitude of the potential depends on the specific
force constant (Kr) for each bond. Similarly the angle (θ) between
each particle connected by two bonds is harmonic with a angle force
constant, Kθ. Conversely the potential for dihedral angles (ϕ, the
angle between particles connected by three bonds) is periodic with a
periodicity of n, an offset of γ and a dihedral constant, Vn.
In AMBER, the only non-bonded terms are the LJ and Coulombic
potentials:
(49) Enon−covalent =
∑
LJ,i<j(
Aij
r12ij
− Bij
r6ij
) +∑Coul.,i<j qiqj4piϵ0rij
where Aij and Bij are pairwise parameters that ultimately determine
the position and depth of the energy minimum as a function of inter-
particle distance (rij), q is the particle electrostatic change and ϵ0 is
the permittivity of the medium.
1.3.1.1.2 Other Common Biomolecular Forcefields Al-
though AMBER may be one of the most popular forcefields, it may
sometimes be better to use an alternative, depending on the particular
system and the question that is being asked. For example, OPLS
(Optimised Potentials for Liquid Simulation) has been developed
as a general, all-atom forcefield that has been parametrised to
reproduce structural and thermodynamic properties of liquids, such
as hydration free energies.[120] CHARMM (Chemistry at Harvard
Molecular Mechanics) is another popular forcefield and has parame-
ters for many biomacromolecules, including proteins,[121] DNA and
lipids. It takes a modular approach in that it is parametrised based
on small fragments and assumes these can be pieced together to
accurately represent whole residues. It is also unique in that it
contains a so-called Urey-Bradley term in the forcefield, which is a
harmonic potential describing a pseudo-bond between particles with
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a 1-3 relationship, which helps account for angle bending. Finally,
GROMOS (Groningen Molecular Simulation) is another popular
forcefield.[122] Like OPLS, it aims to reproduce the thermodynamic
properties of liquid systems. However, it takes a different approach in
that it uses a united-atom model. This is a form of course-graining, in
which a heavy atom and all of its covalently bound hydrogen atoms
are described as a single particle. This has the advantage that many
fewer calculations have to be performed due to fewer overall particles
in the system, but may have an accuracy cost in assuming that the
whole fragment can be described by a single particle.
1.3.1.2 Energetically optimised structures: En-
ergy minimisation
It is often useful to know the lowest energy conformation(s) of a
molecule/system in order to determine its native structure and/or pre-
pare it for subsequent simulations or calculations, such as molecular
docking, molecular dynamics, or prediction of chemical/physical prop-
erties based on the structure. For this reason, energy minimisation
algorithms can be applied to find the configuration of the system that
gives the lowest potential energy in the MM forcefield.
In an ideal world one would generate every possible configuration of
the system in question, then evaluate the energy of each configuration
with the MM forcefield. Out of the entire set, the configuration with
the lowest energy could then be chosen. This lowest energy configura-
tion would be known as the global energy minimum.
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Figure 1.35: Diagram showing the presence of local and global minima on
the potential energy surface. Given the shown starting point, energy minimi-
sation would only find the local minimum. The remaining potential energy
surface must be explored using techniques such as molecular dynamics to over-
come the energy barrier. Source: https://basicmedicalkey.com/computational-
chemistry/
The practical problem with this approach is that most model systems
contain very many particles and the exact position of each particle in
three-dimensional space has an effect on the total potential energy -
often described as a hyperdimensional potential energy surface (PES)
that is a function of every position coordinate in the system (3n, where
n is the number of particles). Therefore it would be computationally
impossible to generate configurations that cover the whole PES for
most model systems. Instead practically energy minimisation must be
performed by starting with an initial configuration and modifying the
atomic coordinates slightly until it is not possible to reduce the energy
of the system any further. This is normally referred to as the local
minimum, since, given the complexity of the PES, it is unlikely that
energy minimisation will find the true minimum (Fig. 1.35).
1.3.1.2.1 Steepest Descent Minimisation The steepest de-
scent method is based on the assumption that, from an initial
configuration, the most efficient way to reach the local energy
minimum is to modify the atomic coordinates in the direction that
gives rise to the most negative gradient of the PES. That is, the
minimisation will proceed in the direction of the steepest gradient
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at each step; the new steepest gradient is then evaluated before
travelling in that direction. This is repeated until the local minimum
is found (in reality until the gradient changes by less than a given
threshold).
(50) xn+1 = xn − kn∇f(xn)
where x is the vector that describes the configuration of the system
and k is the step size needed to reach the minimum in the given search
direction.
While this is perhaps one of the simplest gradient minimisation tech-
niques and each iteration is very fast, overall it is somewhat inefficient
(more iterations needed in total) since the new search direction will
often be orthogonal to the previous search direction. Therefore, the
minimisation will tend to “zig-zag” towards the minimum (Fig. 1.36).
Figure 1.36: Diagram showing the path of the steepest descent algorithm
(green) vs. the conjugate gradient algorithm (red) on a two-dimensional po-
tential energy surface (gradient indicated by blue contours). By mixing the
direction of the current steepest gradient with the previous steepest gradient,
the conjugate gradient algorithm can find the energy minimum (x) in fewer
steps.
1.3.1.2.2 Conjugate Gradient Minimisation Perhaps one of
the most popular gradient minimisation techniques in MM is the con-
jugate gradient method. It is based upon the steepest descent method
but aims to solve the “zig-zagging” problem that makes steepest de-
scent inefficient.
The first iteration of the conjugate gradient method is identical to the
steepest descent method in that the PES is minimised in the direction
of the steepest gradient. However, in subsequent iterations the direc-
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tion of travel is determined by mixing the previous direction with the
direction of the new steepest gradient. By doing so, the minimisation
is more likely to travel in a direction towards the minimum, instead
of in orthogonal zig-zags (Fig. 1.36).
(51) xn+1 = xn − k − nhn
where hn = ∇f(xn)+γnhn−1 and γ is a factor that determines how
much of the previous step should be mixed with the current step.
1.3.1.3 Modelling the structures of Protein-
Ligand complexes: Molecular Docking
Molecular docking is a computational technique used to generate mod-
els of molecular complexes by first searching for a set of possible con-
figurations and then scoring those candidates in some way. There
are many published methods for performing the search and scoring,
and some will be discussed below. Perhaps the most common use
of molecular docking is in the generation of protein-small molecule
complexes[123,124] since: (1) it provides a relatively cheap method for
finding initial hits and optimising leads in the field of structure based
drug discovery; (2) small molecules are computationally the simplest
molecules to dock since there are fewer atoms to alter the configuration
of during the search and to evaluate in the scoring phase. However,
molecular docking can be applied to larger systems, such as modelling
protein-protein interactions.[125]
1.3.1.3.1 Search algorithms To obtain a complete set of all pos-
sible complex configurations, all possible translations, rotations and
conformations of both the receptor and the ligand would need to be
searched. Practically this is currently far too demanding computa-
tionally and so only a subset of possible complex configurations are
generated in reality. This is normally achieved in a number of ways.
Firstly, the actual search space can be limited by defining boundaries
around a specific region of the receptor in which the ligand can be
positioned. Of course, this requires knowledge of which region of the
receptor the ligand may bind to, but this is usually accessible from
previous structural studies, such as a crystal structure of a lead com-
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pound in complex with the receptor.
Secondly, the conformational flexibility of both the ligand and the re-
ceptor can be limited. The simplest form of search is known as rigid
ligand docking, in which both the ligand and receptor cannot change
conformation and only the translation and rotation of the ligand rela-
tive to the receptor can be searched. This allows the search to proceed
rather rapidly, although may lead to unrealistic or high-energy config-
urations of the complex since neither the ligand nor the receptor can
adapt to the presence of one another. Typically such a search would
only be acceptable for high-throughput screening, in which potential
binders must be identified from a pool of 10,000s of molecules, and
more accurate docking would be performed on those molecules that
pass the initial screen.
Perhaps the most popular form of docking is flexible ligand docking,
in which the conformation of the ligand is also searched as well as its
rotation and translation. The receptor is still considered to be rigid.
This of course assumes that the receptor is already in the correct
conformation to accept the ligand, but this is usually approximately
true since one would be starting from a receptor model that is bound to
a related ligand. Furthermore, for many receptor-ligand interactions,
there is no significant conformational rearrangement of the receptor
and so the lock-and-key approximation is still acceptable.
Finally, it is possible to model the receptor flexibly also. Typically, due
to the computational demand, one would only alter the conformation
of a small set of receptor atoms. For example, in protein-ligand dock-
ing one would alter the conformation of only the protein sidechains
within the search space, known as induced fit docking. This method
is of course more accurate since it allows the receptor binding site to
adapt to form a better shape complementarity to the specific ligand
in question, but comes at a significant cost computationally. Further-
more, it still does not address the issue of significant rearrangement
of the receptor upon ligand binding.
In order to generate the conformations described above, there are es-
sentially two major options - a systematic or stochastic approach.[123]
In the systematic approach, starting from an initial configuration, the
various search parameters are varied in a systematic manner. After
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each iteration its score can be evaluated and further changes are made
until the scoring function reaches an energetic minimum. For the
stochastic search, many random configurations are generated and then
evaluated for their score. A popular variation of the stochastic method
is the genetic algorithm, in which randomised search parameters are
encoded in so-called chromosomes.[123] Well-scoring chromosomes are
mixed with other well-scoring chromosomes and the process is repeated
for a given number of generations.
In general, systematic methods provide an efficient way of finding
the nearest minimum energy solution. However, since the result is
dependent on the initial configuration, it is likely that only a local
minimum and not the global minimum will be found. However, this
can be solved by starting the search with multiple starting configura-
tions. Stochastic algorithms are able to cover a much wider part of
the search space and so are more likely to find the global minimum.
However, as a result the computational cost is high and subsequent
iterations may not yield better results.
1.3.1.3.2 Scoring functions Scoring functions aim to estimate
the free energy of binding (∆Gbind) for the receptor-ligand complex
by considering a number of parameters. They can be largely be split
into two families: force field based and empirical. Force field based
scoring functions use a molecular mechanics forcefield to evaluate the
binding free energy, and so rely on discrete physical properties such
as torsion angles and electrostatic interactions. Conversely, empirical
functions define the score based on empirical parameters such as hy-
drogen bonding, hydrophobic interactions and entropic effects. These
parameters usually first optimised using a training dataset of known
compounds. The free energy of binding for an empirical scoring func-
tion is the sum of all the free energies for each parameter (∆Gx):
(52) ∆Gx = Cx
∑
f(x)
where Cx is a constant that is fitted during training of the scoring
function, and f(x) gives a score between 1 and 0 depending on the
distance of that parameter from ideal conditions. An example is that
the Glide[126] scoring function for hydrogen bond angles is 1 for angles
within 30° of 180° but tends to zero outside this range.
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Typically force field based functions may be more generalisable, but
empirical functions can be very well tuned for their specific purpose
and so can score very well in those cases. However one particular
problem of molecular docking is the treatment of solvation potentials.
The process of desolvation and resolvation of the receptor and ligand
to form the complex plays a large role in determining whether binding
is a favourable process or not. Although many functions attempt to
model this implicitly, their performance is mediocre at best.[127] More
accurate solvation effects could be calculated by considering solvation
with explicit solvent atoms, although this is very computationally de-
manding and not commonly performed.[128]
1.3.1.3.3 The Glide docking protocol The Grid-based Ligand
Docking with Energetics (Glide)[126] docking approach is implemented
by the Schrodinger Maestro molecular modelling suite and is often
cited to outperform many other well-known docking approaches. It
uses a semi-empirical approach using both force-field and empirical
terms in its scoring function, a grid-based potential for efficiently cal-
culating non-bonded term (similar in concept to that described for
the particle mesh Ewald), and filter-based approach in which a large
pool of initial conformations is gradually filtered down through several
phases of increasingly accurate docking calculations. The protocol is
described in more detail below (Fig. 1.37):
1. The grid is first calculated around the region of the receptor de-
termined to be the binding site. This grid describes the shape
and non-bonded properties of the receptor using a series of in-
creasingly accurate fields that can interact with the ligand. Since
the grid is precomputed, the receptor contribution to the interac-
tion need not be recalculated at each step, increasing efficiency.
2. A conformational search of the ligand is then performed using
the OPLS3 forcefield to produce many initial low-energy con-
formations of the ligand. This step is skipped if rigid ligand
docking is used.
3. The translation and rotation of each of these conformations is
then systematically searched over the whole volume of the grid
and roughly scored using a discrete version of the scoring func-
tion in which the contribution of different ligand types to the
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score is precalculated with a resolution of 1 Å3 grid boxes. Low
scoring poses are then eliminated from the search.
4. The surviving poses are then minimised using the OPLS3 force-
field, including a local Monte Carlo search of ligand torsion an-
gles which helps to optimise peripheral groups and relieve inter-
nal strain.
5. Finally the full scoring function is applied by calculating the
contribution of each ligand individually.
Figure 1.37: Diagram showing the protocol followed by the Glide docking
method.
The exact form of the glide scoring function is complex so will not
be discussed here. However, it is an empirically based function with
terms for hydrophobic interactions, hydrogen bonding, metal ion coor-
dination, as well as force-field based Coulombic and LJ terms. Further-
more, the scoring function takes into account solvation by explicitly
docking water molecules into the binding site, which is made practical
by the grid-based evaluation of potential. This is a significant improve-
67
ment on other docking techniques, although the limited sampling of
water poses means accuracy is still somewhat limited in that regard.
1.3.1.4 Understanding molecular flexibility and
dynamics stability: Molecular Dynamics
Simulations
Molecular dynamics is the application of time evolution to a molecular
mechanics system using the classical equations of motion.
(53) fi = mx¨i
(54) fi = −∂Epot
∂xNi
where fi is the force acting on a particular particle and xi is the dis-
placement of that particle. In other words, MD consists of simulating
the system at a given finite temperature, in contrast to the energy
minimisation calculations. That is, the total energy of the molecule
will not only contain the potential energy term, but also the kinetic
energy term. Through this the dynamic properties of the system may
be observed, such as changes in structural conformation. Bulk physi-
cal properties can also be calculated, since given that the simulation is
given enough time to thoroughly sample the PES, the time-weighted
distribution of states will be equal to the average of the whole en-
semble, that is the bulk observable properties. This is known as the
Ergodic hypothesis.[129]
Since computers are inherently discrete and computation of the force
and the displacement are inter-dependent, it is necessary to calculate
them in a stepwise fashion. Commonly the so-called velocity Verlet is
used, in which the positions of the particles are updated every time
step (τ ), and the velocities of those particles on every half timestep.
(55) xi(t+ τ) = ri(t) + x˙i(t+
τ
2)τ
(56) x˙i(t+
τ
2) = x˙i(t−
τ
2) +
fi(t)
m
τ
Of course calculation of the force can be very costly computation-
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ally and ideally one would want to increase the timestep as much
as possible to increase performance. However, this has a number of
problems: (1) if the time step is close to the time of the observed
dynamic property that property will be calculated inaccurately, (2)
larger timesteps mean that the particles will move a larger distance
between each timestep. At best this will decrease the accuracy of
the simulation, since the large movements will break its ergodicity.
At worst, it will cause the simulation to crash as the coordinates of
the particles become infinitely large. This is a particular problem for
hydrogen atoms, since the forces applied to them compared to their
mass tends to be very large and so they experience large accelera-
tions. In biomolecular simulations, it has become commonplace to
apply constraints to these hydrogen atoms, such as the SHAKE[130]
and RATTLE[131] algorithms, which essentially fix the bond lengths of
bonds involving hydrogen atoms. In practice a timestep in the order
of several femtoseconds (1-2 fs) is reasonable for atomistic simulations
of biomolecules employing a hydrogen restraint algorithm.
1.3.1.4.1 Statistical Ensembles Statistical ensembles represent
the set of microstates a system can exist in given that a certain set of
parameters remain constant. For example, if an isolated system is con-
sidered, that is no particles or energy can flow in or out of the system,
the system is said to belong to the microcanonical ensemble (NVE) in
which the number of particles (N), volume (V) and total energy (E)
remain constant. All possible microstates of the system must contain
the same total energy, and so any changes to the structure of the sys-
tem that alter its potential energy must be accounted for by an equal
and opposite change in kinetic energy. Since it is not possible for the
potential energy of the system to exceed the total energy, which is
fixed, it becomes difficult for the system to properly explore the PES,
since if any energy barrier exceeds the total energy of the system, the
system will become trapped in the same local space.
Alternative ensembles include the canonical ensemble (NVT) or the
isobaric-isothermal (NPT) ensemble, which hold volume and temper-
ature or pressure and temperature constant respectively. The NVT
ensemble represents a closed system in which heat can be transferred
from an external source. However, for production molecular dynamics
simulations the NPT ensemble is typically used since it most closely
represents the ‘real world’ scenario of an open flask in which the atmo-
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spheric pressure is constant, but the system can expand or contract in
volume depending on its kinetic energy. Nevertheless, in both cases,
the total energy of the system is not fixed, meaning that large poten-
tial energy barriers can be overcome by spontaneous fluctuations in
total energy.
1.3.1.4.2 Periodic Boundary Conditions Given the limita-
tions in computational power, it is usual to simulate very small model
systems. For example, for studying the dynamics of a protein one
may simulate a single protein molecule solvated in a minimal amount
of water. This has the consequence that many of the molecules in
the system are close to the surface between liquid and vacuum, and
may behave differently to what one would expect in reality (i.e. an
infinite continuum of liquid). To try to overcome this effect, while
still remaining computationally viable, it is usual to employ periodic
boundary conditions (PBCs) during the simulation. In such cases, the
simulation box is surrounded by identical ‘images’ of the simulation
box - that is the images have exactly the same configuration of
particles as the simulation box and when the atomic positions of
the particles within the simulation box change, the positions of the
particles within the images change in the same manner. However, the
image particles are still used to apply forces to the particles in the
simulation box, making it appear as if it is within an infinite liquid.
Importantly, if a particle within the simulation box travels across
the boundary from the simulation box to the image, the equivalent
incoming image particle on the opposite face of the box is treated as
the new simulation particle (Fig. 1.38).
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Figure 1.38: Representation of periodic boundary conditions with the
simulation box (black border) surrounded by image boxes. Par-
ticles that leave the simulation box are replaced by the incom-
ing image particle (dashed red line). Used with permission from
https://commons.wikimedia.org/wiki/File:Limiteperiodicite.svg
1.3.1.4.3 Aqueous Solvent Models In reality molecules do
not exist isolation, but surrounded by a vast continuum of solvent
molecules. The solvent has a profound impact on the properties
of the system and so the solvent properties need to be accurately
represented. In the context of biomolecular simulation, only water
will be considered.
For example, the dielectric screening by a solvent strongly affects the
strength of electrostatic interactions, the solvent polarity and any hy-
drogen bonding with the solute can affect the solute structure, and
the viscosity of the solvent affects the diffusion of solute. For example,
calculating the desolvation energy of a small molecule binding to a pro-
tein is important in calculating the binding affinity of that interaction
and so the solvent model must accurately represent that.
1.3.1.4.3.1 Implicit Solvation The simplest solvation model con-
siders the solvent, not to be explicit atomic coordinates, but just a
continuum interaction term that models the average bulk properties
of the solvent.
A popular model is the Generalised Born (GB) approximation, which
models the electrostatic screening by adding an electrostatic interac-
tion between each solute atom and the solvent, where the distance
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parameter is replaced with a parametrised value known as the Born
radius (fGB) that simulates the whether or not a solute atom is solvent
exposed or buried within the solute.
(57) EGB = − 18piϵ0 (1−
1
ϵ
)∑Ni,j qiqjfGB
where ϵ0 is the permittivity of free space and ϵ is the permittivity of
the solvent.
Since there are no explicit solvent atoms, this method is typically rela-
tively fast. However, clearly this model misses a lot of properties that
are important to accurately simulating the solute-solvent interaction.
As a result, it has been reported that simulations utilising implicit
solvents can produce innaccurate ensembles. For example, in pro-
tein simulations, implicit solvents tend to over-stabilise the α-helical
conformation.[132]
1.3.1.4.3.2 Explicit Solvation Explicit solvation simulates the
solvent by including solvent molecules in the model system thereby
allowing the solute to explicitly interact with the solvent. Explicit
solvent simulations are typically more accurate than implicit simula-
tions (given correct parametrisation), since effects such as viscosity
and hydrogen bonding emerge from the explicit interaction.
Figure 1.39: Cartoon of common explicit water models, all of which at least
include the three atomic coordinates of the oxygen and hydrogen atoms. The
4-site and 6-site models also use a single dummy atom (M) to improve the
polarity of the model, whilst the 5-site and 6-site model include additional
coordinates for the oxygen lone pair electrons (L). Used with permission from
https://en.wikipedia.org/wiki/Water_model#/media/File:Water_models.svg
The obvious choice for an explicit water model involves a 3-site model,
with each site corresponding to one of the three nuclei in the water
molecule. The SPC and TIP3P models are popular solvation mod-
els that utilise the 3-site approach. Both enforce a rigid geometry of
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the water molecule with charges on all three atoms. As well as slight
differences in the parametrisation of charges and bond lengths, the
main difference between the two models is that SPC enforces a tetra-
hedral bond angle (109°), whereas TIP3P chooses the value actually
observed for water (105°). Of the two, TIP3P has been shown to bet-
ter reproduce many thermodynamic properties,[133] and has been used
as the solvent in the parametrisation of a number forcefields, including
AMBER[118] and CHARMM.[121]
One major drawback of both TIP3P and SPC are that they signif-
icantly underestimate the viscosity of water, and as such diffusion
based processes occur more rapidly than in reality. This is largely to
do with the dipole moment of the water molecule being inaccurately
modelled. To address this issue, the TIP4P model is a 4-site model, in
which a fourth dummy atom is placed behind the oxygen atom.[134,135]
This dummy atom is massless and does not interact with other atoms
except that it carries the electrostatic charge that should be assigned
to the oxygen atom. In doing so the polarity of the water model is
closer to the true polarity of water and its diffusion properties are
improved.
Further, more complex models also exist that take into consideration
the lone pair electrons on the oxygen atom (TIP5P, TIP6P).[134] As
with TIP4P, these models further increase the accuracy of the water
model. However, these come at a computational cost, since includ-
ing additional coordinates for each solvent molecule can lead to many
thousands of additional calculations, since the solvent atoms typical
make up the majority of the system. Furthermore, as mentioned pre-
viously, many biomolecular forcefields are parametrised based on the
TIP3P model. Therefore, although more complex models do have defi-
nite benefits, TIP3P is still often favoured for computational efficiency
and to ensure the forcefield behaves as expected.
1.3.1.4.4 Dealing with Long Range Interactions The calcula-
tion of non-bonded interactions in incredibly costly since every particle
in the system interacts with every other particle in the system. There-
fore, one would have to calculate N 2 interactions (where N is the
number of particles in the system), which could easily be millions of
calculations per time step. To reduce the computational burden, we
can take advantage of the fact that, although both the LJ and Coulom-
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bic interactions continue to infinity, after a certain distance their ef-
fect is negligible relative to the inherent error of the simulation, and so
they can be ignored. Therefore, a cutoff is usually employed to ignore
all long-range interactions after a certain distance. For example, in
the AmberTools integrator PMEMD, the cutoff by default is 8 Å for
LJ-interactions. However having a hard cutoff in which interactions
are immediately ignored after a certain distance, can lead to its own
artefacts since the interaction energy either side of the threshold is sig-
nificantly different. Therefore other cutoff schemes utilise a switching
function to taper away the interaction to zero after the cutoff.
While the above method works well for LJ-interactions, electrostatic
interactions tend to persist over a longer distance and so need to be
treated with a different method. The Particle Mesh Ewald (PME)[136]
is most commonly employed for efficiently calculating electrostatic
charges in molecular dynamics simulations. Using this method, the
electrostatic potential is split into short- and long-range terms. The
short range term tends to zero rather rapidly and so can be trun-
cated in the same manner described for LJ-interactions. For the long
range interactions, the potential is calculated by representing the elec-
trostatic charge as a grid of electrostatic density values. The force
applied to each particle by the long-range electrostatic potential can
then be calculated based on its position in the grid.
1.3.1.4.5 Typical Simulation Protocol Assuming one has a
suitable model of the system of interest, which may be derived exper-
imentally (X-ray crystallography, NMR) or by modelling (homology
modelling, molecular docking), molecular dynamics simulations may
be prepared using the following steps:
1. Generation of Model Topology
• The first step in preparing for molecular dynamics simulations
involves defining the forcefield parameters for each particle in
the system. Such parameters are typically printed in a topology
file, that also tends to describe features such as connectivity,
and may be prepared manually or more typically by software
that recognises the format of the input model. For example,
the AmberTools software suite has tools that can automatically
produce topology files for proteins, carbohydrates, lipids from
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Protein Data Bank (PDB) files.
2. Solvation
• Solvent molecules (usually water for biomolecular simulations)
are then added to the system to solvate the model. Typically
one would add as few as possible to reduce computation time,
but enough so that particles cannot directly interact with their
own images. This would depend on the cutoff for long range
interactions, and the rule of thumb is to solvate the solute suffi-
ciently that it is at least twice the distance of the cutoff from its
image. The shape of the simulation box can also be defined at
this point. A cubic box is conceptually the simplest to compute
but more recently more complex boxes, such as the truncated
octahedron, have been developed which allow fewer total solvent
molecules to be used.
3. Neutralisation
• Typically one would want to to ensure that the total electronic
charge of the system is zero, since this represents how the system
would exist in reality and charged systems could lead to very
high potential energies that could destabilise the system. For
this reason, counter ions can be placed within the simulation
box to neutralise any electronic charge. Most forcefields have
parameters for many atomic ions, although for most biomolecu-
lar simulations one would usually use either sodium or chlorine
ions.
4. Minimisation
• Although the initial model may have been minimised prior to
molecular dynamics, the additional of solvent molecules and ions
will often put the system into a high energy state due to steric
clashes or non-optimal non-bonded interactions. Trying to be-
gin the simulation without first finding the local minimum will
often lead to unstable simulations. Usually the minimisation
will be spilt into two stages: (1) the solute molecules will be
restrained so that only the solvent molecules, which are most
likely the furthest from being optimised, can be moved during
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minimisation. (2) The minimisation is then repeated with no re-
straints. This procedure prevents high energy interactions with
the solvent from distorting the conformation of the solute atoms
significantly.
5. Heating
• Heating is simulated by gradually adding kinetic energy to the
system (which initially has no temperature) over a period of time
(usually hundreds of picoseconds) until the system reaches the
desired simulation temperature. This must be performed grad-
ually since a sudden large increase in kinetic energy will make
the simulation highly unstable. Heating is performed using the
NVT ensemble, since energy cannot be added to the system us-
ing the NVE ensemble, and in the NPT ensemble the increasing
kinetic energy would cause the system to continuously expand
to maintain the pressure.
6. Equilibration
• Since in production one would usually use the NPT ensemble,
a short period of time is required after heating to switch to the
NPT ensemble and ensure that the system is at thermodynamic
equilibrium, in particular to equilibrate the density of the sol-
vent. The equilibration stage is performed under the same con-
ditions as the production dynamics, except that the trajectory
is typically not saved or analysed.
7. Production
• The conditions used during equilibration are continued and now
the coordinates are saved at given intervals to create a molecu-
lar dynamics trajectory. Production dynamics are typically the
longest stage, ranging from 1-1000 ns, depending on the infor-
mation required and computing power available.
1.3.1.4.6 Enhanced Sampling Methods While molecular dy-
namics is a useful technique for understanding the dynamic properties
of a system, its use is usually limited to transitions that occur on a
very short timescale due to the computational restraints on simulation
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time. Since overcoming the transition barrier between two states is a
stochastic process and the probability of a transition is governed by
the energy needed to overcome this barrier, a number of techniques
have been derived to increase the probability of such a transition and
therefore enabled the simulation to sample more of the PES in the
same amount of simulation time. These are known as enhanced sam-
pling methods.
1.3.1.4.6.1 Accelerated Molecular Dynamics Accelerated
Molecular Dynamics (aMD) is an enhanced sampling technique that
increases the probability of overcoming energy barriers, thereby
accelerating the simulation, by applying a boost potential (∆Epot)
that effectively increases the potential energy of the system (E∗pot)
and reduces the energy barrier.[137]
(58) E∗pot = Epot +∆Epot
The magnitude of the boost is determined by the difference between
the true potential and a predetermined threshold (Ethres) and an ac-
celeration factor (α). The energy threshold determines the maximum
energy that can have a boost potential applied to it. Exactly how to
choose this threshold is discussed elsewhere,[138] but is normally based
from finding the average potential energy of the system over the course
of a short ‘traditional’ molecular dynamics trajectory. The accelera-
tion factor has the effect of flattening the PES depending on its value,
with small values flattening it more. The flatter the PES, the faster
the PES can be sampled, but this comes at a cost in accurately know-
ing the shape of the PES. For a moderate boost, a value of 0.2× the
number of atoms in the system is typically used.
(59) ∆Epot =
(Ethres − Epot)2
α + (Ethres − Epot)
where Epot < Ethres
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Figure 1.40: The effect of the accelerated molecular dynamics boost potential
on the potential energy surface. The true surface is shown (black) compared
to increasingly strong boost factors (blue to red). For energies larger than the
threshold (dashed purple) no boost is applied. Taken from [139]
While the aMD procedure can be used simply for accelerated confor-
mational sampling, any observable property calculated from the aMD
simulation (A∗) can be reweighted to determine the true value of that
observable (A) in real time. For example, the potential energy over
some reaction coordinate (r) of interest may be reweighted to find the
true potential energy.[137]
(60) ⟨A⟩ = ⟨A ∗ (r)exp(β∆Epot(r))⟩⟨exp(β∆Epot(r))⟩
where β = 1
kBT
. However, it has been demonstrated that such
reweighting can be very noisy and as such the calculated observables
may not be very accurate, especially for more complex systems such as
proteins.[140] More recently a modification to the method has been pub-
lished, known as Gaussian Accelerated Molecular Dynamics (GaMD),
which has been shown to provide a more accurate reweighting by en-
suring that the boost potential follows a Gaussian distribution.[141]
The aMD procedure can be applied to either the whole PES, just to the
dihedral potential, or using a dual-boost in which boost potentials are
applied to both the whole PES and the dihedral potential. The latter
has proven particularly effective in exploring the folding of proteins.[138]
Unlike some enhanced sampling techniques (e.g. umbrella sampling),
aMD does not require any prior knowledge of the system and so can
be used when the ‘desired transition’ is unknown.
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1.3.1.4.6.2 Adaptive Steered Molecular Dynamics In
steered molecular dynamics (SMD) an external force is applied to
the system in order to steer the system along a particular reaction
coordinate at a given velocity. This is particularly useful for observing
transitions that may occur over time periods much longer than is
accessible by conventional molecular dynamics. For example, the
technique is commonly used for ligand unbinding experiments,[142]
and can be correlated with experimental atomic force microscopy
data.[143]
Since the force required to move the system along the reaction coor-
dinate at a given rate is known, the work done on the system can be
calculated. Of course, the work calculated for a particular trajectory
will be dependent on the initial microstate of the system and the re-
sulting work calculated for multiple trajectories will be different for
each trajectory. In such a non-equilibrium system (i.e. the reaction
coordinate changes at a finite rate) it has been shown that the en-
semble average work (⟨W ⟩) over many independent simulations can
be related to the equilibrium Helmholtz free energy change (∆F ) be-
tween the start and end states, in an equation known as the Jarzynski
equality:[144]
(61) ⟨exp(−βW )⟩ = exp(−β∆F )
To calculate the equilibrium free energy change between the two states,
many independent trajectories must be run over the entire reaction co-
ordinate in order to ensure that the, so-called Jarzynski average work
has converged. Obviously this is very computationally expense and re-
quires vast amounts of computing time. More recently adaptive SMD
(ASMD) simulations have been developed which aim to reduce this
computational demand by splitting the simulation into stages along
the reaction coordinate.[145] After each stage the Jarzynski average
work is calculated and the trajectory with whose work is closest to
this average is used to seed the next stage of simulations. By doing so,
the total amount of simulation time can be reduced, thereby making
this technique more accessible computationally.
1.3.1.4.7 Applications of Molecular Dynamics in Structural
Biology Molecular dynamics is incredibly useful in the field of struc-
tural biology because it gives access to atomic structural and dynamic
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detail not accessible to many experiments. It is particularly comple-
mentary to X-ray crystallography, which can produce a high-resolution
three dimensional model of the structure of interest, but lacks solution
state, dynamic information, and so cannot solely be used to under-
stand the function of a molecule.
For example, molecular dynamics can be used to study conformational
changes in a protein and the factors that may facilitate that. For exam-
ple, we have recently demonstrated the pH dependence on the confor-
mation of the binding site of a serine-rich repeat protein (SRRP) from
L. reuteri by MD,[146] which has be experimentally observed to bind to
different ligands at different pHs. We showed that protonation of a key
structural sidechain at low pH caused conformational rearrangement
of a binding site loop. This was not possible by other means, since the
protein could not be crystallised under these conditions. Furthermore,
simulations have been used to explain allosteric effects, such as long
range conformational changes in response to ligand binding.[147,148]
Molecular dynamics has also found an important role in drug discov-
ery, since other in silico techniques such as docking miss important
solvation and entropic factors. MD has been successful in discrimi-
nating binders from non-binders to a greater degree of accuracy than
docking, thereby accelerating the drug discovery process.[149,150]
As computational power grows further, the power of MD simulations
will continue to increase, giving access to larger systems over longer
timespans. Already microsecond length simulations are accessible,[151]
but with many macromolecular processes taking place over the mil-
lisecond to second timescales, MD is still limited in that regard. For
example, ab initio protein folding is a key goal for structural biolo-
gists, but as of yet only simulations of small peptide folding have been
accessible.[152] Furthermore, large scale simulations of systems such
as the HIV capsid have already been successful.[153] In the future, it
may be possible to simulate entire cellular processes, making MD an
indispensable technique in the study of biological systems.
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1.4 General Objectives of the Thesis
Throughout this thesis the techniques of NMR Spectroscopy and
Molecular Modelling will be used heavily to understand the structural
basis for the molecular recognition of ligands by biologically relevant
carbohydrate active proteins. Within the thesis, it is shown how
these techniques are highly complementary, to use molecular mod-
elling to provide atomic level detail that explains the experimental
observations made by NMR spectroscopy. In particular, we wanted
to investigate the power of combining STD NMR spectroscopy with
molecular docking, using the CORCEMA-ST software to quantifiably
measure the agreement between the experimental and theoretical
data. Furthermore, the powerful computing resources available to our
group enable the routine use of long molecular dynamics simulations
(1 µs) to study large scale protein dynamics.
Overall the objectives are:
• Differential Interaction of Hyaluronan with the Cell
Surface Receptors, CD44 and LYVE-1
– Generate a homology model of the LYVE-1 hyaluronan
binding domain and experimentally demonstrate its valid-
ity.
– Compare and contrast the binding epitopes of a synthetic
hyaluronan tetrasaccharide with CD44 and LYVE-1, using
molecular modelling, including molecular dynamics simula-
tions, to explain the similarities and differences in binding.
• Understanding Ligand Recognition by PsLBP
– Validate X-ray crystallography models of the complexes
of PsLBP with glucose-1-phosphate and mannose-1-
phosphate in the solution state.
– Understand the the recognition of cognate and non-cognate
substrates by PsLBP.
• Characterisation of the Interaction between the
Salmonella enterica effector proteins and their Death
Domain Substrates
– Understand the differences in molecular recognition of tar-
get substrates by the effector proteins SseK1 and SseK2
– Understand the differences in dynamics of the SseK1 and
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SseK2 proteins and how this may affect molecular recogni-
tion
– Generate a molecular model of the SseK2:FADD complex
and experimentally validate the structure
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Chapter 2
Differential Interaction of
Hyaluronan with the Cell
Surface Receptors, CD44 and
LYVE-1
2.1 Introduction
2.1.1 CD44
CD44 is a cell-surface, transmembrane receptor involved in cell-cell
and cell-matrix interactions.[154–156] Its principal ligand is hyaluronan
(HA),[83] an abundant, high-molecular-weight, extracellular matrix gly-
cosaminoglycan (Fig. 2.1) that has a diverse set of functions, includ-
ing imparting compressibility and lubrication to a tissue,[157] water
homeostasis,[158] matrix scaffolding[159] and cell surface interactions.
HA is composed of repeating disaccharides of N-acetyl-glucosamine
(GlcNAc) and glucuronic acid (GlcA) linked by β(1-4) and β(1-3) gly-
cosidic linkages respectively.[82]
CD44 is expressed ubiquitously - being found in numerous embry-
onic and adult tissues, as well as a multitude of cell types, including:
epithelia,[160] endothelia,[161] smooth muscle cells,[162] fibroblasts and
astrocytes. It has been noted that CD44 expression is particularly
elevated in regions of active cell growth,[160,163] which agrees with the
established role of CD44 plays in cell adhesion and migration.[154–156]
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Figure 2.1: Chemical structure of hyaluronan, a high-molecular-weight gly-
cosaminoglycan consisting of repeating disaccharide units of glucuronic acid
(GlcA) and N-acetyl-glucosamine (GlcNAc) linked via β(1-3) and β(1-4) gly-
cosidic linkages respectively.
It is then perhaps unsurprising that over-expression of CD44 has
been implicated as an important factor in the malignancy of many
cancers[156,164,165] and much work has been dedicated to targeting CD44
for the diagnosis and treatment of cancer.[166,167] However, contradic-
tory evidence exists showing that CD44 can both promote and inhibit
cancer progression, as reviewed in [168].
This discrepancy may be explained in part by two factors: (1) vari-
able splicing of the CD44 gene, and (2) changes in post-translational
modifications to the CD44 protein.
2.1.1.1 Variable splicing of CD44
The CD44 gene consists of 19 exons, at least 12 of which can be
variably-spliced (Fig. 2.2),[169] leading to a multitude of potential
splice variants. The vast majority of the variable exons are found
within the membrane-proximal region of the extracellular domain.
The remaining variable exons are found in the cytoplasmic tail. The
standard isoform of CD44 (CD44s) is defined as containing none of
the variably-spliced exons, whereas those isoforms containing one or
more variable exons are known as variant CD44 (CD44v).[165]
In the literature, it has been generally observed that CD44v isoforms,
which typically contain a longer extracellular domain, promote
aggressive tumour growth and metastasis.[170–174] This is in contrast
to CD44s which is more abundantly expressed in non-metastatic
tumours and down-regulation of CD44s is associated with increased
tumourigenicity.[174–176]
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Figure 2.2: Variable splicing of CD44 exons. Top: Full CD44 pre-mRNA
transcript containing all CD44 exons. Exons 1-5, 15-17 (red) are conserved
in all CD44 variants, whereas exons 6-14 (blue) are variably spliced. If exon
18 (black), which contains a premature stop codon, is spliced into the final
transcript, the resulting protein will not contain the sequence encoded by exon
19 (red and blue). Bottom: mRNA transcript for CD44s, which contains none
of the variably spliced exons.
2.1.1.2 Post-translational modification of CD44
Differential post-translational modification of the CD44 protein is also
responsible for the variation in its function.[177,178] For example, Ser291
and Ser325 in the cytoplasmic domain of CD44 are known to be phos-
phorylated by Ca2+/calmodulin-dependent protein kinase II[179] and
protein kinase C[180] respectively; the inhibition of either process im-
pairs cell mobility. CD44 is also known to be acylated at Cys286 and
Cys295, leading to its association with lipid rafts, which is essential
for endocytosis of CD44 and its ligands.[181] Furthermore, CD44 can
be cleaved by sheddases,[182,183] a class of protease that cleaves the ex-
tracellular domain of transmembrane proteins. Sheddases are often
also up-regulated in cancer.[184] Cleavage of the CD44 extracellular
domain (into so-called soluble CD44) has been shown to promote cell
migration since the cleaved intracellular domain can act as a transcrip-
tional promoter of the CD44 gene.[185,186] However, a separate study
has shown that over-expression of soluble CD44 inhibits cell adhesion
since the soluble binding domains compete with the membrane-bound
binding domains for HA binding.[187]
However, perhaps the most puzzling post-translational modifications
made to CD44 are the N- and O-glycosylation of its extracellular do-
main (Fig. 2.3). It is well known that the covalent modification of
proteins with glycans can exert a number of effects,[7] including shield-
ing, regulation and recognition. In the case of CD44, there are nu-
merous confounding reports that both N- and O-glycosylation can
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have either an inhibitory or activating effect. For example, multi-
ple studies report that inhibition of either N- or O-glycosylation re-
duces HA-binding to CD44.[188,189] Conversely, N-glycans terminated
by sialic acid residues have been shown to have an inhibitory ef-
fect on CD44, whilst treatment with neuraminidase is able to restore
receptor function.[190–192] Finally, O-glycosylation of CD44 has also
been observed to have an inhibitory effect.[193] Interestingly, most of
CD44’s predicted O-glycosylation sites are found within the variable
exons,[194] suggesting that the degree of O-glycosylation can vary wildly
between CD44 isoforms. Conversely, CD44s contains 6 potential N-
glycosylation sites, with only an additional 2 being found in some
longer isoforms. To further confound the issue, glycosylation is no-
toriously heterogeneous,[195] with levels of glycosylation and glycan
structure varying greatly between cell types and environmental condi-
tions.
Figure 2.3: Cartoon showing the overall topology of CD44 (right) and LYVE-1
(left) including the location of N- (green zig-zags) and O-glycosylation (red
zig-zags) sites and cysteine residues (gold circles). Taken from [196].
In summary, CD44 is an important receptor in the adhesion and mi-
gration of cells under healthy and pathological conditions. Its activity
is dependent on a number of different factors, including variation in
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splicing and variation in post-translational modifications. To further
understand its function, CD44 should be studied from a structural
point of view.
2.1.1.3 The Structure of CD44
The structure of CD44 can be decomposed into 4 main domains:[169,197]
(1) a hyaluronan-binding domain (HABD), (2) a variable membrane-
proximal stalk, (3) a transmembrane domain, and (4) a cytoplasmic
domain.
2.1.1.3.1 The Hyaluronan-Binding Domain of CD44 The
CD44 hyaluronan-binding domain (HABD) contains a consensus
amino acid sequence homologous to the so-called Link domain[197]
- a structurally conserved domain of approximately 100 residues
containing a HA-binding site. The Link domain is found in a number
of HA-binding proteins,[198] including the proteoglycans aggrecan[199]
and versican,[200] and TSG-6.[201] Apart from CD44, the only other
known receptor containing the Link domain is LYVE-1.[198,202]
The three-dimensional structure of the Link domain was first solved
using NMR for the human TSG-6 protein.[203] A X-ray crystal struc-
ture of the TSG-6 HABD was solved later (Fig. 2.4 i. and iii.).[72]
The domain is a compact globular shape with a well-defined, large hy-
drophobic core. It consists of 2 α-helices and 6 β-strands; the strands
β1, β2 and β6 come together to form an antiparallel β-sheet, whilst a
second antiparallel β-sheet is formed by β3, β4 and β5. A hook-like
loop is formed between the β4 and β5 strands and is stabilised by a
disulfide bond between a pair of cysteine residues. A second disulfide
is formed between the α1 helix and the β6 strand by another pair
of cysteine residues. HA binds laterally along a cleft adjacent to the
hook-like loop.[204]
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Figure 2.4: Three-dimensional structures of the HABDs of TSG-6 (PDB ac-
cession code: 2PF5) and CD44 (PDB accession code: 1UUH). i: Cartoon
representations of TSG-6 (green) and CD44 (cyan) HABDs. Both contain the
consensus Link domain fold, although CD44 HABD requires N- and C-terminal
extensions for hyaluronan binding. Disulphide bridges highlighted shown as
yellow sticks. ii & iii: Surface representations of CD44 (carbons in cyan) and
TSG-6 (carbons in green) HABDs respectively.
Across all known Link domains, the primary sequence within sec-
ondary structural elements is highly conserved,[205] highlighting the
existence of a consensus Link domain fold. The four cysteine residues
are also highly conserved, indicating their importance in defining the
Link domain fold.
The Link domain of CD44 shares approximately 37% identity with the
Link domain of TSG-6.[201] However, the Link domain of CD44 alone
is not sufficient to bind HA - elements further downstream are addi-
tionally required for HA binding.[197,206–209] The X-ray crystal structure
of the human CD44 HABD (Fig. 2.4 i. and ii.)[210] reveals three new
β-strands (β0, β7, β8) that extend both the N- and C-terminus of the
consensus Link domain and continue the antiparallel β-sheet formed
previously by β1, β2 and β6. An additional pair of cysteine residues
found in the N- and C-terminal extensions form a third disulfide bond.
The C-terminal extension contains a number of basic residues that
have been shown to be important for HA binding to CD44.[206–209] How-
ever, these residues are far from the HA-binding site of Link domains
and the X-ray crystal structure of the murine CD44 HABD bound
to a HA octasaccharide[211] suggests that only one of these residues
(Arg155) directly contacts HA (Fig. 2.5). A NMR study[212] of the
human CD44 HABD shows that, upon binding of HA, the C-terminal
extension unfolds, causing the CD44 HABD to transition from an or-
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dered (O) to a so-called partially disordered (PD) state (Fig. 2.6).
This behaviour is missed by X-ray crystallography since the act of
crystallisation selects for low conformational entropy. Molecular dy-
namics simulations show that the O-to-PD transition frees the basic
residues of the C-terminal extension to interact with HA, which en-
hances binding.[213] Furthermore, CD44 HABD mutants that constitu-
tively adopt the O-state bind HA with lower affinity than the wild-
type and the equilibrium between O- and PD-states has been shown
to be important in lymphocyte rolling in the high-shear environment
of the vascular endothelia.[214] Other studies have tried to explain the
interaction of HA with the C-terminal extension through multiple HA
binding modes,[210,215] although the evidence for this is not convincing.
Figure 2.5: The three-dimensional structure of the murine CD44 HABD (cyan)
bound to a HA octasaccharide (yellow) (PDB accession code: 2JCR). Left:
Surface representation of the CD44 HABD, showing the HA-binding groove and
deep pocket accommodating the HA GlcNAc methyl group. Right: Cartoon
representation highlighting residues of interest - R45, Y46, R82, Y83, I92, I100,
and R155 in murine CD44 (R41, Y42, R78, Y79, I88, I96, and R150 in human
CD44).
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Figure 2.6: The ordered (O) to partially-disordered (PD) transition in the CD44
HABD. The HA (yellow) bound X-ray crystal structure of the CD44 HABD
(cyan, PDB accession code: 2JCR) is compared against the PD structure
obtained by NMR (orange, PDB accession code: 2I83). For clarity only the
lowest energy structure of the NMR-derived ensemble is shown for residues
19-146, and the 5 lowest energy structures are shown for residues 147-178. In
several structures the PD C-terminal extension is in close proximity to the HA
binding site.
The binding mode of HA observed in the murine CD44 HABD crys-
tal structure[211] (Fig. 2.5), taken together with the understanding
that the C-terminal extension undergoes an O-to-PD transition,[212] ap-
pears to explain the interaction CD44:HA most successfully. The bind-
ing mode of HA positions it along the groove adjacent to the hook-like
loop, as observed in TSG-6.[204] The groove is lined by aliphatic, aro-
matic and basic residues, and the interaction is dominated by a large
number of hydrogen bonds. In particular, Arg45 (Arg41 in human
CD44) forms several contacts with HA and mutation of this residue
completely abolishes HA binding.[207] It has also been suggested that
this residue could be involved in affinity switching since it is found
in two different conformations in X-ray crystal structures.[211] This
hypothesis is also supported by molecular dynamics simulations.[213]
The binding-site residues, Tyr42, Arg78 and Tyr79 (human CD44 se-
quence) have also been shown to be critical for HA-binding.[207] Of
these, Tyr79 (Tyr83 in murine CD44) forms one side of a hydropho-
bic pocket into which the methyl group of a GlcNAc residue of HA is
inserted[211] (Fig. 2.5).
2.1.1.3.2 The Membrane-proximal Stalk of CD44 The
membrane-proximal stalk of CD44 links the HABD to the transmem-
brane domain and is expected to adopt an elongated structure.[154] Its
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length is highly variable, ranging from only 46 amino acid residues
in CD44s, up to 381 amino acid residues in the variant containing
all variable exons (CD44v1-10). The stalk contains numerous motifs
for post-translational modifications, varying depending on which
exons are present, including attachment of O-glycans and proteolytic
cleavage as discussed in Section 2.1.1.2. One particularly interesting
example is that CD44 variants containing the v3 exon (Fig. 2.2) can
be modified with heparan sulfate (HS),[216] which in turn can bind
and present HS-binding growth factors - a behaviour which may have
implications in the development of cancer.
2.1.1.3.3 The Transmembrane Domain of CD44 The trans-
membrane domain of CD44 makes a single pass through the cell mem-
brane and consists predominantly of hydrophobic residues, with the ex-
ception of a single cysteine residue (Cys286).[154] This cysteine residue,
through acylation is important in the formation of lipid rafts, as
discussed in Section 2.1.1.2. In addition, this unpaired cysteine is
able to induce dimerisation of CD44 molecules through formation of
a disulfide bond with the equivalent cysteine of an adjacent CD44
molecule.[217] This dimerisation enhances hyaluronan binding through
increased avidity and is important for observing CD44 activity in
cells.[218]
2.1.1.3.4 The Cytoplasmic Domain of CD44 The standard
form of the cytoplasmic domain of CD44 consists of 72 amino acid
residues.[177] This is termed the ‘long-tail’ form and exists in almost all
observed forms of CD44. A ‘short-tail’ form is possible by inclusion
of exon 19, which contains an alternative stop codon, but has only
been detected in chondrocytes and has impaired HA-internalisation
properties.[219] As discussed in Section 2.1.1.2, the cytoplasmic tail can
be modified at several positions, which affects its function. In addition,
the cytoplasmic tail can interact with the cell cytoskeleton by binding
to a number of adaptor proteins. The CD44 sequence from Arg292-
Lys300 constitutes a FERM-binding motif,[177] which facilitates the
interaction of CD44 with the actin cytoskeleton mediated by bind-
ing of ERM (ezrin/radixin/moesin) proteins.[220] In addition, the se-
quence from Asn304-Leu318 constitutes an ankyrin-binding site,[221]
which also mediates the interaction of CD44 with the actin cytoskele-
ton. In this way, HA-binding to CD44 can directly affect cell adhesion
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and migration by restructuring the actin cytoskeleton.[222,222–225]
2.1.2 LYVE-1
Like CD44, LYVE-1 is a cell-surface, transmembrane receptor for
hyaluronan (HA). LYVE-1 is 41% homologous to CD44[226] and
is the only other known receptor containing the HA-binding Link
domain.[198] It was originally believed to be expressed exclusively
in the lymphatic endothelia[226] (hence the name LYmphatic Vessel
Endothelial receptor 1) but has since been observed in embryonic
vascular endothelia;[227] it is subsequently down-regulated during
vascular remodelling. Unlike CD44, which is the predominant HA
receptor in many cell types,[83] LYVE-1 appears to be predominantly
inactive both in vitro and in vivo.[228] Therefore it has been of great
interest to understand the function of LYVE-1, the factors that affect
its activation, and how and why these differ from CD44.
2.1.2.1 Function of LYVE-1
While CD44 appears to be active to some degree under many condi-
tions, for a long time the factors required to activate LYVE-1 were
elusive. More recently it has been discovered that LYVE-1 activity
is highly dependant on both clustering of LYVE-1 on the cell sur-
face and organisation of HA into polyvalent complexes involving HA
crosslinking by HA-binding matrix proteins.[229,230] It has since been
shown that cells, including Group A Streptococci,[231] macrophages[229]
and dendrocytes,[232] that are encapsulated in an organised HA-matrix
can be taken up into the lymphatics via binding to LYVE-1 on the
surface of lymphatic vessels (Fig. 2.7).
This also has important implications in cancer progression, since
the lymphatic vessels provide a major route for metastasis[233,234]
and LYVE-1 may facilitate the uptake of cancer cells into the
lymphatics.[196,230,235–237] Furthermore, the up-regulation of CD44
on the surface of many cancer cells[156,164,165] may help to organ-
ise the HA-matrix surrounding the cancer cell. Indeed, it has
been shown that CD44, HA and LYVE-1 can form stable ternary
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complexes.[226] Furthermore, LYVE-1 appears to play an important
role in lymphangiogenesis.[238,239]
Figure 2.7: Cartoon showing the proposed function of LYVE-1 (blue cir-
cles) which is expressed on the surface of lymphatic endothelial cells (yellow).
Through binding to hyaluronan (HA, red lines) it can uptake HA into the lym-
phatic vessels or traffick cells expressing CD44 through formation of a ternary
complex. Taken from [196].
2.1.2.2 Structure of LYVE-1
Although LYVE-1 transcripts can be variably spliced, in contrast
to CD44 only one is translated into a functional protein containing
the Link domain.[226,240] This single functional isoform consists of 322
amino acid residues, shorter even than the 361 residue CD44s, re-
sulting in an extracellular domain that is truncated by 29 residues in
comparison.[241] Despite this, the degree of glycosylation on the LYVE-
1 extracellular domain is still comparable to CD44s, with 27 potential
O-glycosylation sites (32 in CD44s) and 2 N-glycosylation sites (Asn53
and Asn130; 6 sites in CD44s)[194,228] (Fig. 2.3).
Experiments in HEK293T cells have shown that the LYVE-1
N-glycosylation sites are important for effective binding of HA, in par-
ticular Asn130.[228] Conversely, the presence of sialylated O-glycans
has an inhibitory effect an LYVE-1 binding to HA. It is important
to remember however that these experiments represent only one cell
type and, as observed for CD44,[188–193] the effect of glycosylation on
the function of the receptor can vary drastically depending on the cell
type and environmental conditions. However, what is clear is that
glycosylation of the LYVE-1 extracellular domain can have a drastic
impact on its binding to HA.
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2.1.2.2.1 The Hyaluronan-Binding Domain of LYVE-1 The
hyaluronan-binding domain (HABD) of LYVE-1 shares 51% homol-
ogy with the HABD of CD44.[242] Like CD44, the HABD of LYVE-1
consists of a consensus Link module extended at both the N- and C-
termini, including the additional disulfide-forming cysteine pair that
stabilises the extension.[242] No experimentally derived structure yet
exists for the LYVE-1 HABD, but homology modelling suggests that
it may share many similar features with the HABD of CD44, includ-
ing: (1) a HA-binding cleft adjacent to the hook-like loop, (2) a
hydrophobic pocket to accept the methyl-group of GlcNAc residues
within HA, and (3) interaction of HA with residues far from the HA-
binding site.[242]
Perhaps the most distinguishing feature of the LYVE-1 HABD, ac-
cording to the homology model, is the lack of intra-molecular hydro-
gen bonds between the LYVE-1 HABD and HA,[242] in direct contrast
with CD44.[211] Instead, LYVE-1 appears to mediate its interaction
with HA predominantly via electrostatics, as indicated by the pres-
ence of multiple charged basic residues surrounding the binding site
(Arg99, Lys105, Lys108, Lys117, Arg122). This is supported by exper-
imental evidence that the interaction of LYVE-1 with HA is strongly
diminished with increasing ionic strength of the buffer.[242] Despite the
predominantly electrostatics-driven interaction, LYVE-1 surprisingly
conveys a higher specificity for HA even than CD44;[226] LYVE-1 binds
solely to HA, whereas CD44 has a minor specificity for chondroitin sul-
fate as well.[83]
An important factor modulating the affinity of the CD44 HABD
for HA is the unfolding of the C-terminal extension (see Section
2.1.1.3.1)[212,214] such that several basic residues within the extension
can interact with HA.[213] These residues are not present in the
LYVE-1 HABD.[242] Furthermore, binding kinetics experiments show
that LYVE-1 HABD monomers can form a binary complex with HA
far more rapidly than the CD44 HABD can.[212,214,243,244] Together
these suggest that unfolding of the HABD C-terminal extension does
not occur in LYVE-1.
2.1.2.2.2 The Membrane-proximal Stalk of LYVE-1 The
membrane-proximal stalk of LYVE-1 is severely truncated compared
to most CD44 isoforms, yet is still heavily glycosylated (see Section
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2.1.2.2.2). Like CD44, LYVE-1 can also be proteolytically cleaved
by metalloproteases to form soluble, truncated, membrane-detached,
extracellular domains.[245,246] The LYVE-1 cleavage site is found
between Phe226 and Glu229 within the membrane-proximal stalk.
Cleavage of LYVE-1 extracellular domains has been shown to inhibit
lymphangiogenesis.[245,246] This has important consequences in cancer,
with high levels of LYVE-1 cleavage associated with lower levels of
metastasis and better outcomes for patients.[235,247]
Another interesting feature of the LYVE-1 membrane-proximal stalk
is a series of basic residues(RRKK, Arg195-Lys198) preceding a single,
unpaired cysteine residue (Cys201).[202,242] The cysteine is redox-labile
and is able to form LYVE-1 homodimers under reducing conditions.[243]
Furthermore, this dimerisation is essential for for binding to HA in vivo
and therefore represents a redox-switch that allows LYVE-1 to respond
to environmental conditions. The function of the basic residues is not
understood, although they must have some importance due to their
conservation across murine and human LYVE-1.[202] Although specula-
tion, it may be that they modulate the redox potential of Cys201, since
chemically local positive charge will push the redox equilibrium to-
wards oxidation, and positively charged redox agents have been shown
to accelerate the formation of disulfide bonds in proteins.[248]
2.1.2.2.3 The Transmembrane Domain of LYVE-1 Similarly
to CD44, the transmembrane domain of LYVE-1 is a single-pass an-
chor containing a single unpaired cysteine residue (Cys257),[202] in
conservation with CD44 (Cys286).[154] However, it has been reported
that Cys257 in LYVE-1 does not form a disulfide bond to create
homodimers,[243] as in CD44 (see Section 2.1.1.3.3).[154] It may be that
it is still involved in endocytosis, as observed for CD44, since LYVE-1
does act as an endocytic receptor,[202] although this hypothesis has not
been tested.
2.1.2.2.4 The Cytoplasmic Domain of LYVE-1 The cy-
toplasmic domain of LYVE-1 is involved in signalling pathways
that induce lymphangiogenesis and permeability of endothelial cell
junctions.[230] The exact nature of this signalling is still unknown since,
although the LYVE-1 cytoplasmic domain contains phosphorylation
sites, there is no evidence for them becoming phosphorylated.[202,226]
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However, LYVE-1 signalling appears to be closely coupled to the
MAPK/Erk signalling pathway in both junctional permeability and
lymphangiogenesis signalling.[230] Furthermore, LYVE-1 signalling can
be blocked through inhibition of growth factor receptors, including
EGFR, PDGFR and VEGFR, indicating that LYVE-1 may recruit
their kinase activity for downstream signalling.
2.1.3 Summary
Both CD44 and LYVE-1 are important receptors for hyaluronan (HA)
that have implications in cell trafficking and some disease states, such
as cancer. Despite their high sequence homology, they have many
unique characteristics, that may be a result of their differences in
tissue expression, thereby allowing them to adapt to their own unique
niches.
CD44 has been extensively studied and the factors surrounding its
function are well known. This is in part due to its earlier discovery and
characterisation, but also due to its ease of expression. For example,
the X-ray crystal structure of the CD44 HA-binding domain (HABD)
was published over 15 years ago,[210] since high-purity, homogeneous
samples of the CD44 HABD can be readily produced from E. coli.[197]
In contrast, LYVE-1 was discovered far more recently and so the lit-
erature surrounding its function is still in its infancy. Furthermore,
attempts to produce samples of the LYVE-1 HABD for structural
characterisation have failed. It is believed that the glycans present on
native LYVE-1 are essential for proper folding and solubility.
2.1.4 Objectives
The aim of this chapter is to elucidate some of the structural features
responsible for the unique function of LYVE-1, and compare them
to CD44, using a combination of Saturation Transfer Difference NMR
Spectroscopy and Molecular Modelling. Specifically the objectives are:
• To characterise the molecular recognition of HA by CD44 in
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solution state.
• To characterise the molecular recognition of HA by LYVE-1 in
solution state.
• To carry out a comparative study between both receptors.
2.2 Materials and Methods
2.2.1 Nuclear Magnetic Resonance Spec-
troscopy
The synthetic hyaluronan tetrasaccharide (HA4S) was synthesised by
Dr Jose Luis de Paz (IIQ, CSIC-US, Seville, Spain)[249] and was as-
signed based on 1D 1H NMR, 1H-1H COSY, 1H-1H TOCSY, 1H-13C
HSQC and 1H-1H NOESY NMR experiments. For the TOCSY the
mixing time was set to 80 ms and for the NOESY a number of ex-
periments were acquired, with mixing times ranging from 300-1200
ms. The concentration of HA4S was 3.5 mM in 99% D20 and the as-
signment experiments were acquired at 298 K. For saturation transfer
difference NMR spectroscopy, all samples were prepared in a buffer
containing 137 mM NaCl, 10 mM Na2HPO4, 2.7 mM KCl and 1 mM
KH2PO4 at pH 7.4, using D2O as the solvent. Final protein and lig-
and concentrations were 130 µM and 2.7 mM respectively. STD NMR
experiments were performed using a train of 50 ms Gaussian pulses
applied on the f2 channel at either 0.6 ppm (on-resonance) or 40 ppm
(off resonance). A spoil sequence was used to destroy unwanted mag-
netisation and a 40ms spinlock pulse (3.8kHz) was used to suppress
protein signals (stddiff.3). A range of saturation times were used to
construct the STD NMR build up curves (0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 6,
7, 8 s), with 128 scans per experiment. The recycle delay (d1) was set
to 8 s. The experimental temperature for STD NMR experiments was
280 K. All experiments were performed on a Bruker Avance III 800
MHz spectrometer equipped with a 5-mm TXI 800 MHz H-C/N-D-05
Z BTO probe.
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2.2.2 Homology Modelling
The coordinates of murine CD44 bound to HA8[210] (PDB accession
code: 2JCR) were used as a template for the human CD44 and LYVE-1
HABD sequences. These sequences were aligned to the template using
the ClustalW algorithm.[250] The Schrödinger Prime software[251] was
used to construct an energy-based all-atom model with the OPLS3
forcefield,[120] keeping the HA8 model from the template. Regions of
low sequence homology were refined using extended serial loop sam-
pling in the Prime software.
2.2.3 Molecular Docking
The conformational flexibility of the HA4S ligand was considered by
performing a conformational search using Schrödinger’s MacroModel
software.[252] Conformers were generated by Monte Carlo torsional sam-
pling, eliminating structures with RMSD < 0.5 Å from existing struc-
tures or with a potential energy > 5 kcal mol-1 from the minimum
energy structure according to the OPLS3 forcefield. Restraints of
100 kcal mol-1 were applied to all internal ring torsions so that the
favoured 4C1 ring conformation was preserved. Generated structures
were minimised by the conjugate gradient method, converging on a
threshold of 0.05 kcal mol-1. Docking calculations were performed us-
ing Schrödinger’s Glide software.[126,253] A cubic receptor grid with side
length of 30 Å was generated by centring on the HA8 ligand. Glide
docking of HA4S conformers was performed using standard precision,
enhanced sampling and a distance-dependant dielectric constant of 2.
The resulting poses were clustered using the hierarchical agglomerative
average linkage algorithm.
2.2.4 Molecular Dynamics Simulations: Equili-
bration
Complexes were parametrised using AMBER ff14SB[116] and GLY-
CAM_06j for protein and carbohydrate moieties respectively. Model
systems were generated by solvating with explicit TIP3P water
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molecules within a truncated octahedron bounding box buffered from
the complex by 10 Å (for ASMD, this was increased to 20 Å) and
neutralising with Na+ ions. Conjugate gradient minimisation was
run with 20 kcal mol-1 Å-2 restraints on solute atoms, converging
on a threshold of 1 x 10-4 kcal mol-1 Å-1, before repeating with no
restraints. The restraints were reapplied to solute atoms before
heating at constant volume to 310 K over a period of 500 ps. The
system was then equilibrated at constant pressure (1 atm) over
a period of 1.3 ns, with the restraints being released slowly over
the last 800 ps. In all cases periodic boundary conditions and the
particle mesh Ewald method were applied. A Langevin thermostat
with a collision frequency of 5 ps-1 and a Berendsen barostat with a
relaxation time of 2 ps were used. The SHAKE algorithm was used
to restrain all bonds involving hydrogen, allowing a timestep of 2 fs
to be used. A cutoff of 8 Å was used for non-bonded interactions.
2.2.5 Molecular Dynamics Simulations: Pro-
duction
For standard production dynamics, parameters were used as described
above, with no restraints applied. Simulations were run in triplicate
for 100 ns each, saving coordinates every 10 ps.
For adaptive steered molecular dynamics, the distance between the
methyl group of GlcNAc3 and the Cδ 1 of I88 (CD44) or I97 (LYVE-
1) was increased from 3 to 33 Å over a total of 30 ns using a restraint
of 5 kcal mol-1. Each stage was repeated 30 times, each with a random
seed to generate a unique trajectory. At the end of each stage, the
Jarzynski average[144] was calculated and the trajectory closest to this
average was used to initiate the next stage. Coordinates were saved
every 2 ps.
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2.3 Results
2.3.1 Nuclear Magnetic Resonance Assignment
of a Synthetic Hyaluronan Tetrasaccha-
ride
A synthetic tetrasaccharide of hyaluronan (HA4S, Fig. 2.8) was
chosen for studying the interaction of hyaluronan (HA) with CD44
and LYVE-1 by Nuclear Magnetic Resonance (NMR) spectroscopy.
HA4S contained a N-acetylglucosamine (GlcNAc) non-reducing ter-
minal residue and a para-methoxyphenyl (PhOMe) linker covalently
bound to the glucuronic acid (GlcA) reducing terminal residue via a
β-glycosidic bond. This was chosen for two reasons: (1) the repetitive
nature of glycosaminoglycans and inherent low spectral dispersion
of carbohydrates[20,254]makes studying a longer construct by NMR
spectroscopy extremely challenging, (2) the PhOMe linker retains
the anomeric configuration of the reducing terminal residue, thereby
deconvoluting the spectrum by reducing the number of species present
in solution (absence of anomeric equilibrium).
Figure 2.8: Chemical structure of the synthetic hyaluronan tetrasaccharide.
The NMR assignment of HA4S (Table 2.1) was achieved through a
combination of Correlation Spectroscopy (COSY), Total Correlation
Spectroscopy (TOCSY), Nuclear Overhauser Effect Spectroscopy
(NOESY), and 1H-13C Heteronuclear Single Quantum Correlation
(HSQC) NMR spectroscopy experiments.
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Table 2.1: Assignment of the chemical shifts of 1H and 13C nuclei of HA4S.
Experiments were performed in an 800 MHz NMR spectrometer at 298 K.
Only non-exchangable proton resonances were observed since the sample was
prepared in D2O.
Residue Position δ 1H (ppm) δ 13C (ppm)
GlcNAc1 1 4.44 100.58
2 3.61 55.23
3 3.43 73.81
4 3.37 75.78
5 3.37 69.52
6 3.67 60.50
6’ 3.82 60.50
Me 1.94/1.96 22.29
GlcA2 1 4.38 103.1
2 3.26 72.44
3 3.49 73.42
4 3.63 76.18
5 3.65 79.54
GlcNAc3 1 4.49 100.6
2 3.77 54.09
3 3.64 82.30
4 3.41 75.21
5 3.44 68.31
6 3.70 60.50
6’ 3.84 60.50
Me 1.94/1.96 22.29
GlcA4 1 4.91 101.2
2 3.51 72.44
3 3.60 73.51
4 3.74 76.62
5 3.74 79.80
PhOMe ortho 7.01 118.0
meta 6.89 114.9
Me 3.72 55.65
The TOCSY experiment was used to separate the HA4S resonances
into groups corresponding to individual (as yet unclassified) hexopyra-
nose residues (Fig. 2.9). This was possible because the glycosidic bond
between residues separates inter-residue protons from one another by
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more than 3 bonds - couplings over a greater number of bonds than
this are typically too weak to be detected.[255]
Figure 2.9: Section of the TOCSY spectrum of HA4S, showing the diagonal
peaks corresponding to each anomeric proton resonance. Cross peaks corre-
spond to proton resonances within the same spin system, and therefore within
the same residue.
Subsequently, the anomeric protons of each residue were easily iden-
tifiable since the resonances of these protons typically lay within the
δ 4.4-5.5 ppm region,[254] well dispersed from any non-anomeric car-
bohydrate resonances. The anomeric carbon resonances, observed in
the 1H-13C HSQC (Fig. 2.10), are typically also shifted downfield
considerably compared to non-anomeric carbon resonances.
Figure 2.10: Section of the 1H-13C HSQC spectrum of HA4S, with reso-
nances from the PhOMe and GlcNAc methyl groups omitted for clarity. Cross
peaks correspond to correlations between proton and carbon resonances cou-
pled through one bond and therefore correspond to each individual position on
the pyranose ring.
Due to the dispersion of the anomeric proton resonances it was also
straightforward to identify the chemical shift of the H2 protons, since
the H1-H2 cross-peaks in the COSY spectrum (Fig. 2.11), which
identifies through-bond correlations through 3J-coupling, were well iso-
lated.
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Figure 2.11: Section of the COSY spectrum of HA4S showing the diagonal
peaks corresponding to each anomeric proton resonance. Cross peaks corre-
spond to proton resonances coupled to these anomeric protons through three
bonds and therefore, in this case, come from protons at position 2 in the
pyranose rings.
In the assignment of small molecules, it is common to determine
the connectivity of the whole spin system by continuing to trace the
cross-peaks from one resonance to another.[255] This too is possible for
carbohydrates, but the narrow spectral dispersion of non-anomeric
proton resonances make this a challenge. Here, the H3, H4, and
H5 resonances of each residue could be assigned by comparing the
through-bond COSY and TOCSY experiments with the through-space
NOESY experiment. In pyranoses with the same configuration as β-
D-glucose, including GlcNAc and GlcA, the CH protons lay in two
distinct planes:[27] H1, H3 and H5 below the ring (α face), and H2 and
H4 above the ring (β face). Protons within each plane are in close
proximity to one another, and therefore give rise to strong cross-peaks
in the NOESY spectrum (Fig. 2.12). In this way, the H3, H4, and H5
resonances of each residue were assigned.
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Figure 2.12: Section of the NOESY spectrum of the synthetic hyaluronan
tetrasaccharide, showing the diagonal peaks corresponding to each anomeric
proton resonance. Cross peaks correspond to proton resonances dipolarly cou-
pled to these anomeric protons through space. These include intra-residue
NOEs (and are also observed in the TOCSY experiment) and inter-residue
NOES (not observed in the TOCSY experiment). Only well isolated inter-
residue cross-peaks are labelled for clarity.
The GlcA residues could then be distinguished from the GlcNAc
residues, since GlcA does not contain exocyclic protons on the C6
carbon (H6 and H6’). Furthermore, the C2 carbon atoms of GlcNAc
resonate much further upfield than in GlcA due to the presence of
the amide of the N-acetyl group of GlcNAc.
The H6 protons of GlcNAc were identified by through-bond correlation
with the H5 resonance. The H6 and H6’ resonances also gave rise to a
unique identifying pattern in the 1H-13C HSQC spectrum (Fig. 2.10)
since they show correlation to the same carbon resonance. The methyl
of the N-acetyl group of GlcNAc could be easily identified because both
the proton and carbon resonances can be found far upfield compared
with all other proton and carbon resonances within the carbohydrate
residue. However, they could not be distinguished from one another
since the methyl group is not within the same spin system as the
remaining protons in the same residue. Furthermore, no intra-residue
NOESY cross-peaks were clearly identifiable.
The position of each residue within the HA4S sequence could then be
assigned using knowledge of the pattern of the glycosidic linkages.[20]
For example, the GlcNAc3 residue in HA4S forms a glycosidic bond
with the previous GlcA residue via the C3 carbon. This bond is not
present in GlcNAc1. Therefore the chemical shift of the GlcNAc3 C3
carbon is shifted downfield relative to that of GlcNAc1. For the GlcA
residues, their position in the HA4S sequence could be distinguished,
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since the anomeric proton resonance of GlcA4 was shifted downfield
relative to that of GlcA1 due to the presence of the PhOMe linker.
Finally the chemical shifts of the PhOMe linker could easily be as-
signed, since the methyl protons resonated far upfield compared to
the aromatic protons. The ortho- and meta-protons could be distin-
guished from one another due to the presence of a NOESY cross-peak
between the GlcA4 anomeric proton and the aromatic ortho-proton.
2.3.2 STD NMR Study of the binding of the
synthetic hyaluronan tetrasaccharide to
CD44 and LYVE-1
To gain structural details of the interactions of HA4S with CD44 and
LYVE-1, saturation Transfer Difference (STD) NMR spectroscopy
experiments were performed for the samples containing synthetic
hyaluronan tetrasaccharide (HA4S) in the presence of either CD44
(Fig. 2.13) or LYVE-1 (Fig. 2.15). Binding of HA4S to both receptors
was detected by the STD NMR, which showed unambiguous signals
in the difference spectrum. The relatively low ligand-to-protein ratio
of 21:1 used for these experiments led to chemical shift perturbations
observable in the ligand signals, so that a different pattern of signals
were observed for HA4S in the presence of CD44 or LYVE-1, com-
pared to HA4S alone. STD NMR build up curves were constructed
(Fig. 2.14A, Fig. 2.16A) by measuring the STD intensity of each
resolvable resonance of the STD NMR spectrum for saturation times
ranging from 0.5 s to 8 s. Since the STD NMR experiments were
based on one-dimensional 1H NMR experiments, it was not possible
to resolve all assigned resonances and therefore STD NMR build
up curves for several protons are missing. The STD NMR build
up curves were used to extract the initial rate of STD intensity
build up (STD0) for each proton resonance by fitting each build up
curve to the monoexponential equation described in Eqn. 45 (CD44:
Table 2.2, LYVE-1: Table 2.3). Binding epitope maps could then be
constructed for HA4S binding to CD44 or LYVE-1 by plotting the
normalised STD0 values onto a structure of HA4S (Fig. 2.14B, Fig.
2.16B).
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Analysis of the STD NMR build up curves (Fig. 2.14, Fig. 2.16) re-
veals that, in general, the STD intensities observed for HA4S binding
to either CD44 or LYVE-1 are comparable. In both cases, STD in-
tensity is spread along the length of the tetrasaccharide, indicating a
longitudinal mode of binding, compatible with the observation that
HA binds across a shallow groove along the CD44 HA binding do-
main (HABD) (Fig. 2.5), as seen in the X-ray crystal structure of the
murine CD44 HABD bound to a HA octasaccharide.[211] These results
indicate that HA4S also binds to LYVE-1 in a similar manner. This
is the first experimental demonstration of the similarity of binding
modes of hyaluronan to LYVE-1 and CD44.
2.3.2.1 The Binding of HA4S to CD44
The binding epitope map of HA4S binding to CD44 (Fig. 2.14) re-
veals that the majority of close contacts between HA4S and CD44
occur between the central two residues of HA4S (GlcA2-GlcNAc3), in
particular the methyl group of GlcNAc3, which receives the largest
amount of saturation. Again, this agrees with the X-ray crystal struc-
ture of the murine CD44 HABD bound to a HA octasaccharide,[211]
which highlights that this central disaccharide does indeed make the
greatest number of contacts with the CD44 HABD, and shows the
methyl group of the GlcNAc residue buried within a deep hydropho-
bic pocket (Fig. 2.5). Furthermore, the fact that only a low degree
of saturation is observed for the methyl group of GlcNAc1 shows that
only one predominant binding mode is present - that is to say that
there is no significantly populated binding mode in which the GlcNAc1
methyl is buried within the hydrophobic pocket. This further suggests
that the minimum recognition motif of HA for binding to CD44 is at
least GlcAβ(1-3)GlcNAc.
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Figure 2.13: Reference (blue) and difference (red) spectra for HA4S in the
presence of CD44. Measured using a saturation frequency of 0.6ppm at 800
MHz and a saturation time of 2 s. Presence of additional signals is due to
some protein signals not being fully removed by the spinlock.
Figure 2.14: A: STD NMR build up curves for HA4S in the presence of CD44.
Graphs are plotted by residue (GlcNAc1 - PhOMe; top left - bottom right) and
positions of each proton resonance are marked on inset legends. Plots show
experimentally measured STD intensities (dots) and curves calculated by fitting
to Eqn. 45 (lines). B: Binding epitope map for the interaction of HA4S with
CD44. Colours represent the normalised values of STD0 for proton resonances
at the indicated positions (low - high, cold - hot). The R group represents the
PhOMe linker, which is omitted for clarity.
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Table 2.2: Initial rate of STD intensity build up (STD0) for each proton reso-
nance of HA4S in the presence of CD44. Normalised values (STD0(norm.))
are calculated by dividing STD0 by the largest STD0 value. a/b: STD intensity
measured for overlapping resonances.
ResiduePosition ksat (s-1)
STDmax
(%)
STD0 (%
s-1) STD0(norm.)
GlcNAc1 1 0.33 15.8 3.25 0.27
4 0.27a 6.40a 1.71a 0.14a
5 0.27a 6.40a 1.71a 0.14a
Me 0.43 28.3/12.6 12.1/5.38 1.00/0.44
GlcA2 1 0.47 18.5 8.61 0.71
2 0.31 19.6 6.08 0.50
3 0.33 18.9 6.29 0.52
GlcNAc3 1 0.43 15.8 6.83 0.56
2 0.41 16.0 6.60 0.55
Me 0.43 28.3/12.6 12.1/5.38 1.00/0.44
GlcA4 2 0.30 14.0 4.17 0.34
3 0.33 18.9 3.00 0.25
4 0.32b 12.6b 4.03b 0.33b
5 0.32b 12.6b 4.03b 0.33b
PhOMe ortho 0.27 8.56 2.01 0.17
meta 0.26 7.74 2.28 0.19
Me 0.42 2.41 1.03 0.08
2.3.2.2 The Binding of HA4S to LYVE-1
The binding epitope of HA4S binding to LYVE-1 (Fig. 2.16) is intrigu-
ing since the only strong contact appears to be the methyl group of Glc-
NAc3; the remainder of the epitope shows normalised STD values of
between 0.1 and 0.4 uniformly distributed across HA4S (Fig. 2.14, Ta-
ble 2.3). Such an observation is indicative of a transient protein-ligand
complex, since in such cases the residence time of the ligand within
the binding pocket permits the saturation to spread only to those pro-
tons that are in closest proximity to the protein protons. Indeed, this
agrees with experimental observations that the LYVE-1-HA system
exhibits much faster binding kinetics than CD44-HA.[212,214,243,244] Fi-
nally, again the low degree of saturation on the GlcNAc1 methyl group
suggests that LVYE-1 also has requirements for a minimum structural
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motif, that is at most a trisaccharide of GlcA-GlcNAc-GlcA.
Figure 2.15: Reference (blue) and difference (red) spectra for HA4S in the
presence of LYVE-1. Measured using a saturation frequency of 0.6ppm at 800
MHz and a saturation time of 2 s. Presence of additional signals is due to
some protein signals not being fully removed by the spinlock.
Figure 2.16: A: STD NMR build up curves for HA4S in the presence of LYVE-
1. Graphs are plotted by residue (GlcNAc1 - PhOMe; top left - bottom right)
and positions of each proton resonance are marked on inset legends. Plots
show experimentally measured STD intensities (dots) and curves calculated by
fitting to Eqn. 45 (lines). B: Binding epitope map for the interaction of HA4S
with LYVE-1. Colours represent the normalised values of STD0 for proton
resonances at the indicated positions (low - high, cold - hot). The R group
represents the PhOMe linker, which is omitted for clarity.
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Table 2.3: Initial rate of STD intensity build up (STD0) for each proton reso-
nance of HA4S in the presence of LYVE-1. Normalised values (STD0(norm.))
are calculated by dividing STD0 by the largest STD0 value. a/b: STD intensity
measured for overlapping resonances.
ResiduePosition ksat (s-1)
STDmax
(%)
STD0 (%
s-1) STD0(norm.)
GlcNAc1 1 0.27 6.95 6.68 0.29
2 0.37 9.39 3.51 0.15
3 0.40 9.34 3.70 0.16
Me 0.49 13.6 22.97/6.69 1.00/0.29
GlcA2 1 0.35 16.2 5.72 0.25
2 0.22 14.8 3.25 0.14
5 0.33 12.2 4.02 0.17
GlcNAc3 1 0.39 16.9 6.68 0.29
2 0.41 16.0 3.51 0.15
3 0.36 13.9 4.96 0.22
5 0.42 15.6 6.59 0.29
Me 0.59 38.9 22.97/6.69 1.00/0.29
GlcA4 2 0.34 21.6 7.28 0.32
PhOMe ortho 0.29 13.8 3.91 0.17
meta 0.30 12.9 3.81 0.17
Me 0.42 7.80 3.90 0.17
2.3.3 Homology modelling of the human CD44
and LYVE-1 Hyaluronan Binding Domains
in Complex with hyaluronan
Since human CD44 was used for STD NMR experiments, a homology
model of the human CD44 hyaluronan (HA) binding domain (HABD)
was produced (Fig. 2.17 A) from the X-ray crystal structure of the
murine CD44 HABD bound to a HA octasaccharide.[211] With the
murine and human CD44 HABDs sharing 88% identity and 96% sim-
ilarity, alignment of the two sequences resulted in only a one residue
deletion in the human CD44 HABD relative to mouse (Fig. 2.18). The
subsequent minimised homology model of the human CD44 HABD
bound to a HA octasaccharide differed from the X-ray crystal struc-
ture of the murine complex only by an RMSD of 0.173 Å (Cα) (Fig.
2.17), with almost all of this deviation due to the deletion of a residue
110
in the loop between β5 and β6 and in the loop between β6 and β7.
Figure 2.17: Cartoon representation of the X-ray crystal structure of the murine
CD44 (green, PDB accession code: 2JCR) superimposed with the homology
models of the human CD44 HABD (cyan, A) and the human LYVE-1 HABD
(pink, B).
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Figure 2.18: Multiple sequence alignment of the human CD44 and HABD
sequences to murine CD44. Identical (*), strongly similar (:) and weakly
similar (.) properties according to the Gonnet PAM matrix[256] are highlighted.
Relative to the murine CD44 sequence, the human CD44 HABD contains 1
deletion and the human LYVE-1 HABD contains 5 insertions.
Conversely, the LYVE-1 HABD shares only 37% identity and 54%
similarity to the murine CD44 HABD. Nevertheless, the sequence can
be aligned with only 1 insertion in the loop between β6 and β7 and
4 insertions in the loop between β3 and β4. Overall, the resulting
LYVE-1 homology modelled structure (Fig. 2.17 B) has a RMSD of
only 0.164 Å (Cα) from the murine CD44 HABD structure.
According to this model, the topology of the HA-binding groove
of the LYVE-1 HABD has some striking differences compared to
that of CD44 (Fig. 2.19). Firstly, in agreement with previous
descriptions,[242] there are no hydrogen bonding interactions between
HA and the sidechains of the LYVE-1 HABD. In addition, there
appears to be no interaction between the C-terminal extension and
HA. This leaves a wide opening at the non-reducing terminal proximal
end of the groove. The reducing terminal proximal end of the groove
appears to be somewhat narrower in LYVE-1 than in CD44, due to
the positioning of Lys108 and Trp116. This differs slightly from the
previously published model,[242] in which the conformation of the loop
between β5 and β6 (which contains W116) is modelled differently.
However, it should be noted that that model was derived from the
X-ray crystal structure of the apo-form human CD44 HABD (PDB
accession code: 1UUH), which does adopt a different conformation
to the murine HA-bound form. Furthermore, the modelling software
used here, Prime, has demonstrated a higher accuracy than other
homology modelling programs, particularly in loop regions.[257,258]
Unfortunately, there is limited data on the importance of W116 in the
HA-binding interaction, since the only mutant produced (δW116Y)
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was somewhat conservative and produced little effect on binding.[242]
Finally, the hydrophobic residues (Ile100 and Ala103) of the hook-like
loop in CD44, which are known to be essential for the interaction
with HA, are replaced with charged, flexible lysine residues (Lys105
and Lys108) (Fig. 2.19 right). The only major feature which is
conserved, is the hydrophobic binding pocket that accommodates a
GlcNAc methyl group - the residues that form this are absolutely
conserved (muCD44: Tyr83 and Ile92, huLYVE-1: Tyr87 and Ile97).
Figure 2.19: Left: Surface representation of the homology model of the human
LYVE-1 HABD, showing a superposition of an octasaccharide of HA from
the X-ray crystal structure of murine CD44 (yellow, sticks). Right: Cartoon
representation of the homology model of the human LYVE-1 HABD (pink),
showing key binding residues (pink, sticks).
2.3.4 Molecular Docking Models of the human
CD44 and LYVE-1 Hyaluronan Binding
Domains in Complex with a Synthetic
Hyaluronan Tetrasaccharide and Valida-
tion with CORCEMA-ST
To produce a model of HA4S in complex with the human CD44 and
LYVE-1 HABDs, Glide was used to dock HA4S into the binding groove
of the models produced above. The resulting docking poses were clus-
tered and the pose closest to the centroid of each cluster was retained
for analysis. For CD44, three major clusters were found, each with
approximately 28% occupancy (Fig. 2.20, Table 2.4). However, only
one of these clusters was close to the HA structure in the X-ray crystal
structure of the murine CD44 HABD (Cluster 2, RMSD: 0.963 Å, in
place, heavy atoms) and agreed qualitatively with the experimental
STD NMR data, as well as being compatible with the known inter-
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actions with CD44. Furthermore, this docking pose showed the best
docking score (Glide Emodel: -162 arb. units) and had the smallest
variance (5.28 Å2), indicating better convergence. Therefore it was
only this docking pose that was considered for further analysis.
Table 2.4: Docking statistics for HA4S docking to homology models of human
CD44 and LYVE-1 HABDs. The RMSD is calculated in place for the heavy
atoms of HA4S relative to the HA octasaccharide in the X-ray structure of the
murine CD44 HABD, and corresponds to the representative HA4S structure
closest to the centroid of its cluster. Docking score given in arbitrary units
(AU). Variance (σ2)of the RMSD of cluster members is also shown.
Protein Cluster
Occupancy
(%)
RMSD
(Å)
Docking
Score (AU) σ2 (Å2)
CD44 1 28.0 14.5 -133 6.99
2 28.0 0.963 -162 5.28
3 27.4 6.76 -134 7.12
LYVE-
1
1 54.2 0.836 -94.6 2.11
Figure 2.20: Best docking pose of HA4S (yellow) bound to a homology model
of the human CD44 HA binding domain (cyan). The HA octasaccharide (grey)
from the X-ray crystal structure of the murine CD44 HABD is shown for com-
parison.
Since the docking pose of HA4S has such significant overlap with
the HA octasaccharide in the X-ray crystal structure of the murine
CD44 HABD, and the key HA binding residues are conserved between
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murine and human CD44, a detailed discussion of the interaction can
be found in Section 2.1.1.3.1. However, it should be noted that it is
GlcA2 and GlcNAc3 in HA4S that make the apparent key disaccharide
pair for interaction with CD44, with the methyl group of GlcNAc be-
ing found in the hydrophobic pocket of the CD44 HA binding groove.
It is also interesting to note that the PhOMe linker is positioned and
oriented such that it may act as a good substitute for the hydropho-
bic surface of the GlcNAc residue that would occupy that space in a
longer HA construct.
In the case of LYVE-1, only one major cluster was observed, with
an occupancy of 54% (Fig. 2.21, Table 2.4). This too is very sim-
ilar to the HA octasaccharide in the X-ray crystal structure of the
murine CD44 HABD and has an RMSD of 0.836 Å (in place, heavy
atoms). The binding pose of HA4S in the binding groove of the LYVE-
1 HABD is comparable to that of HA4S in the binding groove of the
CD44 HABD, in particular the GlcNAc3 methyl group being buried
in the hydrophobic pocket of the binding groove. This is in excellent
agreement with the STD NMR observations (Fig. 2.14, Fig. 2.16). In-
terestingly, the carboxylate groups of GlcA2 and GlcA4 are located in
close proximity to Lys105 and Lys108 respectively. Like in the CD44
model, the PhOMe linker occupies the same space as would be occu-
pied by a GlcNAc residue in a longer HA construct, stacking directly
above Trp116. Although the value of the docking score is less negative
for LYVE-1 compared to CD44, it should be noted that comparison
of docking scores between two different systems can be inaccurate, so
their relative values should not be considered too seriously.
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Figure 2.21: Best docking pose of HA4S (yellow) bound to a homology model
of the human LYVE-1 HA binding domain (cyan). The HA octasaccharide
(grey) from the X-ray crystal structure of the murine CD44 HABD is shown
for comparison.
To validate the molecular models of the complexes of HA4S with the
HABDs of human CD44 and LYVE-1, the CORCEMA-ST program
was used to predict theoretical STD NMR build up curves based on
the 3-dimensional models. In the case of the CD44-HA4S complex
(Fig. 2.22), the NOE R-factor, which describes the overall agreement
between the experimental and theoretical data, was 0.151, indicating
an excellent fit between the experimental and theoretical STD NMR
build up curves. In general a value of 0.3 is considered a good fit.
For LYVE-1 the overall RNOE was 0.272 (Fig. 2.23), which is con-
sidered a good fit, especially considering the the receptor model was
a homology model built from a template with only 54% similarity. In
fact, if the aromatic moiety is removed from the calculation, the RNOE
value is 0.198. This shows that the receptor-carbohydrate interaction
is modelled extremely well, and the model complex presented here is
very close to the true structure of the complex in the solution state. As
for the PhOMe group of HA4S in the model of the LYVE-1-HA4S com-
plex, the predicted STD NMR intensities are slightly stronger than the
experimental intensities. There are a couple possible explanations for
this: (1) the specific broadening of the PhOMe group in the presence
of LYVE-1 suggests that in the HA4S-LYVE-1 complex the T2 of the
PhOMe protons are significantly shorter than the rest of the molecule;
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(2) in the model of the HA4S-LYVE-1 complex, the PhOMe group
is in close proximity to the loop between β5 and β6. The chemical
properties of the amino acid residues in this loop are quite dissimilar
to those in either human or murine CD44 and modelling loops is chal-
lenging, so it may be that the conformation of this loop is not in full
agreement with the true structure. Nevertheless, this data provides
valuable information on the structure of the LYVE-1 HABD, which is
yet to be solved experimentally.
Figure 2.22: Saturation Transfer Difference (STD) Nuclear Magnetic Reso-
nance (NMR) predicted by CORCEMA-ST for the molecular docking model
of HA4S in complex with the human CD44 HA binding domain. Graphs are
plotted by residue (GlcNAc1 - PhOMe; top left - bottom right) and positions
of each proton resonance are marked on inset legends. The RNOE factor
compared to the experimental STD NMR data is 0.151.
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Figure 2.23: Saturation Transfer Difference (STD) Nuclear Magnetic Reso-
nance (NMR) predicted by CORCEMA-ST for the molecular docking model
of HA4S in complex with the human LYVE-1 HA binding domain. Graphs
are plotted by residue (GlcNAc1 - PhOMe; top left - bottom right) and posi-
tions of each proton resonance are marked on inset legends. The RNOE factor
compared to the experimental STD NMR data is 0.272 (0.198 discounting the
PhOMe residue).
2.3.5 Molecular Dynamics Simulations of the
human CD44 and LYVE-1 Hyaluronan
Binding Domains in Complex with a
Hyaluronan Tetrasaccharide
To assess the stability and understand the dynamics of the modelled
complexes, 100 ns molecular dynamics simulations of CD44 and LYVE-
1, both in complex with a hyaluronan (HA) tetrasaccharide (HA4)
were performed in triplicate. Analysis of the root mean square devia-
tions (RMSD) of CD44 (Fig. 2.24 A), LYVE-1 (Fig. 2.24 B) and HA4
in complex with either receptor (Fig. 2.24 C,D), shows that overall
there is little conformational change in either the receptor or the ligand
over the course of the simulations. The feature of note for the receptor
RMSDs is that there is a relatively large conformational change (~3
Å) in the LYVE-1 HABD for the final 40 ns of run 2. However, since
there is no corresponding change in the conformation of the ligand,
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it is likely that this change occurs in a region of the protein far from
the HA binding site. Indeed, clustering based on the RMSD of the
receptor Cα atoms indicates that there are some small changes in the
structure of the C-terminal extension. A similar but far smaller (~1.4
Å) change in RMSD is seen for the backbone of CD44 and likewise the
change is not accompanied by any conformational change in HA4S, so
is likely in a region far from the HA binding site. The RMSD of HA4
was determined using a no-fit calculation, meaning that in each frame
of the trajectory HA4S was not superimposed on top of its reference
prior to calculation, to take into account rotations and translations
relative to its receptor. In CD44, the RMSD values of HA4 remain
close to 1.5 Å indicating no significant translation or rotation, whereas
they fluctuate to higher RMSD values in complex with LYVE-1.
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Figure 2.24: Root mean squared deviation (RMSD) plotted as a function of
time. A-B: RMSD of CD44 (A) and LYVE-1 (B) Cα atoms. C-D: No-fit
RMSD of HA4 heavy atoms in complex with CD44 (C) or LYVE-1 (D). For
all plots, RMSD values are plotted for each of 3 independent replicas (blue,
orange, green)
Analysis of the root mean squared fluctuations (RMSF) of HA4 in
complex with CD44 or LYVE-1 reveal that generally the binding in-
teraction in LYVE-1 is more flexible relative to CD44 (Fig. 2.25), in
line with there being fewer hydrogen bonding interactions unlike that
seen in CD44. In particular, the central GlcA2-GlcNAc3 pair, which is
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the key binding motif in CD44, is significantly more flexible in LYVE-
1 compared to CD44. Indeed, in the case of LYVE-1 there appears to
be some translational motion of HA4 within the binding groove (Fig.
2.26), with the only consistent interactions being the methyl group
of GlcNAc3 in the hydrophobic pocket of the binding groove, and a
hydrogen bond between the backbone amide Gly107 and the carboxy-
late of GlcA4 - indeed GlcA4 exhibits the lowest RMSF of HA4S in
the case of LYVE-1 (Fig. 2.25).
Figure 2.25: Root mean squared fluctuation (RMSF) of HA4 residues in com-
plex with either CD44 (left) or LYVE-1 (right).
Figure 2.26: Cartoon representation of CD44 (cyan) and LYVE-1 (pink) in
complex with the representative structures of HA4 (yellow) for each cluster
calculated from k-means clustering. Representative structures chosen as those
closest to the centroid of each cluster.
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2.3.6 Adaptive Steered Molecular Dynamics of
the unbinding of a Hyaluronan Tetrasac-
charide from the human CD44 and LYVE-1
Hyaluronan Binding Domains
In order to deepen our understanding about the differences in dy-
namics and hence in affinity between the complexes of HA and CD44
or LYVE-1, we resorted to Adaptive Steered Molecular Dynamics
(ASMD) simulations, which allow the ligand to be virtually pulled
from the binding site, and the forces and interactions involved in the
process can be monitored. ASMD simulations were performed using
models of a hyaluronan tetrasaccharide (HA4) in complex with either
the CD44 or LYVE-1 HABDs. In the case of CD44, a large initial
force of approximately 400 pN was required to break the majority of
hydrogen bonds known to be key in forming the complex of HA and
CD44 (Fig. 2.27). After this point, little force is required to pull HA4
further from the binding site, except for a feature at approximately 10
Å, which corresponds to breaking the interaction with Arg41, the key
residue known to be essential for HA binding to CD44. Interestingly,
the conformation of Arg41 changes from the so-called high-affinity B-
form, to the low-affinity A-form as HA4 is removed from the binding
site (Fig. 2.28). This may be a mechanism by which HA is directed
towards the binding site and would provide the first evidence for the
role of Arg41 in affinity switching.
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Figure 2.27: Left: Force as a function of distance for pulling HA4 from the
binding site of CD44(top) and LYVE-1 (bottom). Distance measured as the the
distance between the GlcNAc3 methyl group and the center of the hydrophobic
binding pocket. Right: Number of hydrogen bonds formed between HA4 and
CD44 (top) or LYVE-1 (right) as a function of time. HA4 was pulled at a rate
of 2 Åns-1.
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Figure 2.28: Cartoon representation of HA4 unbinding from the human CD44
HABD. Structures shown at 4 ns intervals (dark to light). The key residue
Arg41 is shown (yellow circle) highlighting the conformational change from B
to A form.
Conversely, the force required to remove HA4 from the binding site
of LYVE-1 cannot be described by a single high-force event, but a
general force of about 150 pN occurring over a distance of about 10
Å (Fig. 2.27), reflecting the difference in structure of the binding site
(Fig. 2.29). This force is required to overcome the electrostatic inter-
actions with Lys105 and Lys108 and the counted hydrogen bonding
interactions come predominantly from the interaction of HA4 with
these same residues.
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Figure 2.29: Cartoon representation of HA4 unbinding from the human LYVE-1
HABD. Structures shown at 4 ns intervals (dark to light).
2.4 Discussion
The lymphatic hyaluronan (HA) receptor LYVE-1 is of great interest
due to its implication in various inflammatory diseases, but particu-
larly in cancer.[233–235] Lymphangiogenesis is becoming better under-
stood as a key player in cancer prognosis, and major route for metas-
tasis is through the lymphatic system - both of which are mediated
through the interaction of LYVE-1 on the surface of the lymphatic
endothelia[196,238] and HA that is found ubiquitously in the extracel-
lular matrix. Despite this, structural studies have been limited due
to challenges in preparing samples of sufficient quality for X-ray crys-
tallography or protein-observed NMR experiments (discussion with D.
G. Jackson). In particular, LYVE-1 appears not to be expressed well
in hosts that do not possess glycosylation machinery (for example, E.
coli). Here, for the first time, the interaction between LYVE-1 and HA
has been studied by ligand-based NMR in combination with molecular
modelling, providing valuable molecular detail of the interaction. Fur-
thermore, we have compared this interaction with that of CD44 and
HA, and discuss the fundamental differences between the two protein
ligand systems.
A homology model of the LYVE-1 HA binding domain (HABD) has
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already been described in a previous study.[242] However, a model of
the complex with HA was not produced from that study. Since that
model was built from the X-ray crystal structure of the unliganded
human CD44 HABD (PDB accession code: 1UUH), a new model was
produced here, using the HA-bound X-ray crystal structure of the
murine CD44 HABD (PDB accession code: 2JCR). This was chosen
since there are some small conformational changes in the structures
of the ligand-free and -bound forms of CD44, and it is likely that the
HA-bound form of LYVE-1 more closely resembles the structure of
HA-bound CD44.
The molecular models of LYVE-1 in complex with HA are validated
by excellent agreement with theoretical STD NMR build up curves
predicted by CORCMEA-ST (Fig. 2.16 and Fig. 2.23) and show
that almost all the key hydrogen bonding interactions, known to be
essential for the CD44-HA interaction, are missing in the LYVE-1-
HA complex (Fig. 2.19). The only preserved interaction appears
to be the burial of a GlcNAc methyl group within the hydrophobic
binding pocket of the HA-binding groove. This is supported by the
STD NMR data, which shows that only the GlcNAc3 methyl group of
the synthetic HA tetrasaccharide (HA4S) receives a significant amount
of saturation (Fig. 2.16). This is in contrast to to the STD NMR data
for the CD44-HA4S interaction, in which saturation is spread across
the central two residues (Glc2A-GlcNAc3) (Fig. 2.14).
Interestingly, the positively-charged residues, Lys105 and Lys108,
are positioned in close proximity to the carboxylate groups of GlcA
residues in the LYVE-1-HA complex (Fig. 2.19). Given that there
are very few other interactions, it appears that the LYVE-1-HA
interaction is predominantly electrostatic in nature, which agrees
with the observation the the interaction is highly modulated by the
ionic strength of the buffer.
Finally, the ASMD simulations performed here, which pull the HA
ligand from the binding site, highlight the effect of these profound
differences in binding site properties. In particular, the CD44-HA in-
teraction requires a large force to initially to break the network of
hydrogen bonding interactions that hold the central GlcA-GlcNAc
disaccharide within the binding groove (Fig. 2.27 and Fig. 2.28),
whereas, for LYVE-1, a weaker force is required over a longer distance
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(Fig. 2.27 and Fig. 2.29). This may be explained by the different
niches inhabited by these receptors, since CD44 is known to play an
important role in leukocyte attachment to the endothelia in the high-
flow vascular environment, whereas the flow-rate of the lymphatics is
typically much gentler.
2.5 Conclusions
In this chapter a combination of STD NMR spectroscopy and molec-
ular modelling has been used to generate an experimentally validated
homology model of the LYVE-1/HA complex. Using this data, as well
as long molecular dynamics simulations, the structure and dynamics
of the LYVE-1-HA complex have been compared and contrasted to
the CD44/HA complex, which has already been thoroughly studied.
Overall the conclusions were:
1. The overall three dimensional structure of the LYVE-1 hyaluro-
nan binding domain (HABD) is comparable to that of CD44 and
also possesses a binding groove in which HA binds in a longitu-
dinal fashion.
2. The properties of the binding groove in the LYVE-1 HABD dif-
fer dramatically to that in CD44. While CD44 interacts with
HA through an ordered hydrogen bonding network presented
through the sidechains surrounding the binding groove (as well
as the hydrophobic pocket that recognises the N-acetyl group
of GlcNAc), the binding groove of LYVE-1 is largely missing
these interactions and instead appears to predominantly utilise
electrostatic attraction (although the hydrophobic pocket is still
present).
3. The LYVE-1/HA interaction appears to be more transient and
requires less force to break compared to the CD44/HA interac-
tion. This may be useful in each of the receptors’ native environ-
ments, since the high flow in the vascular endothelium requires
a tighter interaction for adhesion (CD44) compared to the low
flow of the lymphatic endothelium (LYVE-1).
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Chapter 3
Understanding Ligand Recog-
nition by PsLBP
3.1 Introduction
The synthesis of protein and DNA is a highly reproducible process due
to their template driven mechanism - new DNA is synthesised based
on complementary base pairing to an existing strand, and proteins are
synthesised by translation of mRNA in the ribosome. Both of these
processes are tightly controlled and linear in nature - that is, each
nucleotide base/amino acid is added sequentially to the growing chain.
The result is a homogeneous sample in which, assuming there are no
errors or subsequent modifications, one may expect every molecule to
be identical.
The same cannot be said of glycan synthesis. Instead, the endoplas-
mic reticulum (ER) and Golgi are lined with various glycan processing
enzymes, that add (glycosyltransferase) or remove (glycosidase) moi-
eties from the glycan chain, each with their own specificity.[259] Since
the concentration of these enzymes varies across cell-type and specific
environmental conditions of the cell, so too can the structure of the
produced glycans vary considerably.[260] This, in part, explains why the
field of glycobiology for a long time has fallen behind its counterparts
in the study of DNA and proteins.
For the function of glycans and their physiological effects to be fully
understood, it will be necessary to produce homogeneous glycan
samples. Furthermore, since glycans and glycan-binding proteins
are found ubiquitously and play such an important role in functions
such as cell mobility and communication,[261] many research groups
are exploiting this in order to develop novel diagnostics[262] and
therapeutics,[263] utilising carbohydrates to recognise specific cell
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types and, in some cases, deliver a therapeutic payload.[264] All of
these again call for reproducible synthesis of their carbohydrate
moieties.
Unfortunately, the chemical synthesis of carbohydrates is incredibly
complex and costly, owing predominantly to the large number of
stereocenters and reactive functional groups of the monosaccharide
precursors. Typically such reactions take place over very many steps
and suffer from poor yields.[265] Therefore recent efforts have focussed
on enzymatic synthesis of carbohydrates, which benefits from the in-
nate highly stereo- and regiospecific nature of carbohydrate-active
enzymes.[95]
3.1.1 Enzymatic synthesis of carbohydrate
derivatives
The vast majority of studies into enzymatic synthesis of carbohydrates
has focussed on glycosyltransferases, which catalyse the formation of
glycosidic bonds between two carbohydrate moieties, typically using
a sugar-nucleotide donor (Fig. 3.1 top).[266] However, such donors
tend to be expensive. Furthermore, many glycosyltransferases suffer
from low stability, and their narrow substrate specificity limits their
usefulness in broad academic and industrial applications.
Figure 3.1: Simplified typical mechanism of glycotransferases (top) and glyco-
side phosphorylases (bottom). NDP = nucleotide diphosphate.
However, more recently, another class of enzymes has emerged as
promising candidates for enzymatic synthesis of carbohydrates. The
glycoside phosphorylases catalyse the reversible cleavage of glycosidic
linkages by transferring inorganic phosphate to the non-reducing sugar
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(Fig. 3.1 bottom).[267] The reverse reaction, which results from per-
forming the reaction in the presence of an excess of sugar 1-phosphate
as the donor substrate and a corresponding mono- or oligosaccharide
as an acceptor substrate, may be used to instead synthesise glycosidic
linkages. Such a reaction is synthetically attractive, since the sugar
1-phosphate donors are typically far more accessible and stable than
the sugar-nucleotides utilised by glycosyltransferases.
In addition, glycoside phosphorylases typically exhibit far broader ac-
ceptor substrate specificity, making them synthetically useful for a
large number of applications. For example, cellobiose (Glcβ-1-4Glc)
phosphorylase has been shown to be capable of using mannose,[268]
xylose and simple alcohols as acceptor substrates,[269] while cellodex-
trin (Glcβ-1-4Glc oligosaccharides) phosphorylase has been shown to
accept both G1P and Gal1P as donor substrates.[270]
Many synthetic monosaccharides can be prepared to contain chemical
modifications that may give them more favourable properties com-
pared to their natural counterparts, such as higher binding affinity to
specific receptor targets, better bioavailability, or they may be used
as markers.[271] Some glycoside phosphorylases have been shown to
tolerate such modifications, allowing for a relatively facile pathway to
producing oligosaccharides containing such modifications, such as may
be utilised in a glycomimetic drug or nanoparticle-based therapeutic/-
diagnostic. For example, fluoro-sugars, in which one or more of the
hydroxyl groups is replaced with fluorine, seem to be well tolerated by
many glucoside phosphorylases.[272] Furthermore, sucrose phosphory-
lase has been used to transfer a number of non-carbohydrate moieties
to glucose, including hydroquinone, cytosine mono phosphate and ben-
zoic acid.[273]
3.1.2 Laminaribiose phosphorylase from Paeni-
bacilus sp. (PsLBP)
Recently, the group of Rob Field (John Innes Centre, Norwich, UK)
demonstrated that the laminaribiose (Glcβ-1-3Glc) phosphorylase
from Paenibacillus sp. (PsLBP) is capable of accepting mannose-
1-phosphate (M1P) as a non-cognate donor substrate, leading to
the facile synthesis of the unnatural disaccharide Manβ-1-3Glc.[274]
130
Furthermore, they reported the crystal structure of PsLBP in complex
with G1P (PDB ID: 6GH2) and M1P (PDB ID: 6GH3). These are
only the second reported structures of a glycoside phosphorylase in
complex with its donor substrate, after a sophorose (Glcβ-1-2 Glc)
phosphorylase from Lachnoclostridium phytofermentans in complex
with G1P (PDB ID: 5H42).[275]
Our understanding of donor substrate recognition by glycoside phos-
phorylases is therefore severely limited and warrants further study.
Here we perform STD NMR spectroscopy experiments coupled with
molecular modelling to further understand the interaction between
PsLBP and its substrates.
3.1.3 Objectives
The aim of this chapter is to provide experimental solution state infor-
mation for the interaction of the glycoside phosphorylase PsLBP and
its substrates, both cognate and non-cognate, to complement and vali-
date the model complexes derived from X-ray crystallography. Specif-
ically the objectives are:
• Use quantitative STD NMR calculations to validate the
X-ray crystallography derived models of the PsLBP/G1P and
PsLBP/M1P complexes in the solution state.
• Use STD NMR epitope mapping to obtain structural informa-
tion about the interaction between PsLBP and the acceptor sub-
strate, Glc, as well as the reaction products (reverse reaction)
laminaribiose and Manβ-1-3Glc.
3.2 Materials and methods
3.2.1 NMR Spectroscopy
All samples were prepared in D2O with [D11]Tris (25 mM, pH 7.4)
and contained final protein and ligand concentrations of 50 µM and
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6 mM respectively (protein omitted in assignment experiments). All
experiments were performed at 278 K on a Bruker Avance III 800
MHz spectrometer equipped with a 5 mm TXI 800 MHz H-C/N-D-05
Z BTO probe. All carbohydrate ligands were assigned based on 1D
1H, 1H-1H COSY, 1H-1H TOCSY, 1H-13C HSQC and 1H-1H NOESY
NMR experiments. For the TOCSY the mixing time was set to 80
ms and for the NOESY the mixing time was set to 1000 ms. STD
NMR spectroscopy experiments were performed by using a train of
50 ms Gaussian pulses applied on the f2 channel at either 0.8 (on-
resonance) or 40 ppm (off-resonance). A spoil sequence was used to
destroy unwanted magnetisation and a spin lock was used to suppress
protein signals (stddiff.3). The recycle delay (d1) was set to 5 s. The
total saturation time and number of scans were selected according
to Table 3.1. The measured STD intensities were fitted to Eqn 45 to
calculate STD0, which was then used to plot binding epitopes following
normalisation against the largest STD0 value.
Table 3.1: Total saturation time and number of scans selected for STD NMR
spectroscopy measurements.
Saturation Time
(s) No. Scans
Saturation Time
(s) No. Scans
0.5 512 2 128
0.75 512 3 128
1 256 5 128
1.5 256
3.2.2 Preparation of Molecular Models
Crystal structures were imported into Schrödinger Maestro and pre-
pared with the Protein Preparation Wizard. All non-protein or non-
ligand atoms were removed. Protons were then added to the model,
using PROPKA to predict the protonation state of polar side chains
at pH 7.[276] The hydrogen-bonding network was automatically opti-
mised by allowing asparagine, glutamine, and histidine side chains to
be flipped. The model was then minimised by using the OPLS3[120]
force field and a heavy-atom convergence threshold of 0.3 Å. Because
STD NMR spectroscopy experiments were performed in D2O, the po-
lar protons were removed from the ligand prior to CORCEMA-ST
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analysis.[277]
3.2.3 CORCEMA-ST calculations
Protein chemical shifts were predicted by using the SHIFTX2[278] web-
server, according to experimental conditions. All protein protons
within 15 Å of the ligand were considered in the calculation. The
instrument field strength, solvent type, ligand concentration, and pro-
tein concentration were set according to experimental values. The
free and bound ligand correlation times were optimised to be 0.3 and
300 ns respectively, based on reasonable values for a monosaccharide
binding to a 200 kDa protein. The non-specific leakage was also opti-
mised to 0.8 Hz. The internal correlation time was set to 10 ps and
the methyl-X order parameter was set to 0.85, according to previously
published values.[277] All protein protons with resonances between 0.6
and 1 ppm were considered to be instantaneously saturated to account
for line broadening. For G1P, the equilibrium constant and kon were
optimised to 25,000 M-1 and 105 M-1 s-1 respectively. For M1P, the
equilibrium constant was reduced to 16,000 M-1. Both values were
in agreement with the affinities typically observed for carbohydrate-
binding proteins.
3.3 Results
3.3.1 STD NMR and CORCEMA-ST of G1P and
M1P binding to PsLBP
Crystal structures of G1P and the non-cognate donor substrate M1P
in complex with PsLBP were obtained by the group of Prof. Rob
Field.[274] However, such models only provide a snapshot of the com-
plex in the solid phase, whereas ideally the complex should be studied
in the solution phase, with access to dynamic information. Therefore
we studied the interaction of these substrates with PsLBP by STD
NMR.
Initially experiments were conducted at 298 K. However, at this tem-
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perature, G1P was rapidly converted to laminaribiose (LB) (Fig. 3.2).
This shows that the enzyme must be capable of hydrolysing G1P to
Glc and inorganic phosphate; the pool of Glc can then be used as an
acceptor for reaction with the remaining G1P in order to form LB.
Therefore, it was necessary to reduce the temperature to 278 K before
it was possible to conduct the full STD NMR build-up experiment
without any detectable hydrolysis of G1P (Fig. 3.3).
Figure 3.2: Spectra of G1P in the presence of PsLBP before (blue) and after
(orange) 18 hours incubation at 298 K. Significant degradation of G1P can be
seen by the reduction in intensity of G1P peaks, as well as the appearance of
new peaks.
134
Figure 3.3: Reference and STD NMR difference spectra of G1P (reference:
blue, difference: orange) and mannose-1-phosphate (reference: green, differ-
ence: red) each in the presenence of PsLBP. Spectra recorded at 800 MHz,
278 K with a saturation time of 2 s. Difference spectra magnified 20x.
The binding epitope map was obtained from the initial slopes of the
STD build-up curves of G1P and shows a highly uniform epitope,
with relative STD intensities ranging between 84%-100% (Fig. 3.5).
Within this epitope the exocyclic H6 protons exhibit the strongest
STD intensities, followed by H4, whilst H1 and H2 exhibit the weakest
135
STD intensities indicating that the most intimate spatial contacts with
the enzyme are made by the ligand area encompassing C4 and C6
(Table 3.2). This is in good agreement with the crystal structure of
the G1P/PsLBP complex, in which H4 and H6 face the surface of the
interior binding cavity. In particular, the H6 protons are in very close
proximity to the aromatic sidechains of Trp524 and Phe737 (Fig. 3.4).
Conversely, H1 and H2 face the open entrance to the cavity and so
receive less saturation.
Figure 3.4: Crystal structures of G1P (yellow) and M1P (cyan) in complex with
PsLBP.
Figure 3.5: Binding epitope maps of G1P (left) and M1P (right), both in the
presence of PsLBP. Colours represent the normalised STD values for proton
resonances at the indicated positions (low - high, cold - hot).
Table 3.2: Experimental STD intensities measured for G1P binding to PsLBP.
*Normalised against the H6’ proton.
Proton δ (ppm) ksat (% s-1)
STDmax
(%)
STD0
(%) Norm.*
H1 5.13 0.49 3.88 1.89 83.8
H2 3.15 0.62 3.03 1.88 83.5
H3 3.46 0.47 4.18 1.95 86.9
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Proton δ (ppm) ksat (% s-1)
STDmax
(%)
STD0
(%) Norm.*
H4 3.07 0.58 3.62 2.08 92.6
H5 3.60 0.78 2.56 2.01 89.1
H6 3.55 1.34 1.63 2.20 97.6
H6’ 3.42 1.26 1.78 2.25 100
To confirm the agreement between the solid phase crystal structure
and the solution state STD NMR data, CORCEMA-ST[277] was used
to predict theoretical STD NMR intensities based on the 3D coor-
dinates of the G1P/PsLBP complex. After optimisation, the NOE
R-factor between the experimental and predicted STD NMR datasets
was calculated to be 0.09, indicating excellent agreement between the
crystal structure and STD NMR data (Fig. 3.6). It should be noted
that, while most of the CORCEMA-ST parameters are derived from
experimental conditions, in the case of unknown parameters, they can
be optimised iteratively to achieve a final working value. For example,
the dissociation constant of the G1P/PsLBP complex was unknown,
but was optimised for CORCEMA-ST to be 40 µM, which falls within
the typical Kd range of protein-carbohydrate interactions.[279,280]
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Figure 3.6: Experimentally determined STD build-up curves for glucose-1-
phosphate (G1P) and mannose-1-phosphate (M1P) binding to PsLBP (top)
and their respective CORCEMA-ST calculated STD intensities (bottom). The
NOE R-factors (RNOEs) between the experimental and calculated data for G1P
and M1P are 0.09 and 0.23 respectively. For experimental data, circles show
observed STD intensities, whereas curves are determined from least squares
fitting to Eqn. 45.
In contrast, the binding epitope map of M1P exhibits a far wider
range of relative STD intensities, with the weakest intensity, coming
from H1, having an intensity of 48% (Fig. 3.5b, Table 3.3). This
is indicative of a shorter residence time of M1P in the bound state
compared to G1P, since the saturation transferred from PsLBP would
be unable to spread as uniformly in a shorter period of time. This
is understandable since M1P is not the native substrate, and agrees
well with the observation that the catalytic turnover rate is reduced
approximately tenfold for M1P compared to G1P.[274]
In a similar manner as G1P, the most intense STD intensities from the
M1P binding epitope map come from the H6, H4 and H3 protons (Ta-
ble 3.3). This suggests that M1P does indeed bind in a similar binding
mode to G1P, which is in agreement with the crystal structures (Fig.
3.4). The H2 proton of M1P shows particularly weak STD intensity
(55%), especially in comparison to G1P (84%). A difference here is
understandable, since the chirality of this stereocentre is inverted such
that H2 is equatorial in M1P, compared to axial in G1P, although such
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a drastic difference is probably related to the shorter residence time
in the bound state.
Table 3.3: Experimental STD intensities measured for M1P binding to PsLBP.
*Normalised against the H6’ proton.
Proton δ (ppm) ksat (% s-1)
STDmax
(%)
STD0
(%) Norm.*
H1 5.00 0.38 4.94 1.85 48.2
H2 3.63 0.59 3.29 1.94 50.5
H3 3.57 0.84 3.78 3.17 82.5
H4 3.26 0.49 6.61 3.26 84.9
H5 3.64 0.63 3.34 2.11 55.0
H6 3.58 1.17 3.06 3.59 93.3
H6’ 3.40 1.27 3.02 3.84 100
As for G1P, CORCEMA-ST was used to analyse the agreement be-
tween the crystal complex of M1P and PsLBP and the associated
STD NMR data (Fig. 3.6). All parameters were kept identical to
those optimised for G1P, with the exception of the complex dissocia-
tion constant. This was optimised to 63 µM, which is in agreement
with the proposition that M1P binds to PsLBP with lower affinity
than G1P. Despite these optimisations, the best obtainable RNOE
factor for the M1P/PsLBP complex was 0.23, which is still considered
a very good fit between the crystal structure and STD NMR data.
We consider RNOE factors below 0.3 to be in good agreement, whilst
many other groups accept values below 0.5.
One particularly interesting difference between the two binding epi-
tope maps is that of H5. In the crystal structures, the position of H5
is identical in both the G1P and M1P complexes and it points towards
the aromatic sidechain of Trp524[274] (Fig. 3.4). However, for G1P the
relative STD intensity is 89%, whereas it is 55% for M1P. It may be
that, in solution, the binding mode of M1P may not be as stable as
that of G1P, which would agree with the observation in the crystal
structure that Arg353 coordinates O2 of G1P, an interaction that is
not possible in M1P since O2 is axial (Fig. 3.4).
With regard to absolute STD intensities, on average those of M1P
are higher than those of G1P, with the H6 showing absolute initial
growth rates of STD build up of 2.2% s-1 and 3.6% s-1 for G1P and
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M1P respectively. This is indicative of each substrate having a dif-
ferent binding affinity for PsLBP since different STD intensities here
would be indicative of different fraction of ligand bound. From other
experiments we anticipate the binding affinity of M1P to be lower
than G1P, and since this corresponds to an increase in STD inten-
sity, this would suggest that the affinity of the substrates for PsLBP
was towards the tighter end (µM) of the detectable affinity range by
STD NMR, in agreement with the optimised Kd values obtained from
CORCEMA-ST calculations.
This study highlights a very important aspect of the interpretation
of STD NMR data. Here the molecular recognition of two different
ligands by the same enzyme have been studied by both X-ray crys-
tallography and STD NMR spectroscopy. In this way, the results
demonstrate that a simplistic analysis based exclusively on the bind-
ing epitopes observed by STD NMR (Fig. 3.5) might lead to the
wrong conclusion that the ligands are interacting with the enzyme
with different binding modes. It is only after a quantitative analysis,
using CORCEMA-ST on the X-ray derived 3D molecular models of
the complexes, when the experimental spectroscopic data confirm that
indeed in solution both ligands are binding in similar binding mode, as
shown in the X-ray structures. Hence, the differences in the binding
epitopes are, in this particular case, clearly ascribable to their differ-
ences in residence time in the bound state, i.e. in affinity, and not
to differences in their interaction modes. Thus, this study emphasises
the importance of carrying out quantitative analysis of the STD NMR
results whenever it is feasible, using CORCEMA-ST, in order to avoid
misinterpretations in comparative binding analysis, as the kinetics of
saturation transfer and its relationship to residence time in the bound
state are important parameters to take into consideration in structural
analysis.
3.3.2 STD NMR of Glc binding to PsLBP
In solution, Glc is spontaneously exchanging between its α and β-
anomers such that both species are present in solution (anomeric equi-
librium). This precludes such a detailed study as for G1P and M1P,
for which the configuration is locked by the presence of the phosphate,
since overlapping signals exist from both the α and β-anomers. Nev-
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ertheless, the 1D 1H NMR spectrum showed sufficient resolution to
measure STD intensities for many of the proton resonances in both
the α and β anomers individually.
From the reference NMR spectra, it was clear that both the α and β-
anomers of Glc exist in solution in comparable proportions (Fig. 3.7).
Despite this, the STD intensity from the α-anomer was very weak (Fig.
3.7, Fig. 3.8). For example, the initial growth rate of STD intensity
build up for the anomeric proton of αGlc is about 12% that of βGlc
(Table 3.4). This suggests that PsLBP is selective for the β-anomer,
which is intriguing since the anomeric configuration of Glc would not
impact on the configuration of the enzymatically-formed glycosidic
linkage. The binding epitope map of the α-anomer of Glc will not
be discussed since the STD intensities were too weak to measure with
enough accuracy.
Figure 3.7: Reference and STD NMR difference spectra of glucose (reference:
blue, difference: orange) in the presence of PsLBP. Spectra recorded at 800
MHz, 278 K with a saturation time of 2 s. Difference spectrum magnified 50x.
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Figure 3.8: Experimentally determined STD build-up curves for β-glucose (left)
and α-glucose (right) binding to PsLBP. Circles show observed STD intensities,
whereas curves are determined from least squares fitting to Eqn. 45.
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Table 3.4: Experimental STD intensities measured for Glc binding to PsLBP. Values of STD0 for α Glc (left) and β Glc (right) protons shown. †/‡ STD intensity
measured from same peak. *Normalised against the H6 proton of αGlc and βGlc respectively.
Proton δ (ppm) ksat (% s-1)
STDmax
(%)
STD0
(%) Norm.* δ (ppm) ksat (% s-1)
STDmax
(%)
STD0
(%) Norm.*
H1 5.14 0.29 1.41 0.405 57.3 4.56 0.89 3.88 3.47 51.2
H2 3.45 0.47 0.96 0.457 64.6 3.16 0.60 5.06 3.01 44.5
H3 3.63 - - - - 3.39 0.91‡ 4.06‡ 3.68‡ 54.3‡
H4 3.32 - - - - 3.32 - - - -
H5 3.75 1.23† 0.58† 0.707† 100† 3.37 0.91‡ 4.06‡ 3.68‡ 54.3‡
H6 3.75 1.23† 0.58† 0.707† 100† 3.81 2.10 3.23 6.77 100
H6’ 3.68 0.78 0.74 0.576 81.5 3.64 - - - -
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The binding epitope map of βGlc reveals that the strongest STD inten-
sities again come from the H6 protons (Fig. 3.9). However, moderate
STD intensities are observed for H1, H3 and H5, whilst the STD in-
tensity of H2 is weak. This suggests a fundamentally different binding
mode of βGlc compared to G1P and M1P. This is in agreement with
its role as the acceptor substrate, since it would be expected that βGlc
would bind to a different, but nearby, binding subsite.
Figure 3.9: Binding epitope maps of β-glucose (left) and α-glucose (right),
in the presence of PsLBP. Colours represent the normalised STD values for
proton resonances at the indicated positions (low - high, cold - hot).
These data also suggest two other points. Firstly, the donor subsite
occupied by G1P and M1P must require a hexose-1-phosphate, oth-
erwise it would be expected that αGlc would bind well. Finally, the
structure of the acceptor subsite must be such that α, with its axial
C1-hydroxyl group, is unable to bind with good affinity, perhaps due
to steric interactions.
3.3.3 STD NMR of laminaribiose and Manβ-1-3-
Glc binding to PsLBP
The products of the PsLBP-catalysed reaction between either G1P
or M1P and Glc are LB and Manβ-1-3-Glc respectively. Like Glc,
the reducing termini of LB and Manβ-1-3-Glc may spontaneously ex-
change between the α and β-anomers, leading to two distinct species
in solution. The NMR spectra are further convoluted by the fact that
we are now dealing with disaccharides. In both cases, differences in
anomeric configuration lead to unique resolvable chemical shifts for
each proton of the reducing sugar, as well as the anomeric proton of
the non-reducing sugar.
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Similar to Glc, the α and β configurations of LB and Manβ-1-3-Glc are
present in comparable concentrations in solution (Fig. 3.10), yet the
STD intensities from αLB and Manβ-1-3-Glcα are very weak in com-
parison to their respective β-configurations (Fig. 3.11). This shows
again that PsLBP is selective for the β-configuration of the reducing
sugar and this reducing sugar seems to occupy the same subsite as
the monosaccharide Glc, which would agree with the known reaction.
Furthermore, since the non-reducing sugar, which retains the same
configuration in both species, exhibits negligible STD intensities for
the α-configurations of both LB and Manβ-1-3-Glc, it appears that
the reducing sugar is most important for interaction of the disacharides
with PsLBP. This also agrees with the hypothesis that the subsite spe-
cific for G1P and M1P, which is also expected to be occupied by the
non-reducing sugar of LB and Manβ-1-3-Glc, facilitates the interac-
tion predominantly through interaction with the phosphate group of
the phosphorylated donor substrates.
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Figure 3.10: Reference and STD NMR difference spectra of laminaribiose (refer-
ence: blue, difference: orange) and Manβ-1-3-Glc (reference: green, difference:
red) each in the presence of PsLBP. Spectra recorded at 800 MHz, 278 K with
a saturation time of 2 s. Difference spectra magnified 10x.
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Table 3.5: Experimental STD intensities of LB Glc1 measured for LB binding to PsLBP. *STD0 normalised against H6 of Glc2 in βLB. †Values correspond to
Glc1 H1 in αLB and βLB respectively.
Proton δ (ppm) ksat (% s-1) STDmax (%) STD0 (%) Norm.*
H1 4.39/4.41† 0.76/0.59† 6.98/1.26† 0.740/5.33† 3.67/26.5†
H2 3.04 0.51 6.07 3.10 15.4
H3 3.20 - - - -
H4 3.16 - - - -
H5 3.09 0.63 6.69 4.23 21.0
H6 3.60 1.24 3.70 4.59 22.8
H6’ 3.39 - - - -
147
Table 3.6: Experimental STD intensities of LB Glc2 measured for LB binding to PsLBP. The columns show STD intensities for Glc2α (left) and Glc2β (right).
*STD0 normalised against H6 of Glc2 in βLB.
Proton δ (ppm) ksat (% s-1)
STDmax
(%)
STD0
(%) Norm.* δ (ppm) ksat (% s-1)
STDmax
(%)
STD0
(%) Norm.*
H1 4.91 0.47 1.52 0.714 3.54 4.35 0.77 14.3 11.1 54.9
H2 3.39 - - - - 3.11 0.53 10.5 5.57 27.6
H3 3.58 - - - - 3.39 - - - -
H4 3.54 0.84 1.48 1.24 6.14 3.20 - - - -
H5 3.19 - - - - 3.18 0.86 9.10 7.79 38.7
H6 3.50 1.14 1.22 1.39 6.92 3.57 1.46 13.8 20.1 100
H6’ 3.46 1.18 1.18 1.40 6.93 3.41 1.26 12.6 15.8 78.7
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Table 3.7: Experimental STD intensities measured of Manβ-1-3-Glc Man for Manβ-1-3-Glc binding to PsLBP. *STD0 normalised against H6’ of Glc in Manβ-1-
3Glcβ. †Values correspond to Man1 H1 in Manβ-1-3Glcα and Manβ-1-3Glcβ respectively.
Proton δ (ppm) ksat (% s-1) STDmax (%) STD0 (%) Norm.*
H1 4.55/4.57† 0.54† 3.64† 0.61/1.95† 4.85/15.6†
H2 3.79 0.60 2.85 1.70 13.6
H3 3.33 0.62 2.85 1.76 14.1
H4 3.23 0.73 3.32 2.44 20.0
H5 3.08 0.75 3.02 2.27 18.1
H6 3.56 1.38 5.47 7.52 60.2
H6’ 3.53 1.45 8.64 12.5 100
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Table 3.8: Experimental STD intensities measured of Manβ-1-3-Glc Glc for Manβ-1-3-Glc binding to PsLBP. The columns show STD intensities for Glcα (left)
and Glcβ (right). *STD0 normalised against H6’ of Glc2 in Manβ-1-3Glcβ.
Proton δ (ppm) ksat (% s-1)
STDmax
(%)
STD0
(%) Norm.* δ (ppm) ksat (% s-1)
STDmax
(%)
STD0
(%) Norm.*
H1 4.90 0.75 1.33 1.00 8.01 4.34 0.55 7.75 4.28 34.3
H2 3.32 0.62 2.29 1.41 11.3 3.04 0.47 5.70 2.66 21.3
H3 3.57 - - - - 3.39 1.05 4.91 5.14 41.1
H4 3.19 - - - - 3.19 0.87 6.61 5.75 46.0
H5 3.53 1.03 0.88 0.903 7.23 3.16 0.76 8.20 6.24 49.9
H6 3.48 1.43 0.86 1.23 9.86 3.40 1.12 7.80 9.34 74.7
H6’ - - - - - - - - - -
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Figure 3.11: Experimentally determined STD build-up curves for laminaribiose
(top) and Manβ-1-3-Glc (bottom) binding to PsLBP. Circles show observed
STD intensities, whereas curves are determined from least squares fitting to
Eqn. 45.
The binding epitope map of βLB shows that the strongest STD inten-
sities are present on the reducing sugar (Glc2), in particular the H6
protons again agreeing with the key relevance of the glucose reducing
ring for binding (Fig. 3.12). Moderate STD intensity is seen for the
H1 of the reducing sugar, whilst H2, H4 and H5 of the same residue
exhibit weak STD intensities. This follows a similar pattern to βGlc,
for which the H1 and H6 also make the most significant contacts with
PsLBP. This adds further evidence to suggest that the reducing sugar
of βLB binds to the same subsite as the monosaccharide βGlc and that
it is this residue that is most important for specificity and binding.
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Figure 3.12: Binding epitope maps of laminaribiose (top) and Manβ-1-3-Glc
(bottom), both in the presence of PsLBP. Colours represent the normalised
STD values for proton resonances at the indicated positions (low - high, cold -
hot).
Interestingly, the binding epitope map of the non-reducing sugar
(Glc1) is quite disimilar to the epitope map of G1P, despite the
expectation that they should occupy the same binding site. In
βLB, this sugar exhibits the strongest STD intensities for H1 and
H3, unlike the H4 and H6 of G1P. It is important to note that the
non-reducing sugar of βLB is in the β-configuration, whilst G1P is in
the α-configuration. Therefore, in βLB, the H1 of the non-reducing
sugar is axial and would therefore point towards the protein surface
instead of towards the empty cavity. However, clearly there is
some rearrangement within the binding subsite of the non-reducing
sugar of βLB compared to G1P such that the H4 and H6 protons
are tilted further from the PsLBP surface and such that H3 makes
more intimate contact. This is understandable since the phosphate,
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thought to be essential for binding to this subsite, is no longer
present.
The binding epitope map for Manβ-1-3-Glcβ shows some similarities
to that of βLB (Fig. 3.12), with the H6 of the non-reducing sugar
(Man) making the most significant contacts with PsLBP, whilst the
STD intensities exhibited by the non-reducing sugar are generally
weak, suggesting that Manβ-1-3-Glcβ binds to PsLBP in a similar
manner. However, it is important to highlight that the H6 protons
of the non-reducing sugar of Manβ-1-3-Glcβ show very strong STD
intensities, unlike that observed for βLB. The result indicates that the
inversion of the configuration at C2 of the non-reducing Man of Manβ-
1-3-Glcβ relative to that of the non-reducing Glc of βLB causes Man
to adopt a different binding orientation with its subsite to facilitate
more favourable contacts with the PsLBP sidechains.
It is also interesting that the magnitude of the absolute STD intensities
observed for βLB and Manβ-1-3-Glcβ are comparable (Tables 3.5, 3.5,
3.7, and 3.8), suggesting similar binding affinities. This is in agreement
with the hypothesis that the reducing sugar (Glc2 in LB, Glc in Manβ-
1-3-Glcβ) is most important for binding, since the reducing sugar is
βGlc in both cases. It also suggests that the non-reducing sugar does
not contribute significantly to the binding affinity, which further agrees
with the donor subsite requiring a hexose-1-phosphate for recognition.
3.4 Discussion
The chemical synthesis of oligo- and poly-saccharides is extremely chal-
lenging due to the large number of stereocenters and reactive func-
tional groups present in these molecules. Enzymatic synthesis pro-
vides an attractive alternative because it provides a facile, highly stere-
ospecific, one-step method for forming glycosidic bonds. Glycosidase
phosphorylases (GPs) are attractive candidates because, compared to
glycosyl transferases (GTs) which have previously been extensively
studied for the same purpose, they are typically more stable, utilise
cheaper substrates, and are more promiscuous with regard to substrate
specificity, increasing their utility over a wider range of syntheses.
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The Laminaribiose phosphorylase from Paenibacilus sp. (PsLBP) is
one such enzyme and has been shown to tolerate the non-cognate
donor substrate, mannose-1-phosphate (M1P), as well as its native
donor substrate, glucose-1-phosphate (G1P). Here we have used a com-
bination of STD NMR spectroscopy and molecular modelling to con-
firm the solution structure of the complexes between PsLBP with the
donor substrates G1P and M1P. The results highlight excellent agree-
ment between experimental STD NMR data and STD values predicted
from the crystal structures of the complexes.
In addition, our results suggest a shorter residence time in the bound
state of the non-cognate donor M1P within the donor subsite com-
pared to G1P. This is understandable since the crystal structure shows
that the interaction between the C2 hydroxyl of the donor and the
sidechain of Arg353 in PsLBP is broken by inversion of the stere-
ochemistry at C2 in M1P. Nevertheless, this inversion is tolerated
since the C2 of the donor faces the opening of the donor subsite cav-
ity. This suggests that further substitutions at this position could be
tolerated, although the related cellobiose phosphorylase from Cellvib-
rio gilvus (CgCBP) fails to tolerate N-acetylglucosamine 1-phosphate
(GlcNAc1P).[281] However, chitobiose phosphorylase from Vibrio prote-
olyticus (VpChBP) does use GlcNAc1P as a donor[282] and the architec-
ture of the donor subsite differs only in the positioning of the arginine
that interacts with the C2 substituent (Arg353 in PsLBP, Arg343 in
VpChBP), suggesting that modification of PsLBP could be possible
in order to accommodate larger C2 substituents.
It is unlikely that modifications to the sugar 1-phosphate donor at
positions other than the C2 would be tolerated by PsLBP, since both
the crystal structures and the STD NMR data show strong contacts
at the C4 and C6 positions, both of which face the rear of the donor
subsite cavity so any modification would hinder binding due to steric
interactions. This is supported by the fact that Gal1P, in which the
stereochemistry about C4 is inverted, is incapable of acting as a donor
substrate.[274]
It was not possible to obtain crystal structures of PsLBP in complex
with the acceptor, Glc, nor the reaction products, LB or Manβ-1-3-
Glc. However, using STD NMR it was possible to unravel some details
of these complexes. This underscores the usefulness of STD NMR to
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gain structural details of such weak protein-carbohydrate interactions
that don’t produce complexes stable enough as to be crystallised. In
particular, the β-anomer of Glc and the reducing Glc residue in the
reaction products bound to PsLBP with much higher affinity than
the α-anomer. This is interesting because it highlights two details: (1)
the acceptor subsite tolerates only the β-configuration of the acceptor,
and (2)the donor subsite has no or low affinity for non-phosphorylated
sugars.
It is intriguing as to why PsLBP would select for only the β-anomer
of the acceptor since the configuration here should have little effect on
the enzymatic mechanism. Therefore, it is likely that this selection is
circumstantial and a consequence of the tight β-hairpin gate proposed
to limit the degree of polymerisation to disaccharides.[274] The low
affinity for non-phosphorylated sugars in the donor subsite highlights
that the phosphate is an essential recognition element for this subsite
and may prevent the catalytic activity from being hampered by an
excess of the acceptor substrate.
As of yet, the specificity of the acceptor subsite has not been tested.
Given that the acceptor subsite is intentionally restrictive to prevent
polymerisation past a disaccharide, it may be difficult to add larger
substituents to the acceptor substrate. Furthermore, the STD NMR
data highlight strong contacts with the enzyme particularly at the
C6 position suggesting that modifications here may be unsuccessful.
The STD intensity for the C2 position is particularly weak for both
the acceptor Glc and reducing Glc residue in the reaction products,
suggesting that modification here may be possible.
This work provides fundamental structural details that will aid our
understanding of the substrate specificity of glycoside phosphorylases
and helps pave the way for enzymatic synthesis of a broad range of
carbohydrates.
3.5 Conclusions
In this chapter, STD NMR spectroscopy, including quantitative anal-
ysis using the CORCEMA-ST software, was used to provide solution
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state structural information about the interaction between PsLBP.
Overall the conclusions were:
1. The structures of the complexes of PsLBP with G1P and M1P
derived from X-ray crystallography are in excellent agreement
with the quantitative STD NMR analysis described here, show-
ing that the structures described in the respective models are
valid in describing the interaction in the solution state.
2. The acceptor substrate binding site of PsLBP preferentially
binds to glucose residues in the β anomeric configuration as
shown by very weak STD intensites for the α anomer.
3. The STD NMR binding epitopes combined with the x-ray crystal
structures of PsLBP in complex with G1P and M1P suggest the
PsLBP may tolerate further substitutions at the C2 position of
the donor substrate, making the enzyme synthetically versatile.
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Chapter 4
Characterisation of the Inter-
action between the Salmonella
enterica effector proteins and
their Death Domain Sub-
strates
4.1 Introduction
Salmonella enterica is a species of pathogenic intracellular Gram-
negative bacteria responsible for over 1 billion cases of infection every
year.[283] Over 2500 serovars have been identified,[284] although they
can broadly be categorised as either Typhoidal or Non-Typhoidal
serovars.[285] Typhoidal species are restricted to human hosts and are
responsible for causing enteric fever, a systemic infection resulting
in severe abdominal pain and diarrhoea. Enteric fever is responsible
for over 200,000 deaths per year, predominantly in underdeveloped
regions, particularly in southern Asia and sub-Saharan Africa.[285]
Non-Typhoidal serovars are typically host generalists, that is to
say that they are capable of infecting numerous species of host
organisms. This is a particular problem for industrialised countries,
in which Salmonella is transmitted through industrially produced
food. The most common form of Non-Typhoidal Salmonella infection
is gastroenteritis, an infection of the gastrointestinal tract.[284] Gas-
troenteritis causes symptoms such as diarrhoea and vomiting, and is
usually far more acute with a lower mortality rate than enteric fever.
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4.1.1 Invasion of Host Cells by Salmonella enter-
ica
Like other intracellular pathogens, the success of Salmonella enter-
ica is largely due to its ability to survive and reproduce within the
cells of the host, thereby evading the humoral immune response[286,287]
(Fig. 4.1). Once inside the host, intracellular pathogens can form a
protective host-derived vacuole, for Salmonella called the Salmonella-
Containing Vacuole (SCV) to further shield themselves from intracellu-
lar mechanisms, such as degradation in the lysosome. A unique feature
of Salmonella enterica is their ability to infect and survive within the
harsh environment of leukocytes such as macrophages,[288,289] which
contributes to the immunosuppression of the host.
Figure 4.1: The lifecycle of Salmonella enterica inside a host organism.
Reused with permission of Cota et al[290] under the Creative Commons license
(https://creativecommons.org/licenses/by/4.0/)
Invasion of host cells by Salmonella enterica is mediated predomi-
nantly through the Type III Secretion System (T3SS) (Fig. 4.2),
although recent studies have suggested that Salmonella also possess
T3SS-independent invasion mechanisms.[291,292] The T3SS is a large
complex of bacterial proteins forming a needle-like structure that tra-
verses both the inner and outer bacterial membranes of Salmonella
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and protrudes into the extracellular space (Fig. 4.2).[293] It is capable
of penetrating the host membrane and translocating material directly
from the bacterial cytoplasm to the host cytoplasm. The proteins
translocated from the bacterial pathogen to the host by the T3SS are
known as effector proteins and are responsible for modulating host cell
function, both during invasion and intracellular survival.[293] In fact,
Salmonella enterica encodes two T3SSs, denoted here as T3SS-SPI1
and T3SS-SPI2 (SPI = Salmonella Pathogenicity Island).[293]
Figure 4.2: Left: Cartoon of the structure of the Type III Secre-
tion System (T3SS). Right: Transmission electron micrograph of the
T3SS complex isolated from Salmonella enterica. Reused with per-
mission from Wikimedia Commons under the Creative Commons license
(https://creativecommons.org/licenses/by/2.5/deed.en)
The T3SS-SPI1 is responsible for translocating effectors involved in
the invasion of the intestinal epithelia.[294] These effectors are pre-
dominantly involved in remodelling the host actin cytoskeleton[295–298]
and destabilising the host membrane[299] in order to endocytose the
Salmonella bacterium. Furthermore, after entry into the host cell the
T3SS-SPI1 effector SptP is responsible for deactivating host Rac-1 and
Cdc42, which allows the host cell morphology to return to its native
state.[300] It has been suggested that this acts to maintain the viabil-
ity of the infected host cell, since prolonged expression of Rac-1 and
Cdc42 can be harmful to the cell.
The T3SS-SPI2, on the other hand, is responsible for mediating host
cell function after invasion by the Salmonella bacterium and its ef-
fectors are essential for survival and proliferation of the bacterium
within the host cell.[301] In particular, the effectors SseB, SseC, SseD
and spiC are responsible for the formation of an actin shell surround-
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ing the SCV,[302] which helps to maintain SCV membrane integrity.[303]
Furthermore, the effectors SseF and SseG redirect Golgi vesicles to the
SCV, which have been shown to be important for Salmonella prolifer-
ation within the host.[304]
More recently a new family of Salmonella enterica T3SS-SPI2
effectors have been identified, its members being labelled SseK1,
SseK2, and SseK3.[305,306] The SseK family were originally postulated
as translocated effectors based on their homology to the NleB
effector from Citrobacter rodentium,[307] which was known to be a
secreted effector. Homologous effectors have also been found in
enteropathogenic Escherichia coli (EPEC) and enterohemorrhagic
Escherichia coli (EHEC).[308]
The exact function and purpose of the SseK effectors is still being
elucidated, although it is clear that they are not essential for the vir-
ulence of Salmonella enterica. Knockouts of both SseK1 and SseK2
had no effect on the formation of the SCV and pathogenesis in in-
fected mice apparently proceeded as for wild type Salmonella.[305] Fur-
thermore, experiments in macrophages showed that apoptosis of in-
fected macrophages was SseK independent,[309] although SseK1 and
SseK3 were able to inhibit necroptotic cell death, mediated by the
Tumour Necrosis Factor(TNF)-α induced NF-κB pathway. This is
intriguing since their homologues in E. coli and C. rondentium, the
NleB effectors, have a strong effect on the colonisation abilities of the
pathogen.[310,311]
4.1.2 Function of the SseK effectors from
Salmonella enterica
As well as the intrigue of understanding the role that the SseK proteins
may play in the lifecycle of Salmonella enterica, these enzymes are
also of interest due to their novel enzymatic mechanism. Along with
the NleB effectors,[310,311] the SseK effectors have been shown to func-
tion as glycosyltransferases (GTs), transferring N-acetylglucosamine
residues (GlcNAc) onto arginine sidechains of their targets. Before
this discovery, only one other example of arginine glcosylation had
been reported[312] and the mechanism by which this occurs is not well
understood. What is clear is that the GT activity of the SseK effectors
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is dependent on a DXD-motif (Asp-X-Asp)[306,309], common to many
GTs, that chelates a divalent manganese ion (Mn2+).
In GTs, the enzymatic catalysis can proceed via either a so-called
retaining or inverting mechanism.[85] For retaining enzymes, the
anomeric configuration of the donor substrate is retained in the
formation of the glycosidic linkage with the acceptor substrate,
whereas the configuration becomes inverted in the reaction product
for inverting enzymes (Fig. 4.3). The SseK effectors share some
similarity with some known retaining GTs[313] suggesting they
too may follow a retaining mechanism. However, it is usually
expected that both aspartate residues of the DXD-motif will chelate
the Mn2+ in retaining GTs, whereas only one of these aspartate
residues (the downstream of the two) typically chelates the Mn2+
in inverting GTs.[314] In the X-ray crystal structures of the SseK
effectors (discussed below), only the latter aspartate residue chelates
the Mn2+, pointing towards an inverting mechanism. One group
claims experimental evidence for the SseKs possessing a retaining
mechanism.[313] However, their reasoning is factually incorrect, stating
that the hydrolysis of UDP-GlcNAc yields only α-GlcNAc, which
ignores the chemistry of monosaccharides, in which mutarotation
causes an equilibrium of α- and β-anomers in solution. The lack of
observed signal in the 1H NMR spectrum for the β-anomer of GlcNAc
is explained simply by the fact the this proton typically resonates at
approximately 4.7 ppm in β-GlcNAc,[315] and so is obscured by the
water signal. Therefore there still exists no experimental evidence for
the enzymatic mechanism of these enzymes.
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Figure 4.3: General mechanisms for inverting and retaining glycosyltransferases.
Top: The inverting mechanism showing the backside attack of the acceptor
substrate leading to inversion of anomeric configuration. Bottom: The retain-
ing mechanism showing the formation of a donor-protein intermediate before
attack by the acceptor substrate, leading to overall retention of anomeric con-
figuration. Used with permission of Dr.Brock.Schuman under the Creative
Commons license.
4.1.3 Structures of the SseK effectors
Recently, X-ray crystal structures have been published for each of
SseK1, SseK2, and SseK3.[313,316] These structures consist of UDP-
bound SseK1 (PDB: 5H60); apo- (PDB: 5H61), UDP-bound (PDB:
5H62), and UDP-GlcNAc-bound SseK2 (PDB: 5H63); and apo- (PDB:
6EYR) and hydrolysed UDP-GlcNAc-bound SseK3 (PDB: 6EYT).
Each of the SseK enzymes have close structural homology, and each
consist of a core catalytic domain and a short (approximately 40
residues) domain consisting of two α-helices joined by a short loop
(HLH-domain) that protrudes from the core (Fig. 4.4). The catalytic
domain consists of a fold typical of a GT-A fold type, whilst the HLH-
domain is unique to the SseK effectors. Interestingly, the core cat-
alytic domains of SseK1, SseK2 and SseK3 have a high sequence iden-
tity, with most of the sequence variation between the effectors being
found in the HLH-domain.[313,316] This has led to the proposition that
the HLH-domain may confer substrate specificity, despite its location
far from the catalytic site (Fig. 4.4).
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Figure 4.4: Topology of the SseK effectors, SseK1 (green), SseK2 (cyan) and
SseK3 (pink). The glycosyltransferase type A (GT-A) domain fold and helix-
loop-helix (HLH) protrusion are labelled. The manganese ion (Mn2+) (purple
sphere) and ligands are shown (sticks, SseK1: UDP, SseK2: UDP-GlcNAc,
SseK3: hydrolysed UDP-GlcNAc)
In each case, the donor substrate binding site consists of a deep, open
cavity within the core catalytic domain. The diphosphate moiety of
UDP chelates the Mn2+ ion and the uridine base is stacked between
two aromatic residues (SseK1: Trp51 and Phe187, SseK2: Trp65 and
Phe203, SseK3: Trp52 and Phe190) (Fig. 4.5). In both the SseK2
and SseK3 structures containing a UDP-GlcNAc and hydrolysed UDP-
GlcNAc respectively, the GlcNAc moiety interacts with a number of
absolutely conserved residues; in SseK2 these are Asp204, Arg207,
Asp239, and Arg348 (Asp191, Arg194, Asp226, and Arg335 in SseK3)
(Fig. 4.6). In both cases, the methyl group of GlcNAc is buried in a
pocket adjacent to the Mn2+ ion. Interestingly, the GlcNAc residue in
SseK3 (hydrolysed UDP-GlcNAc) is rotated somewhat relative to the
GlcNAc moiety in SseK2 (UDP-GlcNAc). Furthermore, the ring of
the GlcNAc moiety in SseK2 is distorted somewhat compared to that
in SseK3, and in either structure a nearby asparagine residue (SseK2:
Asn272, SseK3: Asn259) adopts a different rotameric conformation
(the only significant difference in the catalytic site structure between
the two models), hinting at its involvement in the catalytic mechanism.
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Figure 4.5: Stacking of the UDP uridine base between the Trp (SseK1: Trp51,
SseK2: Trp65, SseK3: Trp52) and Phe (SseK1: Phe187, SseK2: Phe203,
SseK3: Phe190) residues of SseK1 (green), SseK2 (cyan) and SseK3 (pink)
effectors. Figure labels correspond to SSeK1 numbering.
Figure 4.6: Structure of the SseK2 (left, cyan) and SseK3 (right, pink) donor
substrate binding site. Shown in the UDP-GlcNAc (SseK2)/hydrolysed UDP-
GlcNAc (SSeK3) closed conformation.
Finally, comparison of the apo- and holo-structures of SseK2 and
SseK3 reveals that, in the apo state the C-terminal loop is highly flex-
ible (Fig. 4.7), whereas in the holo-enzyme it closes over the catalytic
site with the tail arginine residue (SseK2: Arg348, SseK3: Arg335)
interacting directly with the β-phosphate of UDP and the anomeric
carbon of GlcNAc. For this reason, it has been proposed that the
C-terminal loop may act as a so-called lid domain to obscure the cat-
alytic site from the bulk solvent in order to prevent hydrolysis of the
donor.[313,316] It should also be noted however, that in 2 of the 4 SseK2
molecules in the asymmetric unit of the X-ray crystal structure (UDP-
GlcNAc bound) the “lid” is still in an open conformation, suggesting
that it is still somewhat flexible in the holo-enzyme.
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Figure 4.7: The closed (left) and open (right) conformations of the C-terminal
“lid” domain of SseK2 (cyan) bound to UDP-GlcNAc (yellow) and manganese
(Mn2+, purple sphere). Structures taken from chain A (closed) and chain B
(open) of the X-ray crystal structure of SseK2 bound to UDP-GlcNAc (PDB:
5H63).
4.1.4 Substrate specificity of the SseK effec-
tors
The glycosylation targets of the NleB effectors from EPEC, EHEC
and C. rodentium had previously been elucidated as TRADD, FADD,
RIPK1, and TNFR1, which are involved directly in the TNF-α
pathway,[310,317] and GAPDH, which affects nF-κB signalling via
TRAF2 activation.[311] Based on this it was found that SseK1 targets
TRADD and GAPDH, SseK2 targets FADD, and SseK3 targets
TRADD[309,318] (Table 4.1). SseK1 also bound to FADD but did not
glycosylate it, even though the death domains of each TRADD and
FADD are structurally homologous. Intriguingly, although SseK2
glycosylated FADD no interaction could be detected, suggesting a
highly transient or unstable interaction.
Table 4.1: Binding and glycosylation of the host target proteins FADD, TRADD
and GAPDH by the SseK effectors. b. = binding, n.b. = no binding, g. =
glycosylation, n.g. = no glycosylation, n.d. = no data
Effector FADD TRADD GAPDH
SseK1 b./n.g. n.d./g. b ./g.
SseK2 n.b./g. n.d. n.b./n.g.
SseK3 n.b./n.g. n.d./g. n .b./n.g.
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Clearly then, the SseK effectors must possess some as yet unknown
mechanism by which they can bind to and glycosylate their targets,
both of which appear to be a distinct process. Given the homology of
the GT-A-like domains of the SseK effectors it is intriguing to under-
stand the role the HLH-domain may play in ligand recognition and
how this affects catalysis. The purpose of this chapter is to investi-
gate the molecular mechanisms that are involved in acceptor substrate
recognition and glycosylation and to model their interactions, using a
combination of Nuclear Magnetic Resonance spectroscopy and molec-
ular modelling.
4.1.5 Objectives
The aim of this chapter is to provide structural insight into the interac-
tions of SseK1/2 with their acceptor substrates, FADD, TRADD and
GAPDH, using a combination of NMR spectroscopy and molecular
modelling. Specifically the objectives are:
• Provide structural information about the binding mode of the
acceptor substrates using STD NMR spectroscopy to determine
the binding epitope maps of the short substrate peptides,
FADD110-118, TRADD229-237 and GAPDH195-203.
• To understand how the differences in SseK1 and SseK2 may lead
to differential recognition/glycosylation of substrates.
• Generate an experimentally validated model of the SseK2/FADD
complex using a combination of NMR spectroscopy and molec-
ular modelling.
• Determine whether SseK1/2 follow an inverting or retaining en-
zymatic mechanism.
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4.2 Material and Methods
4.2.1 Peptide assignment and STD NMR
All experiments were performed at 288 K on a Bruker Avance III
800 MHz spectrometer equipped with a 5-mm TXI 800 MHz H-C/N-D-
05 Z BTO probe. FADD110-118, TRADD229-237 and GAPDH195-203 (Gen-
script) samples were prepared at 1 mM in 90% H2O/ 10% D2O and
assigned using standard COSY (cosydfesgpph), TOCSY (mlevphpr),
and 1H-13C HSQC (hsqctgpsp) experiments. Apoenzyme samples (Dr
Hurtado Guerrero, Zaragoza, Spain; Prof. Hardwidge, Kansas, USA)
were prepared with 1 mM ligand peptide and 25 µM enzyme in either
25 mM Tris-d11 (SseK1) or 10 mM PBS (SseK2); both at pH 7.4 in
D2O. Holoenzyme samples were prepared in the same way, with the
addition of 25 µM MnSO4 and 25 µM UDP. The residual water signal
was used as a reference for chemical shifts.[319] STD NMR experiments
were performed using a train of 50 ms Gaussian pulses (0.4 mW, B1
field strength 78 Hz) applied on the f2 channel at either 0 ppm (on-
resonance) or 40 ppm (off-resonance). A spoil sequence (2 trim pulses
of 2.5 and 5 ms followed by a 40% z-gradient applied for 3  ms at
the beginning of the experiment) was used to destroy unwanted xy-
magnetization from previous scan and a spinlock (1.55 W, 40 ms) was
used to suppress protein signals (stddiff.3). The saturation time (d20)
was set to 2 s and the recycle delay (d1) was set to 5 s.
4.2.2 Configuration of GlcNAc in glycosy-
lated GAPDH187-203
GlcNAcylated peptide GAPDH187-203 was prepared in the laboratory
of Dr Hurtado Guerrero (Zaragoza, Spain) by adding 7.7 mM
GAPDH187-203 to 50 mM UDP-GlcNAc, 40µM SseK1, and 2 mM
MnCl2 in 25 mM Tris pH 7.5. The reaction was left to proceed at
37 °C for 24 h before purifying the resulting glycopeptide using an
Amicon Ultra 10 KDa MWCO centrifuge filter. NMR experiments
for glycosylated GAPDH187-203 were performed at 298 K, and con-
sisted of a decoupled 1H-13C HSQC (hsqcetgpsi), and TOCSY with
water suppression (mlevgpph19) at 800 MHz, and a non-decoupled
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Perfect-CLIP-HSQC[320] at 500 MHz (with a digital resolution of
1.6 Hz, to determine the 1JC,H coupling of the anomeric carbon of the
transferred GlcNAc residue). The HSQC recycle delay was 1.5 s.
4.2.3 Molecular docking calculations for
FADD-SseK2
Crystal structures of SseK1 (PDB: 5H60), SseK2 (PDB: 5H63), and
FADD (PDB: 3EZQ) were imported into Schrödinger Maestro and pre-
pared with the Protein Preparation Wizard.[321] All buffer molecules
and non-bridging waters were removed. Hydrogen atoms were then
added to the model, using PROPKA to predict the protonation state
of polar sidechains at pH 7.[276] The hydrogen-bonding network was
automatically optimized by sampling asparagine, glutamine, and his-
tidine rotamers. The model was then minimized using OPLS3[120] force
field and a heavy atom convergence threshold of 0.3 Å.
A model of the FADD110-118 peptide was created by truncation of the
FADD crystal structure (PDB: 3EZQ). Conformers were generated
in MacroModel using torsional sampling with the OPLS3 force field,
constraining all backbone atoms. Redundant conformers were elimi-
nated using an RMSD cutoff of 0.5 Å. Any conformer with an energy
5 kcal mol-1 greater than the lowest energy structure was also elimi-
nated. Resulting conformers were then minimized using the conjugate
gradient method, converging on a threshold of 0.05 kcal mol-1. Dock-
ing of FADD110-118 to SseK2 was then performed using Glide.[126,253] A
cubic grid, suitable for peptide docking, was generated. It was centred
on UDP-GlcNAc, with an outer box length of 45 Å and an inner box
length of 40 Å. To account for flexibility, van der Waals potentials of all
receptor and ligand atoms were scaled by 0.5. All ligand conformers
were docked to the receptor using rigid sampling with the SP algo-
rithm. The resulting complexes were then clustered by heavy atom
RMSD to eliminate redundant poses, keeping the structure closest to
the cluster centroid from each cluster. All SseK2 sidechains within 5 Å
of the ligand were then optimized before minimizing using Prime.[251]
A second round of docking was performed, as described above, on the
receptor structures resulting from the minimisation step. The result-
ing complexes were clustered by heavy atom RMSD, and the lowest
energy representative structure was chosen for analysis.
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A model of SseK2 in complex with full length FADD was generated
by aligning the backbone atoms of residues 110-118 in the full-length
structure to the backbone of the docked FADD110-118 structure. Prime
optimization and minimization within 5 Å of the contact surface was
used to eliminate an atomic overlap.
4.2.4 Molecular Dynamics Simulations
UDP charges for use with UDP-GlcNAc were derived using the RESP
fitting method implemented on the RED server.[322] The UDP frag-
ment was generated by replacing the GlcNAc with a methyl group.
In accordance with GLYCAM,[115] the HF/6-31G* level of theory was
used with a weight factor of 0.01 and all aliphatic protons were con-
strained to a charge of 0. The total charge of the UDP fragment was
set to −2. The charge of the methyl group was set to 0.194 before
removing to give a final fragment with net charge −2.194, in keeping
with the modularity of GLYCAM.
Molecular dynamics simulations of SseK1, SseK2, and the
SseK2:FADD complex were performed using the Amber PMEMD
software.[323] Protein atoms were parametrised using the Amber
ff11SB forcefield and the Mn2+ ion was modelled using 12-6-4 LJ-type
parameters (Amber ions234lm_1264_tip3p). UDP-GlcNAc was
parametrised with GLYCAM 06j and GAFF. Each system was
solvated in a truncated octahedral box of TIP3P water, with at least
10 Å between the solute and the edge of the box, before neutralizing
with Na+ ions. The system was minimized using the conjugate
gradient algorithm, converging on a threshold of 10−4 kcal mol−1
Å−1, first with 20 kcal mol−1 Å−2 restraints on solute atoms, before
repeating with no restraints. The system was slowly heated to 310 K
over 500 ps (NVT), before equilibrating the pressure to 1 atm (NPT)
over a further 500 ps. In both cases with 20 kcal mol−1 Å−2 restraints
were used on solute atoms. These restraints were then slowly released
over 800 ps before performing Gaussian accelerated molecular dynam-
ics (GaMD) simulations (800 ns SseK1/SseK2, 500 ns SseK2:FADD
complex), as implemented in AMBER, using a boost potential on
both the dihedral and total potential energies. Here, the simulation
was split into 4 distinct stages. First, conventional dynamics were
run for 2 ns to automatically calculate an initial boost potential. The
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calculated boost potential was then applied and fixed for 400 ps before
allowing it to adapt for a further 5.6 ns. The resulting boost potential
was then fixed before performing production dynamics for 800 ns
(SseK1/SseK2) or 500 ns (SseK2:FADD complex), saving coordinates
every 100 ps. In all cases, the SHAKE algorithm was used to restrain
all bonds involving hydrogen, allowing for a time step of 2 fs. A
Langevin thermostat was used with a collision frequency of 5 ps−1
and the barostat (1 atm) used an isotropic Berendsen algorithm with
a relaxation time of 1 ps. In all cases, periodic boundary conditions
were used, using the particle mesh Ewald to calculate electrostatics.
4.2.5 Production of 15N-labelled FADD and
NMR titration of FADD/SseK2
The full length FADD protein was cloned into the pET15b plasmid
and transformed into E. coli BL21-DE3 cells. Transformed cells were
selected by growing on a LB-agarose medium containing 100 µg mL-1
ampicillin. A starter culture was produced from a single colony by
growing in 5 mL LB containing 100 µg mL-1 ampicillin overnight at
37 °C with 200 rpm shaking before inoculating into 1 L 15N minimal
medium described in [324]. The culture was grown at 37 °C with 200
rpm shaking until the OD600 reached 0.6-0.8. The culture was then
induced with 1 mM isopropyl β-D-1-thiogalactopyranoside (IPTG) be-
fore incubating for a further 4 hours. The bacterial pellet was then
collected by centrifuging at 10,000 x g for 10 min at 4 °C.
The pellet was resuspended in 20 mL pH 7.9 lysis buffer containing 20
mM Tris, 250 mM NaCl, 2.5 mM imidazole which was then lysed by
sonication before centrifuging at 16,000 x g for 20 min at 4 °C. The
resulting suppernatant was then purified using a Ni-NTA column by
washing with 40 mL lysis buffer then 40 mL wash buffer (as lysis buffer
with 3 mM imidazole). The purified protein was then eluted with an
elution buffer (as wash buffer with 1 M imidazole).
Purified 15N-labelled FADD was concentrated to 3 mM and exchanged
to a buffer of 25 mM Tris, 150 mM NaCl pH 7.4 in a solvent of 90%
H2O/10% D2O. 1H-15N HSQC NMR experiments were performed in a
500 MHz spectrometer at 298 K, both in the absence and presence of
SseK2 (3 mM, Dr Hurtado Guerrero, Zaragoza, Spain).
170
4.3 Results
4.3.1 Assignment of the Acceptor Substrate
Peptides by Nuclear Magnetic Resonance
Spectroscopy
To study the binding interaction between SseK1/2 and their acceptor
substrates by Saturation Transfer Difference (STD) Nuclear Magnetic
Resonance (NMR) spectroscopy, short peptides of the target regions
of these substrates were constructed, these were: residues 110-118
of FADD (FADD110-118), residues 229-237 of TRADD (TRADD229-237),
and residues 195-203 of GAPDH (GAPDH195-203). These peptides were
assigned using a combination of Correlation Spectroscopy (COSY),
Total Correlation Spectroscopy (TOCSY), Nuclear Overhauser Effect
Spectroscopy (NOESY), and 1H-13C Heteronuclear Single Quantum
Correlation (HSQC) NMR spectroscopy experiments (1D 1H NMR
spectra are shown in Fig. 4.8, expansions of TOCSY experiments in
Fig. 4.9, and chemical shift are in Fig. 4.8, Table 4.2, Table 4.3, Table
4.4). As with the NMR chemical shift assignment of carbohydrates,
peptides can be separated into distinct spin systems due to the inter-
residue separation of protons by more than 3 bonds by the backbone
amide group. Assignments were made using water as the solvent to
take advantage of the additional amide proton resonances.
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Figure 4.8: 1D 1H NMR spectra of the SseK1/SseK2 acceptor substrate pep-
tides, FADD110-118 (blue), TRADD229-237 (red), GAPDH195-203 (green). Exper-
iments performed at 288 K with 1 mM peptide in a solvent of 90% H2O/10%
D2O.
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Figure 4.9: Expansions of TOCSY spectra of the FADD110-118 (top),
TRADD229-237 (middle) and GAPDH195-203 (bottom) peptides. Marked re-
gions correspond to the proton type of the diagonal peaks. Cross peaks show
protons within the same spin system as the diagonal peak, which mostly cor-
responds to whole amino acid residues. Exceptions occur when the coupling is
interrupted by heteroatoms (eg. Trp).
Table 4.2: Assignment of the Nuclear Magnetic Resonance (NMR) chemical
shifts of 1H and 13C nuclei of FADD110-118. Experiments were performed in an
800 MHz NMR spectrometer at 288 K.
Residue Position δ 1H (ppm) δ 13C (ppm)
Lys110 α 3.71 52.6
β 1.54 30.0
γ 0.98 21.0
δ 1.30 26.1
ϵ 2.54 38.7
Asp111 α 4.52 50.6
β 2.57 37.6
Trp112 α 4.37 54.7
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Residue Position δ 1H (ppm) δ 13C (ppm)
β 3.12 26.5
δ1 7.02 122.7
ϵ3 7.40 117.9
ζ2 7.29 111.6
ζ3 7.14 124.6
η2 6.94 119.0
Arg113 α 3.87 53.5
β 1.40 27.5
γ 1.06 23.7
δ 2.87 40.2
Arg114 α 3.98 53.3
β 1.43 24.0
γ 1.36 24.2
δ 2.99 40.2
Leu115 α 4.12 52.0
β 1.43 24.0
δ1 0.71 21.9
δ2 0.65 20.3
Ala116 α 4.09 49.8
β 1.19 16.2
Arg117 α 4.00 53.7
β 1.94 27.2
γ 1.74 27.1
δ 2.12 31.2
Gln118 α 4.10 53.3
β 1.59 27.6
γ 2.99 40.2
Table 4.3: Assignment of the Nuclear Magnetic Resonance (NMR) chemical
shifts of 1H and 13C nuclei of TRADD229-237. Experiments were performed in
an 800 MHz NMR spectrometer at 288 K. Some 13C resonances are missing
due to ambiguity of the recorded dataset.
Residue Position δ 1H (ppm) δ 13C (ppm)
Lys229 α 3.78 52.76
β 1.67 -
γ 1.21 -
δ 1.48 -
ϵ 2.77 39.1
Trp230 α 4.43 55.1
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Residue Position δ 1H (ppm) δ 13C (ppm)
β 3.05 26.8
δ 7.06 124.3
ϵ3 7.38 117.9
ζ2 7.29 111.7
ζ3 7.04 121.6
η2 6.94 119.3
Arg231 α 3.95 52.5
β 1.40 -
γ 1.26 -
δ 2.89 40.5
Lys232 α 3.85 53.5
β 1.49 -
γ 1.16 -
δ 1.49 -
ϵ 2.77 39.1
Val233 α 3.89 59.5
β 1.88 30.1
γ 0.72 17.9
Gly234 α 3.77 42.0
Arg235 α 4.18 53.2
β 1.58 -
γ 1.44 -
δ 2.99 40.4
Ser236 α 4.24 55.5
β 3.66 60.9
Leu237 α 4.01 53.7
β 1.40 40.1
γ 1.41 24.2
δ1 0.70 22.2
δ2 0.66 20.5
Table 4.4: Assignment of the Nuclear Magnetic Resonance (NMR) chemical
shifts of 1H and 13C nuclei of GAPDH195-203. Experiments were performed in
an 800 MHz NMR spectrometer at 288 K.
Residue Position δ 1H (ppm) δ 13C (ppm)
Leu195 α 3.80 51.5
γ 1.47 39.8
δ1 0.74 21.5
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Residue Position δ 1H (ppm) δ 13C (ppm)
δ2 0.70 20.8
Trp196 α 4.49 55.0
β 3.06 26.7
δ 7.04 124.2
ϵ 7.41 117.9
ζ2 7.28 111.6
ζ3 7.02 121.7
η3 7.41 117.9
Arg197 α 3.92 53.0
β 1.48 28.0
γ 1.16 23.9
δ 2.86 40.4
Asp198 α 4.16 51.2
β 2.48 37.8
Gly199/ α 3.75/3.64 42.6/42.4
Gly201
Arg200 β 1.66 27.6
γ 1.38 24.0
δ 2.92 40.4
Ala202 α 4.10 49.3
β 1.15 16.5
Leu203 α 3.97 53.6
β 1.37 40.2
γ 0.71 20.6
δ1 0.69 22.2
δ2 0.65 20.6
The chemical shift assignments were then used to interpret the binding
experiments by STD NMR, allowing the different saturation transfer
intensities to be ascribed to the specific protons of the acceptor pep-
tides. This is fundamental to generate the map of contacts of the
ligands with the protein receptor, as explained in the following sec-
tion.
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4.3.2 Saturation Transfer Difference NMR
Spectroscopy the Acceptor Substrate
Peptides
In saturation transfer difference (STD) NMR spectroscopy it is gener-
ally regarded as best practice to construct STD NMR build up curves
by repeating the experiments over a number of different saturation
times. However, in this case, the peptides were only stable over a
short period of time and so it was only possible to acquire one time
point for each experiment. Therefore the results should only be treated
qualitatively. A saturation time of 2 s was chosen as the best com-
promise between signal sensitivity while still remaining short enough
to minimise any artefacts. For each acceptor substrate peptide and
for each enzyme (SseK1/SseK2), the STD NMR intensity was mea-
sured for each observable proton for three separate experiments: (1)
in the presence of SseK1/SseK2, (2) in the presence of SseK1/SseK2
and Mn2+, and (3) in the presence of SseK1/SseK2, Mn2+ and UDP.
Surprisingly, each of the FADD110-118, TRADD229-237 and GAPDH195-203
peptides bound to both SseK1 and SseK2 under all conditions (apo-
enzyme, plus Mn2+, and plus Mn2+ and UDP) (Fig. 4.10, Fig. 4.13,
Fig. 4.16). This means that the differences in enzyme specificities
for glycosylation of the peptide substrate might not be explained by
differences in molecular recognition of the ligands, as all the peptides
are recognised by both enzymes. Hence, the specificity seems to be
related to the catalytic step where the specific composition of the
peptide determines whether glycosylation of the arginine residue will
proceed or not. The discrepancy between the STD NMR data and
the data presented in Table 4.1 can be explained by the fact that
STD NMR is optimised for weak affinity binders that fall below the
detection threshold of the high throughput techniques used to generate
these data.
For each system, binding epitopes were constructed by normalising
the STD intensity of each proton at 2 s against the ζ2-proton of the
tryptophan residue of each peptide, since this proton received the
most saturation in most of the experiments and normalising against
the same proton allows relative comparisons to be made between each
system.
177
4.3.2.1 Molecular recognition of FADD110-118 by
SseK1 and SseK2
1H STD NMR spectra characterising the binding of FADD110-118 to
SseK1 and SseK2, under different conditions, are shown in Fig. 4.10.
The experimentally determined STD NMR intensities are collected in
Tables 4.5 and 4.6, for the binding of FADD110-118 to SseK1 and SseK2,
respectively.
Figure 4.10: STD NMR difference spectra for FADD110-118 binding to SseK1
(top) or SseK2 (bottom). Spectra recorded for the apoenzyme (blue), in the
presence of 25 µM Mn2+ (red) and in the presence of 25 µM Mn2+ and 25 µM
UDP (green). Measured using a saturation frequency of 0 ppm at 800 MHz
and a saturation time of 2 s.
In the case of FADD110-118 binding to SseK1, STD intensity is concen-
trated around Trp112 and Leu115 for both the apo-SseK1 and Mn2+-
bound SseK1 systems (Fig. 4.11). Upon addition of UDP, the STD
intensities of these two residues increase relative to the Trp112 ζ2-
proton. Furthermore, the STD intensities of the Arg113 and Arg114
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sidechains increase dramatically. Together this suggests that binding
of the donor analogue, UDP, in some way induces a conformational
rearrangement that positions the arginine sidechains of FADD110-118 in
closer proximity to the SseK1 surface.
Comparatively, in the binding of FADD110-118 to SseK2, in all cases
(apo, plus Mn2+, plus Mn2+ and UDP) the main contact residues of
FADD110-118 appear to be Trp112, Arg113 and Leu115 (Fig. 4.12).
However, there is no significant change upon addition of Mn2+ and/or
UDP.
Table 4.5: STD intensities for a saturation time of 2 s for each proton resonance
of FADD110-118 in the presence of SseK1.
Residue Position
STD (%,
SseK1)
STD (%, SseK1
+ Mn2+)
STD (%, SseK1 +
Mn2+ + UDP)
Lys110 α 4.76 4.11 4.40
β 4.11 4.62 4.81
γ 7.46 7.61 7.91
δ 1.78 2.38 2.25
ϵ 1.73 2.65 2.55
Asp111 β 2.58 3.48 3.52
Trp112 β 3.42 4.11 3.99
δ 6.64 7.91 6.02
ϵ3 5.57 6.08 6.32
ζ2 7.39 7.83 5.79
ζ3 5.79 7.04 6.08
η2 6.44 6.57 5.51
Arg113 γ 4.58 5.10 6.20
δ 3.35 3.77 3.45
Arg114 γ 4.03 5.30 5.51
δ 2.43 3.10 3.35
Leu115 δ1 5.68 6.26 6.77
δ2 6.38 7.91 8.98
Ala116 β 2.65 3.10 3.16
Arg117 α 5.1 5.51 4.24
β 1.98 1.74 1.78
δ 1.69 1.58 1.87
γ 1.73 2.20 1.88
Gln118 β 2.55 2.73 2.48
γ 1.98 2.53 2.76
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Table 4.6: STD intensities for a saturation time of 2 s for each proton resonance
of FADD110-118 in the presence of SseK2.
Residue Position
STD (%,
SseK2)
STD (%, SseK2
+ Mn2+)
STD (%, SseK2 +
Mn2+ + UDP)
Lys110 α 1.17 1.30 1.23
β 1.94 1.63 1.83
γ 4.24 4.15 4.03
δ 1.43 1.15 1.18
ϵ 0.52 0.85 0.71
Asp111 α 1.45 0.76 1.21
β 1.54 1.35 1.41
Trp112 α 1.98 2.12 1.87
β 1.96 2.08 1.81
ϵ3 2.70 2.87 2.41
δ 2.73 2.50 2.22
ζ2 3.38 3.22 2.98
ζ3 3.69 3.22 2.92
η2 3.19 2.81 2.50
Arg113 α 2.65 2.45 2.43
δ 1.71 2.02 1.64
γ 2.76 3.07 2.70
Arg114 α 1.28 1.02 1.01
γ 2.53 2.38 2.27
δ 1.21 1.04 1.03
Leu115 δ1 2.65 2.70 2.68
δ2 2.98 3.04 3.01
Ala116 β 1.35 1.41 1.34
Arg117 α 1.90 1.98 1.61
β 1.23 1.02 0.96
γ 1.48 1.13 1.13
δ 0.77 0.64 0.81
Gln118 β 1.90 2.02 1.98
γ 0.93 0.85 0.92
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Figure 4.11: Binding epitope maps for the interaction of FADD110-118 in the
presence of SseK1, either in the apo-form (top), in the presence of Mn2+
(middle) or in the presence of Mn2+ and UDP (bottom). Colours represent
the normalised STD values for proton resonances at the indicated positions
(low - high, cold - hot).
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Figure 4.12: Binding epitope maps for the interaction of FADD110-118 in the
presence of SseK2, either in the apo-form (top), in the presence of Mn2+
(middle) or in the presence of Mn2+ and UDP (bottom). Colours represent
the normalised STD values for proton resonances at the indicated positions
(low - high, cold - hot).
4.3.2.2 Molecular recognition of TRADD229-237 by
SseK1 and SseK2
1H STD NMR spectra characterising the binding of TRADD229-237 to
182
SseK1 and SseK2, under different conditions, are shown in Fig. 4.13.
The experimentally determined STD NMR intensities are collected in
Tables 4.7 and 4.8, for the binding of TRADD229-237 to SseK1 and
SseK2, respectively.
Figure 4.13: STD NMR difference spectra for TRADD229-237 binding to SseK1
(top) or SseK2 (bottom). Spectra recorded for the apoenzyme (blue), in the
presence of 25 µM Mn2+ (red) and in the presence of 25 µM Mn2+ and 25 µM
UDP (green). Measured using a saturation frequency of 0 ppm at 800 MHz
and a saturation time of 2 s.
For TRADD229-237 binding to SseK1, strong STD intensity is only ob-
served on the Trp230 residue in both the apo-SseK1 and Mn2+-bound
forms of SseK1 (Fig. 4.14). Upon addition of UDP, the STD in-
tensity across TRADD229-237 increases, but particularly across Trp230,
Arg231 and Val233. Again, this suggests that binding of SseK1 to
UDP induces some conformational change that positions Arg231 and
Val233 in closer proximity to the surface of SseK1. Furthermore, the
spread of saturation across TRADD229-237 suggests higher affinity of
TRADD229-237 to the SseK1-Mn2+-UDP complex compared to the apo-
and Mn2+-bound forms.
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In the case of TRADD229-237 and SseK2, like for FADD1110-118, there
appears to be no significant change in STD intensity upon addition of
Mn2+ and/or UDP (Fig. 4.15). Instead, in all cases the STD intensity
is strongest on Trp230 in all cases, with moderate STD intensity found
concentrated around Lys229-Val233.
Table 4.7: STD intensities for a saturation time of 2 s for each proton resonance
of TRADD229-237 in the presence of SseK1.
Residue Position
STD (%,
SseK1)
STD (%, SseK1
+ Mn2+)
STD (%, SseK1 +
Mn2+ + UDP)
Lys229 β 5.57 5.9 7.17
γ 7.24 7.53 12.03
Trp230 α 15.66 12.39 -
β 12.63 11.69 16.77
δ 19.79 18.49 26.26
ϵ3 19.79 18.49 20.37
ζ2 25.02 23.14 17.77
ζ3 23.59 21.82 18.84
η2 22.47 20.58 19.59
Arg231 α 10.70 10.39 12.51
γ 8.39 8.14 16.13
δ 7.39 7.1 9.16
Lys232 γ 6.57 7.32 4.62
Val233 β 11.24 11.57 16.77
γ 9.25 9.43 18.13
Arg235 α 8.07 8.22 9.15
β 6.57 6.77 8.98
γ 6.02 5.84 -
δ 5.00 4.81 5.96
Ser236 α 8.55 8.31 7.68
β 5.25 4.58 5.41
Leu237 α 9.07 8.22 8.47
δ1 6.51 6.70 11.35
δ2 6.83 7.10 12.03
Table 4.8: STD intensities for a saturation time of 2 s for each proton resonance
of TRADD229-237 in the presence of SseK2.
Residue Position
STD (%,
SseK2)
STD (%, SseK2
+ Mn2+)
STD (%, SseK2 +
Mn2+ + UDP)
Lys229 β 2.18 2.68 2.81
184
Residue Position
STD (%,
SseK2)
STD (%, SseK2
+ Mn2+)
STD (%, SseK2 +
Mn2+ + UDP)
γ 2.90 3.35 3.59
Trp230 α 3.29 3.52 3.52
β 2.14 2.60 2.76
δ 4.86 5.68 5.62
ϵ3 4.07 5.00 4.67
ζ2 5.68 6.64 6.64
ζ3 4.58 5.46 5.68
η2 4.68 5.15 5.35
Arg231 α 2.73 3.32 3.07
δ 1.66 1.76 2.00
γ 2.84 3.42 3.52
Lys232 γ 2.55 3.55 4.67
Val233 β 3.29 3.84 3.77
γ 3.96 4.32 4.81
Arg235 α 2.73 2.29 3.10
β 2.38 2.90 3.19
δ 1.28 1.38 1.57
γ 2.08 2.29 3.13
Ser236 α 2.48 2.84 3.04
β 1.2 1.34 1.51
Leu237 α 2.53 2.78 3.25
δ1 2.70 3.01 3.52
δ2 2.95 3.32 3.84
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Figure 4.14: Binding epitope maps for the interaction of TRADD229-237 in
the presence of SseK1, either in the apo-form (top), in the presence of Mn2+
(middle) or in the presence of Mn2+ and UDP (bottom). Colours represent the
normalised STD values for proton resonances at the indicated positions (low -
high, cold - hot).
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Figure 4.15: Binding epitope maps for the interaction of TRADD229-237 in
the presence of SseK2, either in the apo-form (top), in the presence of Mn2+
(middle) or in the presence of Mn2+ and UDP (bottom). Colours represent the
normalised STD values for proton resonances at the indicated positions (low -
high, cold - hot).
4.3.2.3 Molecular recognition of GAPDH195-203 by
SseK1 and SseK2
1H STD NMR spectra characterising the binding of GAPDH195-203 to
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SseK1 and SseK2, under different conditions, are shown in Fig. 4.16.
The experimentally determined STD NMR intensities are collected in
Tables 4.9 and 4.10, for the binding of GAPDH195-203 to SseK1 and
SseK2, respectively.
Figure 4.16: STD NMR difference spectra for GAPDH195-203 binding to SseK1
(top) or SseK2 (bottom). Spectra recorded for the apoenzyme (blue), in the
presence of 25 µM Mn2+ (red) and in the presence of 25 µM Mn2+ and 25 µM
UDP (green). Measured using a saturation frequency of 0 ppm at 800 MHz
and a saturation time of 2 s.
Finally, for GAPDH195-203 binding to SseK1 in the apo-state, the only
strong STD intensities are found on Trp196 (Fig. 4.17). Upon addition
of Mn2+, there is a small increase in the STD intensity of Arg200.
Upon addition of UDP, moderate STD intensities are observed along
the whole of GAPDH195-203, although the β proton of Arg200 displays
a particularly intense STD value.
In the case of GAPDH195-203 binding to SseK2, strong STD intensities
are only observed on Trp196 and there are no significant changes upon
addition of Mn2+ and/or UDP (Fig. 4.18).
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Table 4.9: STD intensities for a saturation time of 2 s for each proton resonance
of GAPDH195-203 in the presence of SseK1.
Residue Position
STD (%,
SseK1)
STD (%, SseK1
+ Mn2+)
STD (%, SseK1 +
Mn2+ + UDP)
Leu195 α 2.12 1.78 2.08
γ 2.84 2.92 3.55
Trp196 β 3.22 2.68 2.50
δ 4.90 3.77 3.29
ϵ3 4.40 4.03 3.73
ζ2 6.70 5.30 4.11
ζ3 6.40 5.05 4.24
η2 6.63 4.85 4.40
Arg197 α 2.38 2.12 2.53
β 3.95 3.62 4.72
δ 1.45 1.48 1.98
Asp198 β 2.00 2.06 1.81
Arg200 β 2.78 3.35 3.96
δ 1.83 1.19 1.73
Ala202 β 2.02 2.33 2.53
Table 4.10: STD intensities for a saturation time of 2 s for each proton reso-
nance of GAPDH195-203 in the presence of SseK2.
Residue Position
STD (%,
SseK2)
STD (%, SseK2
+ Mn2+)
STD (%, SseK2 +
Mn2+ + UDP)
Leu195 α 7.24 6.44 6.63
Trp196 β 6.51 7.83 7.03
δ 10.70 10.70 10.50
ϵ3 10.81 11.57 11.35
ζ2 13.79 14.07 14.34
ζ3 13.10 13.66 13.40
η2 12.76 13.40 13.40
Arg197 α 6.57 7.24 7.68
δ 4.86 4.90 4.58
Asp198 α 7.17 7.53 6.02
β 5.46 6.57 5.51
Arg200 α 6.64 6.97 6.44
β 5.84 5.46 6.08
δ 4.24 4.36 4.58
Ala202 α 5.73 6.08 5.62
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Residue Position
STD (%,
SseK2)
STD (%, SseK2
+ Mn2+)
STD (%, SseK2 +
Mn2+ + UDP)
β 4.62 4.90 4.81
Leu203 α 5.15 5.19 4.90
Figure 4.17: Binding epitope maps for the interaction of GAPDH195-203 in
the presence of SseK1, either in the apo-form (top), in the presence of Mn2+
(middle) or in the presence of Mn2+ and UDP (bottom). Colours represent the
normalised STD values for proton resonances at the indicated positions (low -
high, cold - hot).
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Figure 4.18: Binding epitope maps for the interaction of GAPDH195-203 in
the presence of SseK2, either in the apo-form (top), in the presence of Mn2+
(middle) or in the presence of Mn2+ and UDP (bottom). Colours represent the
normalised STD values for proton resonances at the indicated positions (low -
high, cold - hot).
Overall these results show that both SseK1 and SseK2 are capable of
binding to each of the FADD110-118, TRADD229-237 and GAPDH195-203
peptides, despite the differences in glycosylation of their full-length
counterparts. This suggests that structure outside of these regions is
responsible for determining whether or not the target becomes glyco-
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sylated. In all cases, the tryptophan residue of the peptide displayed
particularly strong STD intensities, indicating that this residue may
be important for recognition. Finally, it appears that, in SseK1, the
binding of Mn2+ and UDP induces some sort of conformational rear-
rangement that allows for tighter binding of the target substrate, but
no such rearrangement occurs in the case of SseK2.
4.3.3 Accelerated Molecular Dynamics of
SseK1 and SseK2
Accelerated molecular dynamics simulations were performed on the X-
ray crystal models of SseK1 and SseK2 both bound to UDP-GlcNAc
and manganese.[316] The root mean squared deviation (RMSD) of the
SseK1 and SseK2 Cα atoms follow a rather jagged trajectory indicat-
ing some transient change in backbone conformation that occur many
times over the period of the simulation (Fig. 4.19). However, the
fact that on average the RMSDs do not change over the course of
the simulations indicates that the structures are stable and the ob-
served changes represent reversible conformational mobility of SseK1
and SseK2 respectively. The changes in RMSD are typically larger for
SseK1, indicating a more significant conformational change.
In the case of SseK1, the bound UDP-GlcNAc also appears to have
some degree of conformational mobility, although RMSD values be-
tween 1-2 Å most likely indicate small shifts in atomic displacement,
not significant changes in binding mode or unbinding from SseK1.
Conversely, the conformation of the bound UDP-GlcNAc in SseK2 is
incredibly stable over the course of the simulation, with an RMSD of
around 0.6 Å from the average structure that remains constant over
the majority of the trajectory. There is a brief event just after 600 ns
in which the RMSD increases to approximately 1.2 Å, but this rapidly
reverts back to its previous conformation.
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Figure 4.19: Root mean squared deviation (RMSD) as a function of time for
SseK1 and SseK2 Cα atoms (top) and for UDP-GlcNAc heavy atoms bound
to either SseK1 or SseK2 (bottom). For UDP-GlcNAc heavy atoms, a no-fit
RMSD calculation was performed after first fitting to protein Cα atoms, in
order to capture both conformational and translational motions.
To investigate the apparent conformational changes in the SseK1 and
SseK2 backbones further, the root mean squared fluctuations (RMSF)
of the Cα atoms were calculated (Fig. 4.20). It is immediately clear
that the N- and C-terminal regions of SseK1 are significantly more mo-
bile than in SseK2 and this may account for larger changes in RMSD
observed for SseK1 compared with SseK2. Other than this, the RMSFs
of SseK1 and SseK2 are comparable, although it appears that a larger
number of residues within the region between residues 150-200 have
heightened flexibility in SseK1 compared to SseK2. Mapping these
fluctuations onto models of SseK1 and SseK2 (Fig.4.21) reveals that,
in both cases there are a large number of residues with high RMSFs in
the HLH region, although these fluctuations are slightly more intense
in SseK1. For SseK1, the large fluctuations in the N- and C-terminal
residues is also visible. For SseK2, there is a loop between two β-
strands (hereafter referred to as beta-loop-beta; BLB) close to the
donor substrate binding site that exhibits a large degree of conforma-
tional flexibility.
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Figure 4.20: Root mean squared fluctuations (RMSF) of Ssek1 (top) and SseK2
Cα atoms calculated on a per residue basis.
Figure 4.21: Per-residue root mean squared fluctuations of SseK1 (top) and
SseK2 (bottom) mapped onto their respective X-ray crystal structures. Both
surface (left) and cartoon representations are shown. Map shows RMSF values
of larger than 3 Å(red), between 3 and 1.5 Å(yellow) and less than 1.5 Å(cyan).
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Principal component analysis (PCA) can further elucidate the mo-
tions of a system by transforming the Cartesian space into 3N (where
N is the number of atoms) eigenvectors (principal components; PCs),
where each subsequent eigenvector describes less of the variance in
the system. Importantly, projection of these vectors back into Carte-
sian space, allows the concerted motions of the system to be analysed.
In the case of these simulations, the motions of the Cα atoms were
considered. In both cases, the first three eigenvectors accounted for
more than 40% of the variance in the backbone motion and the first
principal component (PC1) of both systems accounted for 25% of the
variance respectively (Fig. 4.22). Subsequent eigenvectors accounted
for less than 1% of the motion each and so were not considered further.
Figure 4.22: Cumulative fraction of total motion accounted for by the first 10
eigenvectors found by PCA for SseK1 and SseK2 Cα atom motion. For each
system, all eigenvectors were calculated (3N where N is the number of Cα
atoms) and the contribution of each eigenvector was calculated by dividing its
eigenvalue by the sum of all eigenvalues.
For both SseK1 and SseK2, the predominant motion (PC1) is rotation
of the HLH domain towards the catalytic site (Fig. 4.23). For SseK1,
the next two dominant motions are movement of the N-terminal (PC2)
and C-terminal (PC3) regions. In fact, PC3 indicates a distinct open-
ing of the lid such that the donor substrate binding site is exposed.
Conversely, the RMSF plots and PCA projections of SseK2 show that
there is no significant movement of the C-terminal lid domain. It is
interesting that in these two enzymes, the lid apparently opens over
different timescales (unobservable for SseK2) as this may have an im-
pact on their enzymatic activity. The opening of the SseK1 C-terminal
lid may also explain the larger changes in RMSD of the UDP-GlcNAc
ligand in SseK1 compared to SseK2 due to the lack of stabilising in-
teractions with the C-terminal lid. For SseK2, PC2 and PC3 involve
tilting of the HLH domain and BLB motif towards the catalytic site.
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Figure 4.23: The first three principal components (PCs) of PCA analysis for
SseK1 (top) and SseK2 (bottom) projected back onto Xray crystal structures
of either protein. Motions of each PC are highlighted (yellow arrow)
4.3.4 Molecular Docking of FADD to SseK2
In the crystal structure of SseK2, it is clear that the C-terminal lid
domain of SseK2 exists in either a closed or an open conformation.
Since the donor substrate binding site is completely obscured from the
solvent in the closed conformation, a model of the open conformation
was produced my modelling the missing C-terminal residues in the
open conformation. The model of the FADD110-118 peptide, produced
by truncation of an X-ray crystal structure model of FADD (PDB:
3EZQ), was then docked to the open conformation of SseK2 (which
alos contained the coordinates of Mn2+ and UDP-GlcNAc in the donor
binding site).
196
Figure 4.24: Cartoon representation of the docking model of the FADD110-118
peptide (yellow) in complex with SseK2 (cyan surface).
Figure 4.25: Cartoon representation of the model complex of FADD (yellow)
and SseK2 (cyan) derived from molecular docking of the FADD110-118 peptide.
The representative structure of the most populated cluster from molec-
ular docking of FADD110-118 to SseK2 shows the peptide bound close to
the UDP-GlcNAc donor, in a longitudinal mode with the N-terminal
tilted towards SseK2 (Fig. 4.24). This positions Trp112 in close prox-
imity to the protein surface, as well as the other N-terminal residues
of FADD110-118, while the C-terminal residues are far from the SseK2
surface. This is in qualitative agreement with the STD-NMR data,
which shows that saturation is concentrated around the N-terminal
residues of FAD110-118, in particular Trp112. Furthermore, Arg117 of
FADD110-118 is positioned in close proximity to the UDP-GlcNAc donor
substrate in the docking model, which is known to be the target residue
for glycosylation.[317]
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To produce a model of the full length FADD protein in complex with
SseK2 the backbone atoms of residues 110-118 of the full length FADD
model (PDB 3EZQ) were superimposed onto the docked peptide. Af-
ter refinement, this produced a complex with no atomic clashes. Inter-
estingly, the C-terminal helix of FADD was positioned in close prox-
imity to the HLH of SseK2.
4.3.5 Molecular Dynamics Simulations of the
SseK2:FADD complex
Long accelerated molecular dynamics simulations were run on the
model of the SseK2/FADD complex derived from molecular docking
(Fig. 4.25). The root mean squared deviation (RMSD) of the SseK2
Cα atoms did not change significantly over the course of the simulation
(Fig. 4.26 top) indicating that the SseK2 model was not destabilised
by the presence of FADD and that there is not a significant structural
rearrangement of the SseK2 backbone due to the presence of FADD
(other than the opening of the C-terminal lid, which was performed
during the docking stage). The sharp spikes in RMSD are comparable
to those seen in the simulation of SseK2 in the absence of FADD, and
are therefore likely due to rotation of the HLH previously observed.
The RMSD of FADD Cα atoms was calculated by first calculating the
RMSD of SseK2 Cα atoms and then performing a no-fit calculation on
the FADD Cα atoms, in order to observe any translations or rotations
of FADD relative to SseK2. The decrease in RMSD from the average
structure over the first 400 ns indicates that the binding pose of FADD
derived from docking was not optimal and the it took approximately
400 ns to equilibrate the complex (Fig. 4.26 middle). Therefore further
analysis will only consider frames from the trajectory after 400 ns.
In a similar manner the RMSD of UDP-GlcNAc heavy atoms appears
to decrease over the first 400 ns before stabilising (Fig. 4.26 bottom),
indicating that the presence of FADD does cause some small change
to either the position or conformation of UDP-GlcNAc.
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Figure 4.26: Root mean squared deviation (RMSD) as a function of time for
SseK2 Cα atoms (top), FADD Cα atoms (middle) and for UDP-GlcNAc heavy
atoms (bottom). For FADD Cα and UDP-GlcNAc heavy atoms, a no-fit RMSD
calculation was performed after first fitting to SseK2 Cα atoms, in order to
capture both conformational and translational motions.
Clustering based on the Cα atoms of SseK2 and FADD was performed
and it was found that 5 clusters was optimal (Fig. 4.27). Together
the first two clusters accounted for 59% of the trajectory after 400 ns.
In these clusters the HLH was in close proximity to the C-terminal
helix of FADD (Fig. 4.28), the only significant difference being in
that in the most populated cluster there is a small kink in the FADD
C-terminal helix. In the less populated clusters, the HLH is rotated
away from FADD.
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Figure 4.27: Elbow plot showing the SSR/SST (SSR: sum of squared residuals,
SST: total sum of squares) ratio for different number of clusters in k-means
clustering of SseK2 and FADD Cα heavy atoms. The optimal number of clus-
ters is that which gives the best tradeoff between fraction of variance explained
(SSR/SST) and number of clusters, which is at the ‘elbow’ of the plot - in this
case 5.
Figure 4.28: Cartoon representation of the centroid structures of the clusters
from k-means clustering (left: clusters 1-2, right: clusters 3.5) of the simulation
of the SseK2 (cyan) FADD (yellow) complex.
Analysis of the most populated cluster reveals a large amount of com-
plementarity between adjacent residues of SseK2 and FADD (Fig.
4.29). For example, in the HLH domain of SseK2 there is a hy-
drophobic patch (Val169) followed by several charged residues (Lys176,
Asp180) that form complementarity interacts with FADD (Val172,
Asp175, Arg166). Furthermore, within the target region of FADD
(residue 110-118) the residues Arg113 and Arg114 interact with Glu271
and Asp299 of SseK2 respectively. There are also several positively
charged residues (Arg263, Lys264) within the BLB region of SseK2
that interact with complementary residues on FADD (Asp131 and
Glu130). Curiously Asp124 of FADD appears to chelate the man-
ganese ion of SseK2. Of the three arginine residues present in the
acceptor region of FADD Arg117 appears to be in close proximity to
the anomeric carbon and the β-phosphate of UDP-GlcNAc showing
that it may be positioned correctly for glycosylation (Fig. 4.30). We
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also monitored the distances of the three arginine residues to His260
and Glu271, which are implicated in the enzymatic mechanism, al-
though no stable interactions are observed here.
Figure 4.29: Cartoon representation of the centroid structure of the most
populated cluster from k-means clustering of the simulation of the SseK2
(cyan) FADD (yellow) complex. Complementary interactions between SseK2
and FADD highlighted (sticks).
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Figure 4.30: Molecular dynamics of the docking model of the ternary
SseK2:UDP-GlcNAc:FADD complex show significant conformational rearrange-
ments of Arg113, Arg114, and Arg117 of FADD, orienting Arg117 for a front
face attack to GlcNAc, and support the relevance of Glu271 and His260 in ac-
ceptor FADD substrate binding. Calculated distances (Å) for contacts between
the center of mass of the guanidinium groups of Arg113 (black lines), Arg114
(red lines), and Arg117 (green lines) of FADD and a, the anomeric carbon
of GlcNAc of UDP-GlcNAc, b, the center of mass of the carboxylate group
of Glu271 of SseK2, c, the center of mass of the imidazole group of His260
of SseK2, d, the center of mass of the beta-phosphate of UDP-GlcNAc. On
average, Arg117 of FADD is the residue from FADD closest to the anomeric car-
bon of GlcNAc and is the only residue establishing close contacts with His260,
Glu271, and the beta-phosphate of UDP-GlcNAc. e, Representative structure
of the ternary complex of SseK2 (cyan), FADD (yellow) and UDP-GlcNAc
(pink) from GaMD simulations, showing that Arg117 is properly oriented for
a front face attack with close contact with the anomeric carbon of the UDP-
GlcNAc donor substrate. Manganese is shown as a purple sphere and hydrogen
atoms are omitted for clarity.
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The residue pairs within the HLH were monitored over the course
of the trajectory to determine the stability of their interactions (Fig.
4.31). Early in the simulation, the distances between these residues
was large, before coming together after about 600 ns. After this point
the interaction appears to be stable. This further suggests that the
HLH may be involved in recognition since it is able to find and form
stable interactions with the acceptor substrate. Furthermore, the in-
teraction between the FADD arginine residues within the target region
(Arg113, Arg114 and Arg 117) and their partners in SseK2 (Glu271,
Asp299 and UDP-GlcNAc C1) was monitored. Again the interaction
was stabilised after approximately 600 ns. Finally it appears that the
interaction between the Mn2+ ion of SseK2 and Asp124 was stable
much earlier in the simulation and remains so for the duration of the
simulation.
Figure 4.31: Distance measurements for residues involved in complementary
interactions between SseK2 and FADD as a function of time. Residues labelled
as:SseK2 residue - FADD residue.
203
4.3.6 NMR spectroscopy of 15N-labelled FADD
in Complex with SSeK2
To add to the experimental evidence of the proposed complex of SseK2
and FADD, 15N-labelled FADD was first expressed from a recombinant
plasmid in E. coli, following a previously published protocol.[316] FADD
was purified using Ni-NTA affinity column and appeared on the SDS-
PAGE gel at approximately 14 kDa, close to the expected value of 12
kDa (Fig. 4.32).
Figure 4.32: SDS-PAGE gel of 15N-FADD expression and purification showing
the soluble lysate fraction, four wash fractions (W1-4) and four elution fractions
(E1-4). FADD is visible at approximately 14 kDa in the lysate and elution
fractions.
1H-15N HSQC experiments were performed for 15N-FADD in the ab-
sence and presence of SseK2. Due to solubility issues of SseK2, it
was not possible to exceed a protein:ligand ratio of 1:1, meaning that
the FADD binding sites would not have been fully saturated. Still
there are significant differences between the two spectra, which can
be used to qualitatively describe the residues of FADD that are af-
fected by SseK2 binding. Overall the NMR signal of 15N-FADD was
reduced in the presence of SseK2 (Fig. 4.33). This is expected, since
the increased correlation time of the complex would shorten the trans-
verse relaxation time (T2) of the 15N-FADD resonances and therefore
lead to reduced signal. However, there are some residues that are in
the 15N-FADD spectrum that are strongly affected by the presence of
SseK2 and disappear from the spectrum entirely. This is indicative
of restricted mobility of these residues within the complex and there-
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fore suggests that these residues are at the interface between FADD
and SseK2 in the complex. The FADD residues affected most sig-
nificantly by binding to SseK2 are Gly93, Val103, Asn107, Gly109,
Arg113, Arg114, Leu115, Asp123, Thr124, Ile129, Tyr133, Leu137,
Glu139, Arg140, Val141, Glu152, Glu154, Thr157, Cys168, Asn171,
Val173 and Gly191.
Figure 4.33: The 1H-15N HSQC NMR spectra of 15N-labelled FADD in the ab-
sence (blue) or presence of SseK2 (red). Resonances that are significantly per-
turbed by the presence of SseK2 are labelled with their corresponding residues.
15N-FADD present at 0.3 mM with an equimolar concentration of SseK2. Spec-
tra acquired at 500 MHz.
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These residues were then mapped onto the model of the SseK2:FADD
complex (Fig. 4.34). The most significantly perturbed residues of
FADD were those in the model of the FADD/SseK2 complex close
to either the catalytic site or the HLH. Overall the mapping of the
FADD residues affected by SseK2 binding provides good experimental
evidence for the model of the SseK2:FADD complex.
Figure 4.34: Cartoon representation of FADD (yellow) showing residues af-
fected in the 1H-15N HSQC spectrum (red) by FADD binding to SseK2 (cyan).
Shown on a model of FADD only (top, PDB: 3EZQ) and on a model of the
FADD/SseK2 complex.
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4.3.7 Mechanism of Glycosylation of GAPDH187-203
by Ssek1
To determine whether SseK1 is an inverting or retaining enzyme,
GAPDH187-203 was reacted with SseK1 and the unpurified reaction
mixture was analysed by NMR. The shorter GAPDH195-203 construct
was tested prior to this, but affinity was too low to produce enough
glycosylated GAPDH195-203 for the NMR experiment.
The decoupled 1H-13C HSQC NMR spectra of the reaction mixture
(Fig. 4.35a) showed the presence of four resonances in the anomeric
region of the spectrum. Three of these could be assigned to UDP-
GlcNAc, αGlcNAc and βGlcNAc, whilst the fourth previously un-
characterised peak was assigned to GlcNAc covalently bound to an
arginine sidechain. This resonance is significantly shifted upfield in
the 13C dimension relative to the other anomeric resonances, show-
ing a more electron-rich environment, compatible with being bound
to the conjugated pi system of an arginine sidechain. Furthermore, a
comparable upfield shift has been observed for the anomeric carbon
of rhamnose glycosidically linked to arginine.[325]
Figure 4.35: SseK1 is a retaining-glycosyltransferase. NMR spectra showing
the reaction product of GAPDH187-203 with SseK1. a) Decoupled 1H-13C
HSQC spectrum (800 MHz) showing the anomeric region, highlighting the pres-
ence of αGlcNAc-GAPDH187-203, with a large 13C upfield shift relative to the
free species. b) Expansion of 1H-13C CLIP HSQC spectrum (500 MHz) with no
decoupling to measure the anomeric 1JCH coupling inαGlcNAc-GAPDH187-203.
A value of 169 Hz indicates an α-configuration.
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The 1H resonance frequency of 5.06 ppm for the GAPDH187-203-GlcNAc
anomeric proton is typical of an α glycosidic linkage and is close to
the resonance frequency for the anomeric protein of free αGlcNAc.
To confirm this an non-decoupled 1H-13C HSQC experiment was per-
formed on the sample. The measured 1JCH value for the anomeric
position of GAPDH187-203-αGlcNAc was 169 Hz, which is typical of
an α glycosidic linkage also.[326] Together these data show that the
glycosidic linkage of GAPDH187-203-GlcNAc is in the α configuration
and therfore SseK1 functions as a retaining enzyme for the glycosyl
transfer reaction to the GAPDH187-203 acceptor.
4.4 Discussion
The SseK effectors provide an interesting topic of discussion both for
their putative role in Salmonella infection and their novel enzymatic
mechanism. While none of these effectors appear to be absolutely
essential to the virulence of Salmonella, SseK1 and SseK3 have been
shown to inhibit necroptotic cell death,[309] which is a mechanism of
programmed cell death that causes the intracellular contents of the
host cell to leak into the extracellular space, causing an inflammatory
immune response. Mediation of necroptotic cell death by bacterial
pathogens has been documented in a number of species.[327,328] It is
likely that, while not essential, SseK1 and SseK3 provide an advantage
to Salmonella by reducing inflammation at the site of infection. It is
still unclear what the role of SseK2 is, although glycosylation of FADD
does inhibit downstream nF-κB signalling.
The target sequences of FADD, TRADD and GAPDH all share sim-
ilar sequences - in particular a conserved WR-motif. It is there-
fore perhaps unsurprising that all three target peptides (FADD110-118,
TRADD229-237, GAPDH195-203) bind to both SseK1 and SseK2. There-
fore, while this motif appears to be important for binding (the tryp-
tophan of each peptide always shows the strongest STD intensity),
clearly it is not sufficient to confer specificity between SseK1 and
SseK2.
To this end, a model of the SseK2/FADD complex was produced and
validated experimentally by NMR. This complex was chosen for a
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number of reasons. 1) From a practical standpoint FADD is the
only SseK effector target small enough to be reasonably accessible
to conventional NMR techniques. 2) FADD was the only target that
could be reasonably modelled. TRADD consists of two domains, a
death domain and a TRAF-binding domain.[329] Models exist only of
the death domain of TRADD and preliminary docking results sug-
gested that actually the TRAF-binding domain of FADD would be
involved in the interaction with SseK1. Furthermore, the target re-
gion of GAPDH is located within an extended loop region, making
accurate modelling challenging. 3) The interaction between SseK2
and FADD is very weak compared to the interaction of TRADD and
GAPDH with SseK1[309,318] and therefore is probably the least likely
complex to be solved experimentally. Therefore this method of molec-
ular modelling and NMR spectroscopy of the SseK2/FADD complex
provides molecular detail most likely otherwise inaccessible for this
complex.
The model complex shows that the target region of FADD (residues
110-118) interacts directly with SseK2 residues surrounding the cat-
alytic site. It particular Arg113 of FADD interacts directly with
Glu271 of SseK2, a residue that has been identified as being essential
for catalysis to occur in both SseK1 (Glu255) and SseK2 (Glu271). It
is known that it is not Arg113 but Arg117 that becomes glycosylated in
FADD.[317] Therefore it may be that the interaction between Glu271
(SseK2) and Arg113 (FADD) orients the target in such a way that
Arg117 is accessible for glycosylation. Indeed, in this model Arg117
is position in close proximity to the anomeric carbon of UDP-GlcNAc.
Furthermore this may explain why the WR-motif is conserved across
all three targets, if recognition of the arginine residue immediately
downstream of the tryptophan is necessary for proper orientation of
the target.
Finally here is the first experimental evidence that the SseK effectors
work as retaining enzymes, here demonstrated for the GlcNAc trans-
fer to the GAPDH187-203 substrate. Several studies had made claims
either way (retaining or inverting), based on either similarity or very
questionable interpretation of data. However, here the configuration
of the reaction product of GAPDH187-203 with SseK1 was detected di-
rectly by measuring the 1JCH coupling constant at the anomeric, which
was found to be α as in the UDP-GlcNAc donor. Still, there is much
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to be discovered about this unique mechanism, such as the catalytic
residues involved and any intermediates that may exist during the
reaction. Furthermore, it is currently unknown why glycosylation of
these particular target residues is able to induce downstream signalling.
One particularly interesting question that is yet to be answered is what
the pKa of the glycosylated arginine is and whether it is charged at
physiological pH, as unmodified arginine is.
This study has implications particularly in understanding the mech-
anism of substrate recognition and catalysis for this unique group of
enzymes. Furthermore, while these effectors are not essential for in-
fection, targeting them therapeutically may still be of interest since
impairing the ability of Salmonella to suppress inflammation may help
the host better combat the infection and in combination with other
therapies may provide an effective treatment.
4.5 Conclusions
In this chapter a combination of NMR spectroscopy and molecular
modelling was used to provide structural insight into the interaction of
SseK1/2 and their acceptor substrates FADD, TRADD and GAPDH,
and to provide some insight into their glycosylation mechanism. Over-
all the conclusions were:
1. Both SseK1 and SseK2 are capable of binding to each of
the short acceptor peptides, FADD110-118, TRADD229-237 and
GAPDH195-203, showing that recognition of the full length
acceptors must come from interactions outside of the active
site.
2. A model of the SseK2/FADD complex was produced by molec-
ular modelling and validated using STD NMR epitope map-
ping and chemical shift perturbation analysis using 15N-labelled
FADD.
3. The differential recognition of acceptor substrates is most likely
due to differences in the HLH domains of SseK1 and SseK2, as
shown by protein sequence analysis and molecular modelling.
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4. The enzymatic mechanism of SseK1 (and likely SseK2 also) fol-
lows a retaining mechanism, as shown by analysis of the 1JCH cou-
pling constant at the anomeric position of the reaction product
between GAPDH187-203 and UDP-GlcNAc catalysed by SseK1.
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List of Abbreviations
1H NMR 1D Proton NMR
ASMD Adaptive Steered MD
AMBER Assisted Model Building with Energy Refinement
(biomolecular MM forcefield)
CORCEMA Complete Relaxation and Conformational Exchange
Matrix
COSY Correlation Spectroscopy
FADD Fas-associated Death Domain
G1P Glucose 1-phosphate
GAG Glycosaminoglycan
GaMD Gaussian Accelerated MD
GAPDH Glyceraldehyde 3-phosphate Dehydrogenase
Glc Glucose
GlcA Glucuronic Acid
GlcNAc N-acetylglucosamine
Glide Grid-based Ligand Docking with Energetics
GLYCAM Carbohydrate-specific MM forcefield
GP Glycoside Phosphorylase
GT Glycosyltransferase
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GT-A Glycosyltransferase Type-A fold
GT-B Glycosyltransferase Type-B fold
HA Hyaluronan
HABD HA Binding Domain
HLH Helix-loop-helix
HSQC Heteronuclear Single-quantum Correlation
ksat Saturation Transfer Rate Constant
LB Laminaribiose
LBP LB Phosphorylase
LYVE-1 Lymphatic Vessel Endothelial Hyaluronan Receptor 1
M1P Mannose 1-phosphate
Man Mannose
MD Molecular Dynamics
MM Molecular Mechanics
NMR Nuclear Magnetic Resonance
NOE Nuclear Overhauser Effect
NOESY NOE Spectroscopy
NPT Isobaric-Isothermal Ensemble
NVE Microcanonical Ensemble
NVT Canonical Ensemble
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OPLS Optimised Potentials for Liquid Simulation
(general MM forcefield)
PDB Protein Data Bank
PES Potential Energy Surface
RMSD Root Mean Squared Deviation
RMSF Root Mean Squared Fluctuations
STD0 Initial Rate of STD Intensity Growth
STD NMR Saturation Transfer Difference NMR
STDmax Maximum STD Intensity
TOCSY Total Correlation Spectroscopy
TRADD Tumor Necrosis Factor Receptor Type-1-associated
Death Domain
UDP Uridine Diphosphate
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